Solicitation Cover Page

1. Solicitation #: **3530000015** **2. Solicitation Issue Date:** **01/13/2020**

3. Brief Description of Requirement:

The Office of Management and Enterprise Services, on behalf of the Oklahoma Horse Racing Commission, is accepting proposals for Equine Drug Testing.

Solicitation Notice: Please note that on a Request for Proposal (RFP), no pricing shall be released at the time of the opening. Should a public opening be requested, the only information to be released will be a list of bidders without pricing.

All questions regarding this solicitation must be submitted in writing and are to be emailed no later than January 27, 2020 at 3:00 PM CST. Questions are to be emailed to Stephanie.Beshears@omes.ok.gov. Questions received after this date will not be answered. If questions are received, an amendment to this solicitation will be posted on our website listing all questions and answers.

4. Response Due Date[1]: **February 12, 2020** **Time**: **3:00 PM** CST/CDT

5. Issued By and RETURN SEALED BID TO[2]:

U.S. Postal Delivery Address:	**5005 N. Lincoln Blvd. Ste. 300**
	Oklahoma City, OK 73105
Common Carrier Delivery Address:	**5005 N. Lincoln Blvd. Ste. 300**
	Oklahoma City, OK 73105
Electronic Submission Address:	**N/A**

6. Solicitation Type (type "X" at one below)**:**

- ☐ Invitation to Bid
- ☒ Request for Proposal
- ☐ Request for Quote

7. Contracting Officer:

Name: Stephanie Beshears

Phone: 405-522-1037

Email: Stephanie.Beshears@omes.ok.gov

[1] Amendments to solicitation may change the Response Due Date (read GENERAL PROVISIONS, section 3, "Solicitation Amendments")
[2] If "U.S. Postal Delivery" differs from "Carrier Delivery, use "Carrier Delivery" for courier or personal deliveries

Responding Bidder Information

"Certification for Competitive Bid and Contract" ***MUST*** *be submitted along with the response to the Solicitation.*

1. **RE: Solicitation #** 3530000015

2. **Bidder General Information:**

FEI / SSN : _____ Supplier ID: _____

Company Name: _____

3. **Bidder Contact Information:**

Address: _____

City: _____ State: ____ Zip Code: _____

Contact Name: _____

Contact Title: _____

Phone #: _____ Fax #: _____

Email: _____ Website: _____

4. **Oklahoma Sales Tax Permit[1]:**

☐ YES – Permit #: _____

☐ NO – Exempt pursuant to Oklahoma Laws or Rules – Attach an explanation of exemption

5. **Registration with the Oklahoma Secretary of State:**

☐ YES - Filing Number: _____

☐ NO - Prior to the contract award, the successful bidder will be required to register with the Secretary of State or must attach a signed statement that provides specific details supporting the exemption the supplier is claiming (www.sos.ok.gov or 405-521-3911).

6. **Workers' Compensation Insurance Coverage:**

Bidder is required to provide with the bid a certificate of insurance showing proof of compliance with the Oklahoma Workers' Compensation Act.

☐ YES – Include with the bid a certificate of insurance.

☐ NO – Exempt from the Workers' Compensation Act pursuant to 85A O.S. § 2(18)(b)(1-11) – Attach a written, signed, and dated statement on letterhead stating the reason for the exempt status.[2]

[1] **For frequently asked questions concerning Oklahoma Sales Tax Permit, see https://www.ok.gov/tax/Businesses/index.html**
[2] **For frequently asked questions concerning workers' compensation insurance, see https://www.ok.gov/wcc/Insurance/index.html**

7. Disabled Veteran Business Enterprise Act

☐ YES – I am a service-disabled veteran business as defined in 74 O.S. §85.44E. Include with the bid response 1) certification of service-disabled veteran status as verified by the appropriate federal agency, and 2) verification of not less than 51% ownership by one or more service-disabled veterans, and 3) verification of the control of the management and daily business operations by one or more service-disabled veterans.

☐ NO – Do not meet the criteria as a service-disabled veteran business.

Authorized Signature	Date
Printed Name	Title

Certification for Competitive Bid and/or Contract (Non-Collusion Certification)

NOTE: *A certification shall be included with any competitive bid and/or contract exceeding $5,000.00 submitted to the State for goods or services.*

Agency Name: *Oklahoma Horse Racing Commission* Agency Number: *353*

Solicitation or Purchase Order #: 3530000015

Supplier Legal Name: _____

SECTION I [74 O.S. § 85.22]:

A. For purposes of competitive bid,

1. I am the duly authorized agent of the above named bidder submitting the competitive bid herewith, for the purpose of certifying the facts pertaining to the existence of collusion among bidders and between bidders and state officials or employees, as well as facts pertaining to the giving or offering of things of value to government personnel in return for special consideration in the letting of any contract pursuant to said bid;
2. I am fully aware of the facts and circumstances surrounding the making of the bid to which this statement is attached and have been personally and directly involved in the proceedings leading to the submission of such bid; and
3. Neither the bidder nor anyone subject to the bidder's direction or control has been a party:
    a. to any collusion among bidders in restraint of freedom of competition by agreement to bid at a fixed price or to refrain from bidding,
    b. to any collusion with any state official or employee as to quantity, quality or price in the prospective contract, or as to any other terms of such prospective contract, nor
    c. in any discussions between bidders and any state official concerning exchange of money or other thing of value for special consideration in the letting of a contract, nor
    d. to any collusion with any state agency or political subdivision official or employee as to create a sole-source acquisition in contradiction to Section 85.45j.1. of this title.

B. I certify, if awarded the contract, whether competitively bid or not, neither the contractor nor anyone subject to the contractor's direction or control has paid, given or donated or agreed to pay, give or donate to any officer or employee of the State of Oklahoma any money or other thing of value, either directly or indirectly, in procuring this contract herein.

SECTION II [74 O.S. § 85.42]:

For the purpose of a contract for services, the supplier also certifies that no person who has been involved in any manner in the development of this contract while employed by the State of Oklahoma shall be employed by the supplier to fulfill any of the services provided for under said contract.

The undersigned, duly authorized agent for the above named supplier, by signing below acknowledges this certification statement is executed for the purposes of:

☐ the competitive bid attached herewith and contract, if awarded to said supplier;

OR

☐ the contract attached herewith, which was not competitively bid and awarded by the agency pursuant to applicable Oklahoma statutes.

Supplier Authorized Signature	Certified This Date
Printed Name	Title
Phone Number	Email
Fax Number	

TABLE OF CONTENTS

A. GENERAL PROVISIONS

A.1. Definitions

As used herein, the following terms shall have the following meaning unless the context clearly indicates otherwise:

A.1.1. "Acquisition" means items, products, materials, supplies, services, and equipment an entity acquires by purchase, lease purchase, lease with option to purchase, or rental;

A.1.2. “Addendum” means a written restatement of or modification to a Contract Document executed by the Supplier and State.

A.1.3. ”Bid” means an offer in the form of a bid, proposal, or quote a bidder submits in response to a solicitation;

A.1.4. "Bidder" means an individual or business entity that submits a bid in response to a solicitation;

A.1.5. "Solicitation" means a request or invitation by the State Purchasing Director or a state agency for a supplier to submit a priced offer to sell acquisitions to the state. A solicitation may be an invitation to bid, request for proposal, or a request for quotation; and

A.1.6. ”Supplier” or “vendor” means an individual or business entity that sells or desires to sell acquisitions to state agencies.

A.2. Bid Submission

A.2.1. Submitted bids shall be in strict conformity with the instructions to bidders and shall be submitted with a completed Responding Bidder Information, OMES-FORM-CP-076, and any other forms required by the solicitation.

A.2.2. Bids shall be submitted to the Central Purchasing Division in a single envelope, package, or container and shall be sealed, unless otherwise detailed in the solicitation. The name and address of the bidder shall be inserted in the upper left corner of the single envelope, package, or container. SOLICITATION NUMBER AND SOLICITATION RESPONSE DUE DATE AND TIME MUST APPEAR ON THE FACE OF THE SINGLE ENVELOPE, PACKAGE, OR CONTAINER.

A.2.3. The required certification statement, "Certification for Competitive Bid and/or Contract (Non-Collusion Certification)", OMES-FORM-CP-004, must be made out in the name of the bidder and must be properly executed by an authorized person, with full knowledge and acceptance of all its provisions.

A.2.4. All bids shall be legible and completed in ink or with electronic printer or other similar office equipment. Any corrections to bids shall be identified and initialed in ink by the bidder. Penciled bids and penciled corrections shall NOT be accepted and will be rejected as non-responsive. In addition to a hard copy submittal, the bidder will also be required to submit an electronic copy. Electronic responses must be submitted in the identical format contained in the solicitation (for example Microsoft Word, Microsoft Excel, but not Adobe PDF). In the event the hard copy of the price worksheets and electronic copy of the price worksheets do not agree, the electronic copy will prevail.

A.2.5. All bids submitted shall be subject to the Oklahoma Central Purchasing Act, Central Purchasing Rules, and other statutory regulations as applicable, these General Provisions, any Special Provisions, solicitation specifications, required certification statement, and all other terms and conditions listed or attached herein—all of which are made part of this solicitation.

A.3. Solicitation Amendments

A.3.1. If an ”Amendment of Solicitation”, OMES-FORM-CP-011, is issued, the bidder shall acknowledge receipt of any/all amendment(s) to solicitations by signing and returning the solicitation amendment(s). Amendment acknowledgement(s) may be submitted with the bid or may be forwarded separately. If forwarded separately, amendment acknowledgement(s) must contain the solicitation number and response due date and time on the front of the envelope. The Central Purchasing Division must receive the amendment acknowledgement(s) by the response due

date and time specified for receipt of bids for the bid to be deemed responsive. Failure to acknowledge solicitation amendments may be grounds for rejection.

A.3.2. No oral statement of any person shall modify or otherwise affect the terms, conditions, or specifications stated in the solicitation. All amendments to the solicitation shall be made in writing by the Central Purchasing Division.

A.3.3. It is the bidder's responsibility to check the OMES/Central Purchasing Division website frequently for any possible amendments that may be issued. The Central Purchasing Division is not responsible for a bidder's failure to download any amendment documents required to complete a solicitation.

A.4. Bid Change

If the bidder needs to change a bid prior to the solicitation response due date, a new bid shall be submitted to the Central Purchasing Division with the following statement "This bid supersedes the bid previously submitted" in a single envelope, package, or container and shall be sealed, unless otherwise detailed in the solicitation. The name and address of the bidder shall be inserted in the upper left corner of the single envelope, package, or container. SOLICITATION NUMBER AND SOLICITATION RESPONSE DUE DATE AND TIME MUST APPEAR ON THE FACE OF THE SINGLE ENVELOPE, PACKAGE, OR CONTAINER.

A.5. Certification Regarding Debarment, Suspension, and Other Responsibility Matters

By submitting a response to this solicitation:

A.5.1. The prospective primary participant and any subcontractor certifies to the best of their knowledge and belief, that they and their principals or participants:

A.5.1.1. Are not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded by any Federal, State or local department or agency;

A.5.1.2. Have not within a three-year period preceding this proposal been convicted of or pled guilty or had a civil judgment rendered against them for commission of fraud or a criminal offense in connection with obtaining, attempting to obtain, or performing a public (Federal, State or local) contract; or for violation of Federal or State antitrust statutes or commission of embezzlement, theft, forgery, bribery, falsification or destruction of records, making false statements, or receiving stolen property;

A.5.1.3. Are not presently indicted for or otherwise criminally or civilly charged by a governmental entity (Federal, State, or local) with commission of any of the offenses enumerated in paragraph A.5.1.2. of this certification; and

A.5.1.4. Have not within a three-year period preceding this application/proposal had one or more public (Federal, State, or local) contracts terminated for cause or default.

A.5.2. Where the prospective primary participant is unable to certify to any of the statements in this certification, such prospective participant shall attach an explanation to its solicitation response.

A.6. Bid Opening

Sealed bids shall be opened by the Central Purchasing Division at 5005 N. Lincoln Blvd. Suite 300, Oklahoma City, Oklahoma, 73105 at the time and date specified in the solicitation as Response Due Date and Time.

A.7. Open Bid / Open Record

Pursuant to the Oklahoma Public Open Records Act, a public bid opening does not make the bid(s) immediately accessible to the public. The procurement or contracting agency shall keep the bid(s) confidential, and provide prompt and reasonable access to the records only after a contract is awarded or the solicitation is cancelled. This practice protects the integrity of the competitive bid process and prevents excessive disruption to the procurement process. The interest of achieving the best value for the State of Oklahoma outweighs the interest of vendors immediately knowing the contents of competitor's bids. [51 O.S. § 24A.5(5)]

Additionally, financial or proprietary information submitted by a bidder may be designated by the Purchasing Director as confidential and the procurement entity may reject all requests to disclose information designated as confidential pursuant to 62 O.S. (2012) § 34.11.1(H)(2) and 74 O.S. (2011) § 85.10. Bidders claiming any portion of their bid as proprietary or confidential must specifically identify what documents or portions of documents they consider confidential and identify applicable law supporting their claim of confidentiality. The State Purchasing Director shall make the final decision as to whether the documentation or information is confidential pursuant to 74 O.S. §

85.10. Otherwise, documents and information a bidder submits as part of or in connection with a bid are public records and subject to disclosure after contract award or the solicitation is cancelled.

A.8. Late Bids

Bids received by the Central Purchasing Division after the response due date and time shall be deemed non-responsive and shall NOT be considered for any resultant award.

A.9. Legal Contract

A.9.1. Submitted bids are rendered as a legal offer and any bid, when accepted by the Central Purchasing Division, shall constitute a contract.

A.9.2. The Contract resulting from this solicitation may consist of the following documents in the following order of precedence:

A.9.2.1. Any Addendum to the Contract;

A.9.2.2. Purchase order, as amended by Change Order (if applicable);

A.9.2.3. Solicitation, as amended (if applicable); and

A.9.2.4. Successful bid (including required certifications), to the extent the bid does not conflict with the requirements of the solicitation or applicable law.

A.9.3. Any contract(s) awarded pursuant to the solicitation shall be legibly written or typed.

A.10. Pricing

A.10.1. Bids shall remain firm for a minimum of sixty (60) days from the solicitation closing date.

A.10.2. Bidders guarantee unit prices to be correct.

A.10.3. In accordance with 74 O.S. §85.40, ALL travel expenses to be incurred by the supplier in performance of the Contract shall be included in the total bid price/contract amount.

A.11. Manufacturers' Name and Approved Equivalents

Unless otherwise specified in the solicitation, manufacturers' names, brand names, information and/or catalog numbers listed in a specification are for information and not intended to limit competition. Bidder may offer any brand for which they are an authorized representative, and which meets or exceeds the specification for any item(s). However, if bids are based on equivalent products, indicate on the bid form the manufacturer's name and number. Bidder shall submit sketches, descriptive literature, and/or complete specifications with their bid. Reference to literature submitted with a previous bid will not satisfy this provision. The bidder shall also explain in detail the reason(s) why the proposed equivalent will meet the specifications and not be considered an exception thereto. Bids that do not comply with these requirements are subject to rejection.

A.12. Clarification of Solicitation

A.12.1. Clarification pertaining to the contents of this solicitation shall be directed in writing to the Central Purchasing Contracting Officer specified in the solicitation, and must be prior to the closing date of the solicitation.

A.12.2. If a bidder fails to notify the State of an error, ambiguity, conflict, discrepancy, omission or other error in the SOLICITATION, known to the bidder, or that reasonably should have been known by the bidder, the bidder shall submit a bid at its own risk; and if awarded the contract, the bidder shall not be entitled to additional compensation, relief, or time, by reason of the error or its later correction. If a bidder takes exception to any requirement or specification contained in the SOLICITATION, these exceptions must be clearly and prominently stated in their response.

A.12.3. Bidders who believe proposal requirements or specifications are unnecessarily restrictive or limit competition may submit a written request for administrative review to the contracting officer listed on the solicitation. This request must be made prior to the closing date of the solicitation.

A.13. Negotiations

A.13.1. In accordance with Title 74 §85.5, the State of Oklahoma reserves the right to negotiate with one, selected, all or none of the vendors responding to this solicitation to obtain the best value for the State. Negotiations could entail discussions on products, services, pricing, contract terminology or any other issue that may mitigate the State's risks. The State shall consider all issues negotiable and not artificially constrained by internal corporate policies. Negotiation may be with one or more vendors, for any and all items in the vendor's offer.

A.13.2. Firms that contend that they lack flexibility because of their corporate policy on a particular negotiation item shall face a significant disadvantage and may not be considered. If such negotiations are conducted, the following conditions shall apply:

A.13.3. Negotiations may be conducted in person, in writing, or by telephone.

A.13.4. Negotiations shall only be conducted with potentially acceptable offers. The State reserves the right to limit negotiations to those offers that received the highest rankings during the initial evaluation phase.

A.13.5. Terms, conditions, prices, methodology, or other features of the bidders offer may be subject to negotiations and subsequent revision. As part of the negotiations, the bidder may be required to submit supporting financial, pricing, and other data in order to allow a detailed evaluation of the feasibility, reasonableness, and acceptability of the offer.

A.13.6. The requirements of the Request for Proposal shall not be negotiable and shall remain unchanged unless the State determines that a change in such requirements is in the best interest of the State Of Oklahoma.

A.14. Rejection of Bid

The State reserves the right to reject any bids that do not comply with the requirements and specifications of the solicitation. A bid may be rejected when the bidder imposes terms or conditions that would modify requirements of the solicitation or limit the bidder's liability to the State. Other possible reasons for rejection of bids are listed in OAC 260:115-7-32.

A.15. Award of Contract

A.15.1. The State Purchasing Director may award the Contract to more than one bidder by awarding the Contract(s) by item or groups of items, or may award the Contract on an ALL OR NONE basis, whichever is deemed by the State Purchasing Director to be in the best interest of the State of Oklahoma.

A.15.2. Contract awards will be made to the lowest and best bidder(s) unless the solicitation specifies that best value criteria is being used.

A.15.3. In order to receive an award or payments from the State of Oklahoma, suppliers must be registered. The vendor registration process can be completed electronically through the OMES website at the following link: https://www.ok.gov/dcs/vendors/index.php .

A.16. Contract Modification

A.16.1. The Contract is issued under the authority of the State Purchasing Director who signs the Contract. The Contract may be modified only through a written Addendum, signed by the State Purchasing Director and the supplier.

A.16.2. Any change to the Contract, including but not limited to the addition of work or materials, the revision of payment terms, or the substitution of work or materials, directed by a person who is not specifically authorized by the Central Purchasing Division in writing, or made unilaterally by the supplier, is a breach of the Contract. Unless otherwise specified by applicable law or rules, such changes, including unauthorized written Addendums, shall be void and without effect, and the supplier shall not be entitled to any claim under this Contract based on those changes. No oral statement of any person shall modify or otherwise affect the terms, conditions, or specifications stated in the resultant Contract.

A.17. Delivery, Inspection and Acceptance

A.17.1. Unless otherwise specified in the solicitation or awarding documents, all deliveries shall be F.O.B. Destination. The supplier(s) awarded the Contract shall prepay all packaging, handling,

shipping and delivery charges and firm prices quoted in the bid shall include all such charges. All products and/or services to be delivered pursuant to the Contract shall be subject to final inspection and acceptance by the State at destination. "Destination" shall mean delivered to the receiving dock or other point specified in the purchase order. The State assumes no responsibility for goods until accepted by the State at the receiving point in good condition. Title and risk of loss or damage to all items shall be the responsibility of the supplier until accepted by the receiving agency. The supplier(s) awarded the Contract shall be responsible for filing, processing, and collecting any and all damage claims accruing prior to acceptance.

A.17.2. Supplier(s) awarded the Contract shall be required to deliver products and services as bid on or before the required date. Deviations, substitutions or changes in products and services shall not be made unless expressly authorized in writing by the Central Purchasing Division.

A.18. Invoicing and Payment

A.18.1. Upon submission of an accurate and proper invoice, the invoice shall be paid in arrears after products have been delivered or services provided and in accordance with applicable law. Invoices shall contain the purchase order number, a description of the products delivered or services provided, and the dates of such delivery or provision of services. An invoice is considered proper if sent to the proper recipient and goods or services have been received.

A.18.2. State Acquisitions are exempt from sales taxes and federal excise taxes.

A.18.3. Pursuant to 74 O.S. §85.44(B), invoices will be paid in arrears after products have been delivered or services provided.

A.18.4. Payment terms will be net 45. Interest on late payments made by the State of Oklahoma is governed by 62 O.S. § 34.72.

A.18.5. Additional terms which provide discounts for earlier payment may be evaluated when making an award. Any such additional terms shall be no less than ten (10) days increasing in five (5) day increments up to thirty (30) days. The date from which the discount time is calculated shall be the date of a proper invoice.

A.19. Tax Exemption

State agency acquisitions are exempt from sales taxes and federal excise taxes. Bidders shall not include these taxes in price quotes.

A.20. Audit and Records Clause

A.20.1. As used in this clause, “records" includes books, documents, accounting procedures and practices, and other data, regardless of type and regardless of whether such items are in written form, in the form of computer data, or in any other form. In accepting any Contract with the State, the successful bidder(s) agree any pertinent State or Federal agency will have the right to examine and audit all records relevant to execution and performance of the resultant Contract.

A.20.2. The successful supplier(s) awarded the Contract(s) is required to retain records relative to the Contract for the duration of the Contract and for a period of seven (7) years following completion and/or termination of the Contract. If an audit, litigation, or other action involving such records is started before the end of the seven (7) year period, the records are required to be maintained for two (2) years from the date that all issues arising out of the action are resolved, or until the end of the seven (7) year retention period, whichever is later.

A.21. Non-Appropriation Clause

The terms of any Contract resulting from the solicitation and any Purchase Order issued for multiple years under the Contract are contingent upon sufficient appropriations being made by the Legislature or other appropriate government entity. Notwithstanding any language to the contrary in the solicitation, purchase order, or any other Contract document, the procuring agency may terminate its obligations under the Contract if sufficient appropriations are not made by the Legislature or other appropriate governing entity to pay amounts due for multiple year agreements. The Requesting (procuring) Agency's decisions as to whether sufficient appropriations are available shall be accepted by the supplier and shall be final and binding.

A.22. Choice of Law

Any claims, disputes, or litigation relating to the solicitation, or the execution, interpretation, performance, or enforcement of the Contract shall be governed by the laws of the State of Oklahoma.

A.23. Choice of Venue

Venue for any action, claim, dispute or litigation relating in any way to the Contract shall be in Oklahoma County, Oklahoma.

A.24. Termination for Cause

A.24.1. The supplier may terminate the Contract for default or other just cause with a 30-day written request and upon written approval from the Central Purchasing Division. The State may terminate the Contract for default or any other just cause upon a 30-day written notification to the supplier.

A.24.2. The State may terminate the Contract immediately, without a 30-day written notice to the supplier, when violations are found to be an impediment to the function of an agency and detrimental to its cause, when conditions preclude the 30-day notice, or when the State Purchasing Director determines that an administrative error occurred prior to Contract performance.

A.24.3. If the Contract is terminated, the State shall be liable only for payment for products and/or services delivered and accepted.

A.25. Termination for Convenience

A.25.1. The State may terminate the Contract, in whole or in part, for convenience if the State Purchasing Director determines that termination is in the State's best interest. The State Purchasing Director shall terminate the Contract by delivering to the supplier a Notice of Termination for Convenience specifying the terms and effective date of Contract termination. The Contract termination date shall be a minimum of 60 days from the date the Notice of Termination for Convenience is issued by the State Purchasing Director.

A.25.2. If the Contract is terminated, the State shall be liable only for products and/or services delivered and accepted, and for costs and expenses (exclusive of profit) reasonably incurred prior to the date upon which the Notice of Termination for Convenience was received by the supplier.

A.26. Insurance

The successful supplier(s) awarded the Contract shall obtain and retain insurance, including workers' compensation, automobile insurance, medical malpractice, and general liability, as applicable, or as required by State or Federal law, prior to commencement of any work in connection with the Contract. The supplier awarded the Contract shall timely renew the policies to be carried pursuant to this section throughout the term of the Contract and shall provide the Central Purchasing Division and the procuring agency with evidence of such insurance and renewals.

A.27. Employment Relationship

The Contract does not create an employment relationship. Individuals performing services required by this Contract are not employees of the State of Oklahoma or the procuring agency. The supplier's employees shall not be considered employees of the State of Oklahoma nor of the procuring agency for any purpose, and accordingly shall not be eligible for rights or benefits accruing to state employees.

A.28. Compliance with the Oklahoma Taxpayer and Citizen Protection Act of 2007

By submitting a bid for services, the bidder certifies that they, and any proposed subcontractors, are in compliance with 25 O.S. 1313 and participate in the Status Verification System. The Status Verification System is defined in 25 O.S. §1312 and includes but is not limited to the free Employment Verification Program (E-Verify) through the Department of Homeland Security and available at www.dhs.gov/E-Verify .

A.29. Compliance with Applicable Laws

The products and services supplied under the Contract shall comply with all applicable Federal, State, and local laws, and the supplier shall maintain all applicable licenses and permit requirements.

A.30. Special Provisions

Special Provisions set forth in SECTION B apply with the same force and effect as these General Provisions. However, conflicts or inconsistencies shall be resolved in favor of the Special Provisions.

B. SPECIAL PROVISIONS

B.1. Contract Period

The initial contract period will be July 1, 2020 through June 30, 2021, with the option(s) to renew for four (4) additional one (1) year periods, at the same terms and conditions.

B.2. Definitions

B.2.1. **Adverse Analytical Finding -** A report from a Laboratory or other approved Testing entity that identifies in a Sample the presence of a Prohibited Substance or its Metabolites or Markers (including elevated quantities of Endogenous or Threshold Substances) or evidence of the Use of a Prohibited Practice.

B.2.2. **Analytical Testing** - The parts of the Substance Control process involving Sample handling, analysis, and reporting following receipt in the Laboratory.

B.2.3. **Atypical Finding -** A report from a Laboratory that requires further investigation before determination of an Adverse Analytical Finding.

B.2.4. **AORC -** Association of Racing Chemists

B.2.5. **Batch -** A set of samples processed as a group.

B.2.6. **Blood \ Plasma \ Serum Sample** - Equine blood \ plasma \ serum sample taken from a horse.

B.2.7. **"Blood Only"** - Equine blood\plasma\serum sample taken from a horse absent of a collected paired-urine sample.

B.2.8. **Confirmation** - Testing to provide unequivocal identification and quantification of substances in submitted samples.

B.2.9. **Confirmation Procedure -** An analytical test procedure that identifies the presence or concentration of one or more specific Prohibited Substances, Metabolite(s) of a Prohibited Substance, or Marker(s) of the Use of a Prohibited Substance, Threshold Substance, or Prohibited Practice in a Sample. A Confirmation Procedure may also indicate in a Sample a concentration of Threshold Substance greater than a threshold concentration.

B.2.10. **Endogenous Substance** - Any substance that is natural to the untreated horse.

B.2.11. **Fit for Purpose** - Suitability of a test to meet testing objectives.

B.2.12. **In-Competition -** For purposes of differentiating between In-competition and Out-of-Competition Testing, unless provided otherwise in the rules of a relevant State Horse Racing Authority, an In-Competition test is a test wherein a horse is selected for Testing in the period immediately before or after completion of a Competition.

B.2.13. **Instrumentation** - General term for analytical equipment in a laboratory used for the identification and quantification of substances.

B.2.14. **Laboratory** - A Racing Medication Threshold Consortium (RMTC) accredited laboratory applying test methods and processes to provide evidentiary data for the detection and, if applicable, quantification of a substance in urine, blood, and other biological or non-biological Samples.

B.2.15. **Laboratory Documentation Package** - The physical or electronic records produced by the Laboratory to support the issuance of an Adverse Analytical Finding.

B.2.16. **Laboratory Internal Chain of Custody -** Documentation of the sequence of Persons in possession of the Sample and any Aliquot of the Sample taken for Testing. [Comment: Laboratory Internal Chain of Custody is generally documented by a written record of the date, location, action taken, and the individual performing an action with a Sample or Aliquot].

B.2.17. **Marker** - A substance, group of substances, or biological measurements that indicate the Use of a Prohibited Substance or a Prohibited Practice.

B.2.18. **Metabolite** - Any substance produced by a biotransformation process.

B.2.19. **Minimum Required Performance Level (MRPL)** - Concentration of a Prohibited Substance or Metabolite of a Prohibited Substance or Marker of a Prohibited Substance or Prohibited Practice that a Laboratory is expected to reliably detect and confirm in the routine daily operation of the Laboratory.

B.2.20. **Non-Biological Sample/Specimen** - Any material other than tissue samples that is collected for the purposes of Prohibitive Substance Control. Examples of non-biological material include aqueous, semi-solid, and solid substances, unknown solutions, powders, tablets, swabs, syringes, animal feed or other materials officially collected for the purposes of Prohibitive Substance Control.

B.2.21. **Non-Threshold Substance** - A substance for which the documentable detection of that substance at any concentration is considered a Prohibitive Substance rule violation.

B.2.22. **OHRC** – Oklahoma Horse Racing Commission.

B.2.23. **OMES/CP** – Office of Management and Enterprise Services/Central Purchasing

B.2.24. **OSHA** - Occupational Safety and Health Administration

B.2.25. **Out-of-Competition** - Any testing within the enclosure of a facility under the jurisdiction of the OHRC that is not in-competition testing (pre-race testing or postrace testing).

B.2.26. **Pooling** - Combining more than one sample in the test (NOTE – pooling of samples will not be allowed in this contract).

B.2.27. **Post-mortem sample** - Any biological sample obtained after death of the horse.

B.2.28. **Post- mortem and Other Sample** - Any such sample submitted for testing, including but not limited to hair, fluid, tissue, and/or organ samples.

B.2.29. **Presumptive Analytical Finding** - The status of a Sample test result for which there is a suspicious result in the Initial Testing Procedure, but for which a confirmation test has not yet been completed.

B.2.30. **Prohibited Practice -** Any method or practice so described under OHRC Rules of Racing, Section 325:45-1-27.

B.2.31. **Prohibited Substance** - Any substance, chemical, or analog that is not listed by the OHRC Rules of Racing as a permitted substance for a particular breed of horse or is not a naturally occurring substance.

B.2.32. **Quality Manual** - The Quality Manual is a document that describes the Laboratory's quality system. The Quality Manual shall include an Introduction, statement of the Scope, a section on Definitions and Terminology, a section on Management Requirements, and a section on Technical Requirements. The Management Requirements shall include sections on Organization, the Management System, Document control, Review of Contracts, Subcontracting, Purchasing, Service to the customer, Complaints, Control of Non-Conforming Work, Improvement, Corrective Actions, Preventive Actions, Control of Quality Records, Internal Audits, and Management Review. The Technical Requirements shall include sections on Personnel and Personnel Training, Accommodations, Test Methods and Validation, Equipment, Measurement Traceability, Sampling, Handing of Test Items, Quality Control, and Reports and Calibration Certificates.

B.2.33. **Quantitative Testing** - Testing to determine the quantitative results of certain samples; provides for the levels of Phenylbutazone and Furosemide among other substances in both urine and/or serum samples.

B.2.34. **Reference Collection** - A collection of samples of known origin that may be used in the determination of the identity of an unknown substance. For example, a well characterized sample obtained from a verified administration study in which scientific documentation of the identity of Metabolite(s) can be demonstrated.

B.2.35. **Reference Material** - Material, sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process.

B.2.36. **Regulated Therapeutic Substance** - A substance with a recognized therapeutic use in treating horses that are engaged in racing-related activities and for which a Regulatory Threshold has been established by the OHRC.

B.2.37. **Regulatory Threshold** - The Regulatory Threshold is the maximum concentration of a Regulated Therapeutic Substance or Endogenous Substance that is permitted in a test sample under the rules established by the OHRC.

B.2.38. **Remaining Sample** - Any portion of a Sample that is retained by the Laboratory or the OHRC after testing has been completed.

B.2.39. **Repeatability** - Variability, expressed as a standard deviation or relative standard deviation, observed within a laboratory, over a short time, using a single operator, item of equipment, etc.

B.2.40. **Reproducibility** - Variability, expressed as a standard deviation or relative standard deviation, obtained when different laboratories analyze the same Sample.

B.2.41. **Research** - Activities that are directed broadly toward developing industry advances in the detection of Prohibited and Regulated Therapeutic Substances or Prohibited Practices. Examples of demonstration of research activities include, but are not limited to, the publication of research manuscripts and abstracts, reports of method development, white papers (q.v.) presentations, reports of new substance identification, grant applications submitted, research protocols developed, and other current projects.

B.2.42. **RMTC** – Racing Medication and Testing Consortium.

B.2.43. **Sample/Specimen** - Any biological material collected for the purposes of Substance Control testing.

B.2.44. **Split Sample** - A sample collected, sealed and retained for the specific purpose of referee analysis upon the trainer's request.

B.2.45. **Standard Operating Procedure (SOP)** - A set of written instructions that document a routine or repetitive activity used to perform administrative, quality assurance, and technical actions. For technical procedures, SOPs should include the following: Scope and Applicability, Method and Procedure, Definitions, Health and Safety Precautions and Warnings, Cautions and Interferences, Equipment and Supplies, and Data Management.

B.2.46. **Substance Control** - The process including test distribution planning, sample collection and handling, laboratory analysis, results management, hearings and appeals.

B.2.47. **Tampering** - Altering for an improper purpose or in an improper way; bringing improper influence to bear; interfering improperly to alter results or prevent normal procedures from occurring.

B.2.48. **Testing** - The parts of the Substance and Medication Control process involving test distribution planning, Sample collection, Sample handling, Sample transport to the Laboratory, the actual Sample examination, Sample reporting and Sample disposal.

B.2.49. **"The Laboratory"** - The primary laboratory contracted with the OHRC.

B.2.50. **"The Commission"** - The Oklahoma Horse Racing Commission (OHRC) possessing the primary authority and responsibility to adopt and implement Substance Control rules, direct the collection of Samples, the management of test results, and the conduct of hearings, all at the state level.

B.2.51. **Threshold Substance** - A substance for which the detection and quantification of the substance at a concentration in excess of a stated threshold concentration.

B.2.52. **Trainer** - For purposes of substance control, the Trainer is the Person who is the absolute insurer of the condition of the Horse.

B.2.53. **Urine Sample** – Equine urine sample taken from a horse.

B.2.54. **Use** - The application, ingestion, inhalation, injection or consumption by any means whatsoever of any Controlled Therapeutic Substance, Prohibited Substance or Prohibited Practice.

B.2.55. **Without Pooling** - Samples are individually tested.

B.3. 90 Day Extension

The State may extend the term of this contract up to ninety (90) day intervals if mutually agreed upon by both parties in writing.

B.4. Hold Harmless

Supplier agrees to hold harmless Oklahoma Horse Racing Commission and its trustees, officers, servants, employees, agents and consultants, against any claims, demands and liabilities resulting from any act or omission on the part of the Supplier and/or agents, subcontractors, servants, and employees thereof in the performance of this contract.

B.5. Minor Deficiencies or Informalities

B.5.1. "Minor deficiency" or "minor informality" means an immaterial defect in a bid or variation in a bid from the exact requirements of a solicitation that may be corrected or waived without prejudice to other bidders. A minor deficiency or informality does not affect the price, quantity, quality, delivery or conformance to specifications and is negligible in comparison to the total cost or scope of the acquisition.

B.5.2. The State Purchasing Director may waive minor deficiencies or informalities in a bid if the State Purchasing Director determines the deficiencies or informalities do not prejudice the rights of other bidders, or are not a cause for bid rejection.

B.6. Mandatory Vendor Registration for Contract Award (In Addition to Section A.15.3.)

B.6.1. Acquisitions issued by agencies under the authority of Title 74 require vendors to register with Central Purchasing prior to award. Vendors will not be required to register to submit a bid response but will be required to register prior to being awarded a contact and renew their registration prior to each renewal of an award.

B.6.2. Vendors pending contract award to a bid released by the Central Purchasing Division or other Oklahoma state agency MUST register with the state at: https://omes.ok.gov/services/purchasing/vendor-registration

B.6.2.1. Pursuant to 74 O.S. § 85.33.B: A vendor may register with the Central Purchasing Division to be placed on the Supplier List for bid notification.

B.6.2.2. Registration entitles a supplier to receive all bid notices for the commodity classes specified by the vendor in the registration process for a period of one year.

B.6.2.3. The Vendor Registration fee is $25 for EACH family code for which the vendor desires registration.

B.6.2.4. The following items describe information requested by the vendor registration application. To expedite the application process, vendors are encouraged to have the information readily available prior to beginning the registration application. If your company is not currently transacting business in the State of Oklahoma, you may not have some of the items listed. However, any vendor selected for award of a contract with the State of Oklahoma must meet the requirements prior to the issuance of a purchase order.

B.6.2.5. E-mail address - if possible, we encourage all vendors to create a central e-mail address, to which all state bidding e-mail correspondence can be sent. A central e-mail for your organization will assure

personnel changes or employee absences do not inhibit your ability to receive timely notifications of State bidding opportunities.

B.6.2.6. An Oklahoma Sales Tax Permit Number and its Expiration Date or explanation of the exemption status (FAQs)

B.6.2.7. An Oklahoma Secretary of State Filing Number, or explanation of the exemption status (www.sos.ok.gov or 405-521-3911)

B.6.2.8. A Workers Compensation Insurance Certificate (PDF file) or explanation of the exemption status (FAQs)

B.6.2.9. Vendors must complete all 12 steps of the registration application, which require business information about your company, a substitute W-9 form and designation of the commodity codes/classifications your company is interested in. We recommend vendors search UNSPSC Website Code Posting to identify the applicable commodity codes prior to beginning the registration application. However, you will have the option to select and deselect a family, class and commodity during the online registration process before finalizing your application.

B.6.2.10. Payment information related to a bank checking account (example), or VISA, MasterCard or American Express credit card. All payments are made through an encrypted secure server and payment information is not stored after a transaction. You will receive confirmation after your registration is validated and approved by the Vendor Registration Officer.

B.6.3. Note to Vendors: The State of Oklahoma does NOT provide legal advice regarding exemptions from Sales Tax Permit, Secretary of State, and Workers Compensation Insurance registrations

B.7. Indefinite Quantity

B.7.1. This contract is for an indefinite quantity and the State may, or may not buy the quantity mentioned in the contract.

B.7.1.1. This contract is for an approximation of number of samples based on historical information and estimated race days allotted for the contract period. The Commission does not guarantee the exact number of samples that will be sent to the successful bidding laboratory. The exact numbers are dependent on the actual number of live race days and races conducted, the number of horses in those races, and the number of samples finally collected as determined by OHRC rule and the discretion of the Boards of Stewards.

B.8. Payment Schedule

The laboratory, which is contracted with OHRC, will generate a bill for each racetrack that will be forwarded to the OHRC weekly to verify correctness. The bill will be sent to the racetrack, including all billing documentation as well as instructions to make direct payment to the laboratory within ten (10) days of the receipt of the bill, or as otherwise directed by the OHRC Executive Director.

B.9. Non-Performance

Neither the laboratory nor the State of Oklahoma shall be held liable for non-performance under the terms and conditions of this contract due, but not limited to, government restriction, strike, flood, fire, or unforeseen catastrophe beyond either party's control. Each party shall notify the other in writing of any situation that may prevent performance under the terms and conditions of this contract.

B.10. Discrimination

The laboratory shall not discriminate on the basis of race, color, religion, national origin, ancestry, sex, sexual orientation or handicap in any matter relating to employment.

B.11. Unavailability of Funding

If there is a reduction in the number of race days or live races, OHRC cannot guarantee the continued availability of funding for this contract, notwithstanding the consideration stated above. In the event funds to finance this contract become unavailable, either in full or in part, due to such reductions in race days or live racing, OHRC may terminate the contract or reduce the consideration upon notice in writing to the laboratory. Said notice shall be delivered by certified mail, return receipt requested or in person with proof of delivery. OHRC shall be the final authority as to the availability of funds. The effective date of such contract termination or reduction in consideration shall be specified in the notice as the date of service of said notice, or the actual effective date of the reduction, whichever is later. Provided, that reductions shall not apply to payments made for services satisfactorily competed prior to said effective date. In the event of a reduction in consideration, the laboratory may cancel this contract as of the effective date of the proposed reduction upon the provision of advance written notice to OHRC.

C. SOLICITATION SPECIFICATIONS

C.1. Overview

C.1.1. To enforce the Oklahoma Statute codified as Section 208.5 of Title 3A and Commission Rules of Racing, OHRC is seeking a primary substance testing laboratory for the purpose of analyzing equine urine, equine blood / plasma / serum, and/or other tissue samples taken from horses participating at Commission-licensed race meetings within the State of Oklahoma. Additionally, providing analysis of prohibitive substances discovered within the enclosure of Commission-licensed racetracks which may be determined, or which results may aide in the furtherance of an investigation to be in violation of the Rules of Racing or applicable law.

C.1.2. To be effective and maintain continuity in the detection of prohibitive substance use, the substance-testing laboratory must utilize and employ state-of-the-art equipment, technology, research and development, laboratory security, and competent scientific staff. Chemists from a number of racing jurisdictions have determined that specific testing methods such as instrumentation, LC/MS/MS and immunoassay, provide highly sensitive testing techniques for a wide variety of compounds while mass spectrometry provides the best means of unequivocal identification.

C.1.3. To provide analytic services that meet or exceed industry standards and represents the best value to the OHRC in supporting the enforcement of its Rules of Racing regulations. Evaluation will reconcile the needs of the OHRC, the expectations of the horse racing industry, and available funding.

C.1.4. To be considered in the bid process through OMES/CP at the time the bid is submitted, a substance testing laboratory ***must*** state its willingness to authorize a quality assurance monitor laboratory, as may be determined by the OHRC, to release quality assurance testing results to the OHRC when requested by the OHRC, and the bidding laboratory must, as of the bid date, document specific compliance with the equipment and personnel requirements and ability and willingness to comply with the processes as presented in this solicitation.

C.1.5. Candidate laboratories must be RMTC accredited for comparable analytic capabilities. Laboratories conducting testing of biological samples shall be accredited by the RMTC and approved by the Commission. (325:45-1-19d, Official Testing).

C.2. Calendar

July 1, 2020 through June 30, 2021

C.2.1. Live Race Days – **208**

C.2.1.1. Remington Park (One Remington Place, Oklahoma City, OK 73111); Telephone - (405) 424-1000

C.2.1.1.1. Thoroughbred – **67 days** (August – December)

C.2.1.1.2. Quarter Horse, Paint & Appaloosa – **50 days** (March – June)

C.2.1.2. Will Rogers Downs (20900 S. 4200 Road, Claremore, OK 74019); Telephone - (918) 283-8800

C.2.1.2.1. Thoroughbred – **29 days** (March – May)

C.2.1.2.2. Quarter Horse, Paint & Appaloosa – **28 days** (September-November)

C.2.1.3. Fair Meadows (4145 E. 21st Street, Tulsa, OK 74114); Telephone - (918) 743-7223

C.2.1.3.1. Fair Meet – **34 days** (June- July)

C.3. Statement of Work

C.3.1. For the consideration hereinafter expressed, the Laboratory agrees to provide necessary technical, professional, clerical and other personnel, as well as equipment, facilities and supplies to perform chemical or other analysis on equine urine, blood/plasma/serum and/or other specimens/samples and substances provided to it by the Commission.

C.3.2. Specifically, by way of illustration but not limitation, the Laboratory agrees to perform tests on equine specimens transmitted to it by the Commission in order to determine the absence or presence of permitted threshold substances or other prohibited substances as defined by the Rules of Racing and to report the results of said tests to the Commission promptly and to maintain all necessary records, test results, and data supporting said findings in accordance with the provisions in Section A.20., even if contract has been terminated. Records, test results and supporting data shall be the property of the Commission. As part of investigative research purposes, the Commission may request undisputed records, substances tested, test results and supporting data from previously concluded race meets.

C.3.3. The Laboratory and the Commission agree that the selection of the testing methods shall be the responsibility of the Laboratory, provided that all methods used shall be documented and demonstrably acceptable in the scientific community and admissible in a court of law. Specific instrumental testing methods such as LC/MS, LC-MS/MS, HRMS, immunoassay, etc. provide highly sensitive testing techniques and identification for a wide variety of

substances. Laboratories conducting testing of biological samples shall be accredited by the Racing Medication and Testing Consortium (RMTC) and approved by the Commission. (325:45-1-19 Official Testing).

C.3.4. The laboratory shall provide analytical testing for the Commission by applying any or all of the following testing methods listed in Section C.3.5. The OHRC expects the testing laboratory to apply the most common and most efficient types of tests to its samples.

C.3.5. At the discretion of the laboratory, samples may be prepared for testing a range of substances. Instrumental testing techniques, include, but are not limited to the following:

C.3.5.1. Mass spectrometry (MS) - instrument for separating isotopes, molecules, and molecular fragments according to mass

C.3.5.2. High Performance Liquid Chromatography (HPLC) - instrument for separating different constituents of a substance using high pressure to push solvents through a column for analysis

C.3.5.3. Ultra-performance liquid chromatography (UPLC)

C.3.5.4. Enzyme-linked immunosorbent assay (ELISA) - commonly referred as immunoassays

C.3.5.5. Liquid chromatography / mass spectrometry (LC/MS) - analytical technique that combines the separating of a substance with liquid chromatography and the mass analysis capability of mass spectrometry

C.3.5.6. Tandem mass spectrometry (MS/MS) – two (2) mass spectrometers are coupled together using an additional reaction step to increase their abilities to analyze substance samples

C.3.5.7. Liquid chromatography / tandem mass spectrometry (LC/MS/MS)

C.3.5.8. Liquid Chromatography – High resolution Mass Spectrometry / Mass Spectrometry (LC-HRMS-MS) capable of separating mass fragments at the fourth (4^{th}) or fifth (5^{th}) decimal place

C.3.5.9. Triple quadrupole mass spectrometer (QMS)

C.3.5.10. Thin-Layer Chromatography (TLC) – simple, low cost and can be used as a preliminary analytical method prior to HPLC

C.3.5.11. GC/MS (gas chromatography / mass spectrometry)

C.3.5.12. LC/MS (liquid chromatography / mass spectrometry)

C.3.5.13. HPLC/PDA (high performance liquid chromatography / photo diode array)

C.3.5.14. HPLC/MS (high performance liquid chromatography / mass spectrometry)

C.3.5.15. HS-GC/MS (headspace gas chromatography / mass spectrometry) for blood gas analysis & quantitation of total dissolved carbon dioxide (TCO2)

C.3.5.16. Immunofluorescence assay may be utilized as an adjunct to instrumental testing techniques.

C.3.5.16.1. Enzyme-linked immunosorbent assays (ELISA) test sensitivity must have demonstrated competency for detection of prohibitive substances and substances at physiologic concentrations relevant to pharmacologic administrations. Pooling of samples will not be permitted.

C.3.5.16.2. Immunoassays to be rotated at the discretion of the laboratory in conjunction with industry needs and trends.

C.3.5.16.3. The OHRC expects the testing laboratory to apply immunoassay testing in a manner that is consistent with industry standards and within the means of the laboratory. There are no pre-determined number of immunoassay tests per sample.

C.3.6. Testing procedures are to be applied at the discretion of the laboratory.

C.3.6.1. Compounds for calibration of the mass spectrometer

C.3.6.2. Certified or well characterized standard(s) for the analyte(s) being identified

C.3.6.3. Reagent blanks

C.3.6.4. Negative control samples extracted by the same method as the official sample

C.3.6.5. Extract of the official sample containing suspect analyte(s)

C.3.6.6. Reagent blanks of the same matrix as used for sample standards and controls

C.3.6.7. Blank negative control samples which has been supplemented /spiked with analyte(s) of the suspect substance

C.3.6.8. Certified or well-characterized substance standard for each identified analyte being confirmed

C.3.6.9. Date and time of injection shall be clearly annotated on the data obtained.

C.3.6.10. Specific gravity and pH determination shall be conducted on all urine samples and the results recorded.

C.4. Post-Race Sample Testing Estimation

C.4.1. The number of post-race blood/serum/plasma samples for testing is estimated to be 4,992; and the number of post-race urine samples for testing is estimated to be 4,243.

C.4.1.1. Estimated number of race days per year 208

C.4.1.2. Estimated up to twelve (12) races per day

C.4.1.3. Two (2) horses tested per race on average

C.4.1.4. Post-race blood/serum/plasma samples collected on 100% of horses tested

C.4.1.4.1. (208 race days) x (12 races per day) x (2 horses per race) x (100% blood/serum/plasma samples collected per horse) ≈ 4,992 blood/serum/plasma samples estimated to be tested during a typical year of racing.

C.4.1.5. Post-race urine samples collected up to eighty-five percent (85%) of horses tested

C.4.1.5.1. (208 race days) x (12 races per day) x (2 horses per race) x (85% urine samples collected per horse) ≈ 4,243 urine samples estimated to be tested during a typical year of racing in Oklahoma.

C.4.2. Samples derived from horses in Graded and Listed Stakes that are subjected to a scope of increased analysis as prescribed by the Thoroughbred Owners and Breeders' Association American Graded Stakes (TOBA AGS) Committee

C.4.2.1. Up to ten (10) races (estimated) per year Listed and graded races with two (2) to three (3) horses per race tested

C.4.2.1.1. Twenty-five (25) to thirty (30) horses estimated for increased scope of analysis

C.5. Post-Race Sample Testing

C.5.1. Blood/Plasma/Serum and Urine Samples

C.5.1.1. All post-race samples subjected to instrumental testing analysis.

C.5.1.2. Blood (plasma/serum) and paired urine (if collected) samples may also be used to investigate the presence of a substance or it's metabolite in a sample. This preferably, will be accomplished by applying the most efficient, scientifically valid approaches. LC-HRMS/MS type testing is the most preferred. Results in the urine sample may be used as supplemental evidence regarding a positive confirmation. This is to be applied to the analysis of substances in all categories (1 – 5) under the RCI Drug Categorization Guidelines. OHRC directs the laboratory, if possible, to ascertain whether the sample contained the presence of a prohibited substance in the serum as well as the urine. However, positive finding in either is sufficient and confirmation in both serum and urine is not a requirement. OHRC further understands that certain Category 1 and 2 substances are more than likely not detectable in serum and therefore, urine is the accepted testing medium.

C.5.2. A limited number of ELISA tests, for substances lacking a validated instrumental testing method, may also be proposed.

C.5.2.1. The laboratory shall provide justification for each ELISA test it intends to apply to the OHRC's samples.

C.5.2.2. The laboratory must demonstrate that the sensitivity of proposed ELISA test kits is relevant to the OHRC's regulation of the listed substances.

C.5.2.3. ELISA tests may not be rotated; all proposed tests must be applied to all post-race samples.

C.5.3. Samples may not be pooled.

C.5.4. All samples shall be subjected to the same scope of analysis with respect to threshold substances listed in Chapter 45 of OHRC Rules of Racing.

C.5.5. The post-race testing menu for all tested samples include instrumental testing analysis with a scope of testing encompassing all Controlled Therapeutic Substances (as published in the OHRC's Rules of Racing, Chapter 45) with testing sensitivities at or below regulatory thresholds, and the Thoroughbred Owners and Breeders' Association (TOBA) American Graded Stakes Committee (AGS) requirements for stakes and listed races.

C.5.6. Furosemide testing to determine compliance shall be performed on all blood / plasma / serum samples reported on then Furosemide List. Samples containing more than 100 nanograms of Furosemide per milliliter of plasma/serum shall be reported positive to the OHRC.

C.5.6.1. Samples void of furosemide but indicating furosemide use shall be reported as a violation.

C.6. Pre-Race TCO2 Testing

C.6.1. Blood / Plasma / Serum samples may also be used to investigate the presence of sodium bicarbonate and/or other related blood alkalizing substances to determine the total dissolved carbon dioxide (bicarbonate) level. TCO2 testing is mandatory for TOBA/AGS stakes and listed races.

C.6.2. Blood samples identified for TCO2 testing shall be subjected to analysis on a Beckman EL-ISE instrument using validated methodology. If the laboratory proposes to employ a different instrument, it must demonstrate the proposed instrument is equivalent to, and provides results consistent with, Beckman equipment. (Threshold level of 37.0 mmol/liter established from research using the Beckman EL-ISE instrument).

C.6.3. Samples shall be subjected to analysis within 120 hours of collection from the horse. The laboratory shall not analyze samples >120 hours post-collection. The laboratory shall promptly notify the OHRC of any samples excluded from analysis due to sample age and/or stability.

C.6.4. With current estimates, there may be up to 120 samples (10 horses/race x 12 races) requiring TCO2 testing.

C.7. Enhanced Testing

All blood/plasma/serum and pair urine (if collected) samples shall be tested for androgenic-anabolic steroids. Permissible threshold levels for androgenic-anabolic steroids are listed in Chapter 45 (OHRC Rules of Racing).

C.8. Out-of-Competition Testing

Samples will be tested to a scope of analysis as described by the OHRC.

C.8.1. Samples to be tested for anabolic steroids, β-2 adrenergic substances (clenbuterol, albuterol, ractopamine, zilpaterol, etc.) and other prohibitive substances.

C.9. Veterinarian &/or Steward List Testing

Samples (blood +/- urine) shall be subjected to targeted testing analysis (consistent with analytic methods applied to post-race samples as described in Section II) for NSAIDS, corticosteroids, local anesthetics, anabolic steroids, bronchodilators).

C.10. Post-Mortem Tissue Sample Testing

C.10.1. Tissue samples collected from necropsy of a horse that died as a result of a racing fatality or unknown cause may be tested.

C.10.2. Tissue samples collected and submitted include synovial fluid, eye, kidney, blood, urine, liver, muscle tissue, etc.

C.11. Targeted Analysis for Administered Substances

At the discretion of the OHRC, samples may be submitted for targeted analysis for the determination of one or more specific substance(s). The samples submitted shall be relevant to the OHRC's regulations. All samples submitted for targeted analysis will be submitted by the OHRC.

C.12. Non-Biological Substances

C.12.1. For substances bearing content labels, the laboratory shall perform analysis consistent with the RMTC Protocol for Verification of Label Ingredients.

C.12.2. For substances lacking a list of label ingredients, the laboratory shall perform analysis consistent with the RMTC Unknown Sample Protocol.

C.13. Reporting and Notifications

C.13.1. Any reported positives within RCI Category V, IV and III will require appropriate plasma/serum quantitation levels within the levels set forth in the Listed Thresholds for Thoroughbreds (325:45-1-6.1) and Listed Thresholds for Quarter Horses, Paints and Appaloosas (325:45-1-6.2). Laboratory shall maintain equipment (including LC/MS, LC-MS/MS, HRMS, GC-MS) in sufficient quantity to meet reporting requirements.

C.13.2. The Laboratory shall complete the initial testing of the samples submitted within seventy-two (72) hours, or three (3) working days, of receipt of samples. The Laboratory shall provide the results of testing in writing to the Oklahoma Horse Racing Commission (OHRC), E-mail addresses and contacts for reporting will be provided to the lab.

C.13.2.1. Futurity and Derby trial testing – Post race samples from trial races will be delivered within twenty-four (24) hours of collection to laboratory. Testing must be completed within eight (8) days and results reported immediately.

C.13.3. In no event will the Laboratory be required to complete the analysis for the Commission sooner than the seventy-two (72) hours or three (3) working days as provided in Section C.13.2.

C.13.4. All necessary confirmatory testing shall be completed by the Laboratory within an additional five (5) working days, and the results shall be reported by the Laboratory as required by the provisions of this solicitation. The OHRC proposes that negative results be reported in seventy-two (72) hours of receipt. An additional five (5) working days

to complete the confirmation of suspect samples allows the laboratory eight (8) working days to complete testing. Any request for additional time is provided for in OHRC Rules of Racing.

C.13.5. The time limits for the completion of testing may be extended by the Executive Director of the OHRC upon receipt of a written request from the Laboratory for a specific extension of time stating the reasons for the need for such extension.

C.13.6. An Affidavit, correct in its information regarding the sample and test result, shall be provided by the Laboratory via e-mail transmission to the OHRC within twenty-four (24) hours of the Laboratory's determination of a positive test result utilizing the attached OHRC approved form. Positive sample affidavits shall be followed by original documentation delivered by mail. This Affidavit must be notarized. In the event that the notarization becomes an unnecessary process and can be eliminated, the OHRC will promptly vacate the requirement and the laboratory will be notified.

C.13.7. All costs of the required notifications to the OHRC shall be the responsibility of the Laboratory.

C.13.8. All reports will be held in strict confidentiality by the laboratory, which shall make its report available only to the Commission, unless otherwise instructed.

C.13.9. Laboratory must deliver within seven (7) days of OHRC's request of a complete data packet for a given sample.

C.14. Laboratory Equipment

C.14.1. Equipment Requirements:

C.14.1.1. Equipment for liquid-liquid solid phase extraction or comparable method

C.14.1.2. Gas chromatographs/mass spectrometer equipped with flame ionization, electron capture and thermionic specific (nitrogen phosphorous) detectors, computerized data analysis system and computer searchable libraries

C.14.1.3. High performance liquid chromatographs equipped with ultraviolet absorption, fluorescence detectors, diode array, mass spectrometric devices and detectors; the alternate LC/MS – GC/MS techniques are acceptable substitutes

C.14.1.4. Ultraviolet-visible spectrophotometer

C.14.1.5. Ion-specific electrolyte analyzer

C.14.1.6. Equipment to utilize other sensitive testing techniques such as enzyme immunoassay and/or fluoroimmunoassay for such hard to detect substances such as buprenorphine or sufentanil. The bidding Laboratory ***should*** describe equipment in its laboratory that would be used to detect and confirm such substances in equine urine and/or blood / plasma / serum samples using these methodologies.

C.14.1.7. Equipment for bidder laboratory must meet the above specifications or be more modern and technologically advanced than those listed above.

C.14.1.8. Include major equipment (model, manufacturer, use or function) and instruments, including GC-MS, LC-MS, GC, spectrophotometers, immunoassay instruments (for EPO detection, specifically) and include manufacturer, model, detector types, service contracts, and peripherals. Applicable instruments should be listed as systems (i.e., list components and peripherals of each analytical system together).

C.15. Personnel Requirements

C.15.1. Laboratory Personnel Requirements:

C.15.1.1. Laboratory Director

C.15.1.2. Analytical Chemist or other similarly trained scientist with a Ph. D.

C.15.1.3. Consulting Pharmacologist/Toxicologist is preferable

C.15.1.4. Consulting Equine Veterinarian is preferable

C.15.1.5. Technical Drug Analysis Staff

C.15.2. Laboratory Experience Requirements:

C.15.2.1. Not less than three (3) years of analytical testing of equine urine and blood samples. A year shall mean one (1) calendar year during which a minimum of 1,000 such samples were tested; or

C.15.2.2. Experience in drug testing of a character and for a length of time sufficient, in the opinion of the Commission, to be substantially equivalent to requirements of the statement of work.

C.15.2.3. The Laboratory Director and senior chemists shall be professional members in good standing of the AORC and have, relevant to their responsibilities, a scientific degree in one or more of the following fields: chemistry, pharmacology, toxicology, veterinary science, or pharmaceutical science.

C.16. Facility

C.16.1. Laboratory shall have adequate, secure, and sample-appropriate storage space for the Commission's official samples to maintain chain of custody and chemical integrity. The laboratory shall have adequate storage space for testing related supplies and lockable file cabinets for confidential materials including, but not limited to test results, documentation packets, evidentiary materials, and correspondence with the Commission.

C.16.2. The laboratory shall maintain its facilities to satisfy state and/or federal OSHA requirements and the standards set forth through A2LA or similar accreditation.

C.16.3. The laboratory shall have all necessary equipment, instrumentation, and expendables as described herein or as necessary to perform all listed duties of this solicitation.

C.16.4. The Laboratory shall have and maintain all necessary and applicable federal and state licenses and permits to operate as a drug-testing laboratory.

C.16.5. The laboratory shall provide documentation that its facility is OSHA, ISO 17025, and RMTC compliant; and local code compliant.

C.16.5.1. The laboratory shall disclose any deficiencies noted on the most recent accreditation (or re-accreditation) site inspection and provide documentation that said deficiencies have been remedied.

C.16.5.2. The laboratory shall disclose if its accreditation has ever been suspended, revoked, or otherwise sanctioned. The laboratory shall provide the details of any sanction and its resolution.

C.16.6. Quality Control and Quality Assurance

C.16.6.1. The laboratory shall participate in AORC and RMTC external quality assurance programs (EQAP). The results of the laboratory's analysis of single or double-blinded proficiency samples shall be disclosed to the OHRC within thirty (30) days of its receipt of the EQAP's report. For any testing deficiencies, the laboratory shall provide documentation of the correction plan to be implemented, and a timeline for implementation. For any other EQAP(s) in which the laboratory participates, the laboratory shall provide all results, and corrective action plans as required. The laboratory may not substitute other EQAPs for the AORC and/or RMTC programs.

C.16.6.2. The laboratory shall routinely perform analysis of internal blind samples of substances of regulatory interest at relevant concentrations. The laboratory shall notify the OHRC within five (5) business days of a failed analysis and provide a corrective action plan (and timeline) for remedying the deficiency. The laboratory shall provide the OHRC with quarterly reports of EQAP and Internal Blind sample analysis, inclusive of the analytes detected.

C.16.6.3. The laboratory shall provide a full description of its internal quality control measures in its Response and affirm that it has a designated, qualified Quality Assurance/Quality Control officer having the requisite authority to remedy deficiencies identified.

C.17. Other Specifications and Stipulations

C.17.1. Affiliations Accreditations and Government Furnished Resources

C.17.2. RMTC

C.17.3. AORC

C.17.4. For Oklahoma Laboratories: Bureau of Narcotics Certification to handle narcotics;

C.17.5. For out-of-state laboratories: Compliance with all state and federal requirements to handle narcotics; and

C.17.6. Association of Racing Commissioners International (ARCI) Uniform Drug Testing and Quality Assurance Program Member Laboratory, or comparable quality assurance program as determined by the OHRC Other Specifications and Stipulations

C.17.7. The laboratory must list all the professional organizations related to equine substance testing of which it is a member including but not limited to any accreditation it currently holds.

C.17.8. AALA (American Association of Laboratory Accreditation) -accreditation to ISO 17025 Standards

C.17.9. A2LA / ISO-17025 or Equivalent Accreditations

C.17.10. Scope of each A2LA / ISO-17025 or Equivalent Accreditations

C.17.11. Laboratory accreditation is a requirement. Equine testing accreditations are not a requirement, however, will be considered as an evaluation criteria.

C.17.12. Performance, Quality & Timeliness Requirements: The Laboratory must be willing to make available to the OHRC appropriate professional laboratory personnel to appear as expert witness in hearing matters or other related circumstances when requested by the Commission. Compensation to the Laboratory personnel for such

appearance may be made by the OHRC in accordance with provisions of the Oklahoma State Travel Reimbursement Act.

C.17.13. Provide Historical Data for last two (2) calendar years.

C.17.13.1. Number of equine samples tested in the last two (2) years

C.17.13.2. Number of positive equine samples reported in the last two (2) years

C.17.13.3. Number of positive equine samples upheld by Commissions and/or regulatory body

C.17.13.4. Number of positive equine samples overturned by Commissions and/or regulatory body

C.17.13.5. List of equine drug testing contracts and bids completed. Name of jurisdiction and contact, including contracts awarded and cancelled within the last six (6) years.

C.17.14. The solicitation response should include disclosure of any competing business interests or conflicts-of-interest in any laboratory personnel having purchasing authority or the ability to determine analytic practices, if any.

C.18. Shipping and Supply Requirements

C.18.1. The laboratory shall provide to the Commission staff all items necessary to collect, label, process, store, and ship samples, inclusive of: blood collection tubes, blood collection needles, blood/plasma/serum transport tubes, urine collection cups, primary and split sample urine specimen containers with screw caps, non-sterile exam gloves, sequentially numbered barcoded sample ID tags, tamper-proof security tape, shipping containers, security locks, coolants, padding/absorbent fill, secondary watertight receptacles, and shipping labels. The laboratory shall bear all costs associated with the shipment and delivery of supplies to Commission staff.

C.18.2. The laboratory shall furnish all shipping containers, as approved by the Commission, for the samples.

C.18.3. The laboratory shall pay the charges for return shipment of the empty shipping containers from the laboratory to the submitting racetrack.

C.18.4. The OHRC shall furnish the shipping container seals.

C.18.5. The samples will be shipped to the laboratory by common carrier or other methods as mutually agreed.

C.18.6. The Commission will bear the responsibility of bar-coding each sample, packing and delivering samples to a common carrier.

C.18.7. The laboratory shall employ a system of sample identification and history. The system shall not identify the horse, its owner or it's trainer from which the sample was taken.

D. EVALUATION

D.1. Best Value

Proposals will be evaluated on the "best value" determination in accordance with Title 74, §85. The best value criteria for this proposal is listed below in Sections D.1.1. – D.1.4. The State reserves the right to reject any or all evaluation committee recommendations. The OTC reserves the right to accept or reject any or all proposals or any portion thereof.

D.1.1. Operational Costs (Section H.)

D.1.1.1. Cost per Sample (Section H.1.1.1.)

D.1.1.2. Additional Testing (Section H.1.1.5. – H.1.1.9.)

D.1.2. Quality of Proposal and Technical Competency (Section C.3. – C.3.18.)

D.1.2.1. Equine Industry Experience (Sections E.2.2. – E.2.3.)

D.1.2.1.1. Director's Education and Qualifications (Section E.2.2.1.)

D.1.2.1.2. Staff Education and Qualifications (Sections E.2.3.1. – E.2.3.5.)

D.1.2.2. Contract History for the last six (6) years (Section E.2.4.)

D.1.2.2.1. Bidder's Industry and Program Experience and Record of Successful Past Performance of Similar Scope and Complexity. (Please refer to Sections C.17.13.1. – C.17.13.5.)

D.1.2.3. Ability to apply validated methodologies for the detection of substances identified in the Commission-Sanctioned Threshold Directive (Please refer to Attachment A – *OHRC Permitted Substance Thresholds September 2019*). (Section E.2.5.)

D.1.2.4. Accreditation (Section E.2.6.)

D.1.3. Bidder's Facilitation of Data Transfer (Section E.2.7.)

D.1.3.1. Preliminary Testing (Section C.13.2.)

D.1.3.2. Confirmation/Additional Analysis (Section C.13.4.)

D.1.3.3. Reporting Availability (Section C.13.6.)

D.1.4. Anticipated Acceptance by User Groups (Section E.2.8.)

D.1.4.1. Letter of Review by Official Quarter Horse Representative (Section E.2.8.1.)

D.1.4.2. Letter of Review by Official Thoroughbred Representative (Section E.2.8.2.)

D.2. Non-Responsive Proposals

Proposals which do not meet all mandatory requirements of this RFP and/or which fail to provide all required information, documents or materials may be deemed as non-responsive and not be evaluated and considered for award.

E. INSTRUCTIONS TO BIDDER

E.1. Proposal Format

E.1.1. Supplier is to submit two (2) complete copies of their bid response on two (2) separate USB/Flash Drives which includes the completed proposal, including the scanned images of the completed/signed OMES forms. USB/Flash Drives can be Word, Excel, or PDF format, but must be an unprotected document. ***This requirement overrides hard copy submittal requirements of A.2.4 of the General Provisions.***

E.1.2. Faxed or emailed responses will not be accepted. Hard copies of the solicitation are not needed.

E.1.3. Responses to this RFP should be in clear and concise language suitable for inclusion in a contract with the State.

E.2. Proposal Content

At a minimum, suppliers are to prepare and compile all information for the RFP in the order listed below. Failure to provide a response to each of the items listed below may cause a proposal to be deemed non-responsive and not evaluated or considered for contract award.

E.2.1. Submit proposal for Sections C.3. through C.18. Bidder should address each section within Section C, even if it is to simply acknowledge bidder will comply with each section.

E.2.1.1. The bidding Laboratory should describe equipment per Section C.14.16.

E.2.2. Bidder should describe staff experience in the detection and confirmation of substances in equine urine and/or blood samples using the equipment listed in the Laboratory Equipment Requirements (Section C.14.) in response to Laboratory Personnel Requirements (Section C.15.).

E.2.2.1. Résumé's for the listed professionals listed in Section C.15.1. should be provided to the OHRC.

E.2.3. In Response to the Laboratory Experience Requirements (Section C.15.2.), the following shall be submitted:

E.2.3.1. The responding laboratory should provide relevant biographical information (education, degrees achieved, experience, scientific publications, ongoing research, and industry relations/outreach) for the laboratory director, senior chemists, and data review analysts.

E.2.3.2. The responding laboratory should provide an organizational chart and job descriptions for all employees performing contracted services relevant to the OHRC's samples.

E.2.3.3. The responding laboratory should provide documentation of the training program for all employees performing contract services relevant to the OHRC's samples. This documentation should include a description of ongoing proficiency testing and performance review—including a summary of internal proficiency performance, any deficiencies noted, corrective action plans (CAPAs) applied, and CAPAs outcomes.

E.2.3.4. The laboratory should identify and provide contact information for a Key Contact Person to the OHRC. This individual shall be available during standard business hours (8AM – 5PM CST) as well as evenings, weekends, and holidays. The laboratory should also identify and provide contact information for a designated back-up contact for the Commission.

E.2.3.5. The laboratory should describe its succession plan for key laboratory staff.

E.2.3.5.1. Unscheduled changes in key laboratory staff (i.e., laboratory director, laboratory manager, commission key contact, quality control officer, and senior chemist) determined to be unacceptable by the OHRC may result in early termination of the contract.

E.2.4. Bidder should provide historical data for the last six (6) years (Section C.17.13.1. – C.17.13.5.).

E.2.5. The laboratory should provide documentation demonstrating competency in instrumental testing techniques and the ability to detect the presence of prohibitive substances (Section C.3.5.).

E.2.6. List of Accreditation and Scope of Accreditation (Section C.17.1 – C.17.11.).

E.2.7. Bidder should document acknowledgement of Reporting and Notification requirements pertaining to Preliminary Testing (C.13.2.), Confirmation/Additional Analysis (C.13.4.) and Reporting Availability (C.13.6.).

E.2.8. Bidder should provide Letters of Review to demonstrate Anticipated Acceptance by User Groups (Section D.1.4.):

E.2.8.1. Official Quarter Horse Representative

E.2.8.2. Official Thoroughbred Representative

F. CHECKLIST

F.1. Listed below is a checklist of items that are to be completed and returned with the proposal. This is not an all-inclusive list and it is the Supplier's responsibility to ensure that they submit all required and requested documentation:

F.1.1. OMES Form CP076 – Responding Bidder Information

F.1.2. OMES Form CP004 – Certification for Competitive Bid and/or Non-Collusion

F.1.3. Proof of Workers' Compensation Insurance

F.1.4. Signed amendments, if applicable

F.1.5. OMES Vendor/Payee Form, if applicable

F.1.6. Response to Section E.2. – Proposal Content

F.1.7. Response to Section H. – Price and Cost

F.1.8. Two (2) complete copies of bid response on two (2) separate USB/Flash Drives

G. OTHER

G.1. Questions

G.1.1. All questions regarding this solicitation must be submitted in writing and are to be emailed no later than January 27, 2020 at 3:00 PM Central Standard Time. Questions are to be emailed to Stephanie.Beshears@omes.ok.gov. Questions received after this date will not be answered. If any questions are received, an amendment to this solicitation will be posted on our website after this deadline listing all questions received and their answers.

G.1.2. Any communication regarding this solicitation must be sent to the Contracting Officer listed above. Failure to do so, (contacting the agency directly) may result in your proposal being deemed as non-responsive. Please be sure to reference the solicitation number when emailing questions.

G.2. Informational Attachments

G.2.1. OHRC Permitted Substance Thresholds September 2019 – Attachment A

G.2.2. Oklahoma Horse Racing Commission Chain of Custody Form – Attachment B

G.2.3. Racing Calendar – Attachment C

G.2.4. ARCI Uniform Classification of Foreign Substances – Attachment D

G.2.5. 2019 AGSC Drug Testing List – Attachment E

G.2.6. ARCI Endogenous, Dietary, or Environmental Substances Schedule – Attachment F

G.2.7. Please reference this link to access the following attachment below: https://www.ohrc.ok.gov/the-commission/rules-regs

G.2.7.1. Oklahoma Horse Racing Commission, Rules of Racing

G.2.7.2. Oklahoma Statutes, Title 3A, The Oklahoma Horse Racing Act

G.2.7.3. Oklahoma Horse Racing Commission Publications

H. PRICE AND COST

H.1. In consideration of the professional services listed above in Sections C.3. through C.18. to be rendered by the laboratory, the OHRC hereby agrees to pay the flat price amount per sample.

H.1.1. The proposed flat price sample applies to each sample number submitted (urine and blood/plasma/serum).

H.1.1.1. Paired-post race samples (blood & urine)

H.1.1.2. Blood-only post-race samples

H.1.1.3. Paired (blood & urine) and blood-only post-race samples derived from horses in Graded and Listed Stakes

H.1.1.4. Retention time and storage of samples

H.1.1.5. Out-of-competition testing

H.1.1.6. TCO2 Testing

H.1.1.7. Veterinary &/or Stewards List testing

H.1.1.8. Post-mortem samples for investigative research

H.1.1.9. Analysis of confiscated, or otherwise acquired, substances

H.1.2. Operational Cost to the Commission

H.1.2.1. Cost per sample without pooling:

H.1.2.1.1. Year 1 $ _____

H.1.2.1.2. Year 2 $ _____

H.1.2.1.3. Year 3 $ _____

H.1.2.1.4. Year 4 $ _____

H.1.2.1.5. Year 5 $ _____

H.1.2.2. Additional Testing

H.1.2.2.1. Year 1 $ _____

H.1.2.2.2. Year 2 $ _____

H.1.2.2.3. Year 3 $ _____

H.1.2.2.4. Year 4 $ _____

H.1.2.2.5. Year 5 $ _____

H.1.3. The OHRC will defer to the laboratory regarding the number of Immunoassay and instrumentation tests conducted and for which substances the lab tests. Hopefully, by way of laboratory determined rotation, the OHRC will rely upon the laboratory to implement the most cost effective and productive equine testing possible.

H.1.4. The Bid Specs require that at a minimum, the laboratory conduct certain testing using suitable test to meet TOBA/AGS requirements. The examples provided such as immunoassay and instrumental testing are to be utilized and confirm quantification for each sample at the discretion of the laboratory in accordance with the latest industry standards and practices. Minimum testing will test for all threshold substances list in Chapter 45 of OHRC Rules of Racing. In addition, TOBA/AGS quantification testing of graded stakes and listed races is required.

H.1.5. Furosemide quantitation is a current practice applied by the existing laboratory. The OHRC has by rule, established a plasma threshold of 100 ng/ml and a positive report is required for any values greater than 100 Ng/ml of plasma.

H.1.6. TCO2 testing is required for samples obtained from horses in listed and graded stake races under TOBA/AGS requirements.

H.1.7. Phenylbutazolidin will require testing and quantitation by instrumental testing or superior method.

H.1.8. The pricing amount will apply to all testing and confirmation testing applied to each sample submitted. A sample submitted may consist of urine, blood/plasma/serum or blood/plasma/serum only as stated in

ATTACHMENT A

OHRC Permitted Substance Thresholds (September 2019)

Listed Thresholds for Thoroughbreds

Chapter 45-1-6.1

Non-steroidal anti-inflammatories (NSAID)		
Diclofenac	5 ng/ml	plasma or serum
Firocoxib	20 ng/ml	plasma or serum
Flunixin	20 ng/ml	plasma or serum
Ketoprofen	2 ng/ml	plasma or serum
Phenylbutazone	2 ug/ml	plasma or serum
Corticosteroids		
Betamethasone	10 pg/ml	plasma or serum
Dexamethasone	5 pg/ml	plasma or serum
Isoflupredone	100 pg/ml	plasma or serum
Methylprednisolone	100 pg/ml	plasma or serum
Prednisolone	1 ng/ml	plasma or serum
Triamcinolone Acetonide	100 pg/ml	plasma or serum

The presence of more than two permitted NSAIDS is prohibited, or
The presence of more than two permitted corticosteroids is prohibited

Other substances		
Acepromazine	10 ng/ml	urine
Albuterol	1 ng/ml	urine
Butorphanol (total)	300 ng/ml	urine
or Butorphanol (free)	2 ng/ml	plasma or serum
Cetirizine	6 ng/ml	plasma or serum
Cimetidine	400 ng/ml	plasma or serum
Clenbuterol	140 pg/ml	urine
or Clenbuterol	LOD	plasma or serum
Dantrolene (5-hydroxydantrolene)	100 pg/ml	plasma or serum
Detomidine	1 ng/ml	plasma or serum
Dimethyl Sulfoxide (DMSO)	10 ug/ml	plasma or serum
Furosemide	100 ng/ml	plasma or serum
Glycopyrrolate	3 pg/ml	plasma or serum
Guaifenesin	12 ng/ml	plasma or serum
Lidocaine (total 30H-lidocaine)	20 pg/ml	plasma or serum
Mepivacaine	10 ng/ml	urine
or Mepivacaine	LOD	plasma or serum
Methocarbamol	1 ng/ml	plasma or serum
Omeprazole (omeprazole sulfide)	10 ng/ml	plasma or serum
Procaine penicillin	25 ng/ml	plasma or serum
Ranitidine	40 ng/ml	plasma or serum
Xylazine	200 pg/ml	plasma or serum
Androgenic-anabolic steroids		
Boldenone (all genders)	25 pg/ml	plasma or serum
Boldenone (fillies, mares, geldings)	1 ng/ml	urine
Boldenone (intact males, ridglings)	15 ng/ml	urine
Nandrolone (all genders)	25 pg/ml	plasma or serum
Nandrolone (fillies, mares, geldings)	1 ng/ml	urine
Nandrolone (intact males, ridglings)	45 ng/ml	urine
Testosterone (fillies, mares, geldings)	100 pg/ml	plasma or serum
Testosterone (nonpregnant fillies & mares)	55 ng/ml	urine
Testosterone (geldings)	20 ng/ml	urine
Testosterone (intact males & pregnant females)	Not regulated	
Other		
TCO_2	37.0 mmol/liter	blood
Altrenogest (Fillies and Mares)	Allowed	Plasma or serum or urine
Altrenogest (Intact males, ridglings and geldings)	LOD	Plasma or serum or urine

Listed Thresholds for Quarter Horses, Paints and Appaloosas

Chapter 45-1-6.2

Non-steroidal anti-inflammatories (NSAID)		
Diclofenac	5 ng/ml	plasma or serum
Firocoxib	20 ng/ml	plasma or serum
Flunixin	20 ng/ml	plasma or serum
Ketoprofen	2 ng/ml	plasma or serum
Phenylbutazone	2 ug/ml	plasma or serum
Corticosteroids		
Betamethasone	10 pg/ml	plasma or serum
Dexamethasone	5 pg/ml	plasma or serum
Isoflupredone	100 pg/ml	plasma or serum
Methylprednisolone	100 pg/ml	plasma or serum
Prednisolone	1 ng/ml	plasma or serum
Triamcinolone Acetonide	100 pg/ml	plasma or serum

The presence of more than two permitted NSAIDS is prohibited, or
The presence of more than two permitted corticosteroids is prohibited

Other substances		
Acepromazine	10 ng/ml	urine
Albuterol	*LOD*	*any sample*
Butorphanol (total)	300 ng/ml	urine
or Butorphanol (free)	2 ng/ml	plasma or serum
Cetirizine	6 ng/ml	plasma or serum
Cimetidine	400 ng/ml	plasma or serum
Clenbuterol	*LOD*	*any sample*
Dantrolene (5-hydroxydantrolene)	100 pg/ml	plasma or serum
Detomidine	1 ng/ml	plasma or serum
Dimethyl Sulfoxide (DMSO)	10 ug/ml	plasma or serum
Furosemide	100 ng/ml	plasma or serum
Glycopyrrolate	3 pg/ml	plasma or serum
Guaifenesin	12 ng/ml	plasma or serum
Lidocaine (total 30H-lidocaine)	20 pg/ml	plasma or serum
Mepivacaine	10 ng/ml	urine
or Mepivacaine	LOD	plasma or serum
Methocarbamol	1 ng/ml	plasma or serum
Omeprazole (omeprazole sulfide)	10 ng/ml	plasma or serum
Procaine penicillin	25 ng/ml	plasma or serum
Ranitidine	40 ng/ml	plasma or serum
Xylazine	200 pg/ml	plasma or serum
Androgenic-anabolic steroids		
Boldenone (all genders)	25 pg/ml	plasma or serum
Boldenone (fillies, mares, geldings)	1 ng/ml	urine
Boldenone (intact males, ridglings)	15 ng/ml	urine
Nandrolone (all genders)	25 pg/ml	plasma or serum
Nandrolone (fillies, mares, geldings)	1 ng/ml	urine
Nandrolone (intact males, ridglings)	45 ng/ml	urine
Testosterone (fillies, mares, geldings)	100 pg/ml	plasma or serum
Testosterone (nonpregnant fillies & mares)	55 ng/ml	urine
Testosterone (geldings)	20 ng/ml	urine
Testosterone (intact males & pregnant females)	Not regulated	
Other		
TCO_2	37.0 mmol/liter	blood
Altrenogest (Fillies and Mares)	Allowed	Plasma or serum or urine
Altrenogest (Intact males, ridglings and geldings)	LOD	Plasma or serum or urine

ATTACHMENT B

OKLAHOMA HORSE RACING COMMISSION
CHAIN OF CUSTODY FORM

Racetrack: _____ City: _____

THIS FORM IS TO BE RETURNED TO THE BOARD OF STEWARDS WITHIN FORTY-EIGHT (48) HOURS OF SHIPMENT TO THE THE LABORATORY BY THE PERSON DEPOSITING THE BOX(ES) WITH THE SHIPPING AGENT. THE STEWARDS SHALL FORWARD THIS FORM TO THE OHRC LAW ENFORCEMENT DIVISION UPON RECEIPT.

Test Barn Samples from the following Race Date(s):

_____ MM/DD/YYYY _____ MM/DD/YYYY _____ MM/DD/YYYY _____ MM/DD/YYYY _____ MM/DD/YYYY

DATE	TIME	OFFICIAL TITLE	PRINTED NAME	SIGNATURE
_____	_____	Official Veterinarian	_____	
_____	_____	OHRC Representative	_____	
_____	_____	Shipping Agent Rep	_____	

Name of Shipping Agent Company: _____

Shipping Destination: _____

Additional Information: _____

_____

Sample Box Seal Number: _____ **Box Number:** _____

ATTACHMENT C

Final Approval 10/17/19

OKLAHOMA HORSE RACING COMMISSION

2800 N. Lincoln Boulevard, Suite 220, Oklahoma City, OK 73105

ALLOTTED
LIVE RACE DAYS FOR CY 2020

REMINGTON PARK, OKLAHOMA CITY…….117 LIVE PARI-MUTUEL RACE DAYS

Global Gaming RP, LLC d/b/a Remington Park; Scott Wells, President and General Manager; Matt Vance, Vice President of Operations; One Remington Place, Oklahoma City, OK 73111; (405) 424-1000

QUARTER HORSE, APPALOOSA AND PAINT RACE MEETING
[50 Race Days]

March 6, 7, 8, 12, 13, 14, 15, 19, 20, 21, 22, 26, 27, 28, 29
April 2, 3, 4, 5, 9, 10, 11, 16, 17, 18, 19, 23, 24, 25, 26, 30
May 1, 2, 3, 7, 8, 9, 10, 14, 15, 16, 17, 21, 22, 23, 24, 25, 28, 29, 30

THOROUGHBRED RACE MEETING
[67 Race Days]

August 21, 22, 26, 27, 28, 29
September 2, 3, 4, 5, 7, 10, 11, 12, 16, 17, 18, 19, 23, 24, 25, 26, 27,
October 1, 2, 3, 7, 8, 9, 10, 14, 15, 16, 17, 21, 22, 23, 24, 28, 29, 30, 31
November 4, 5, 6, 7, 11, 12, 13, 14, 18, 19, 20, 21, 23, 24, 27, 28
December 2, 3, 4, 5, 7, 8, 11, 12, 13

WILL ROGERS DOWNS, L.L.C., CLAREMORE……57 LIVE PARI-MUTUEL RACE DAYS

Cherokee Nation; Mark Enterline, Consulting General Manager, 20900 S. 4200 Road, Claremore, OK 74019; 918/283-8800

THOROUGHBRED RACE MEETING
[29 Race Days]

March 16, 17, 23, 24, 25, 30, 31
April 1, 6, 7, 8, 13, 14, 15, 20, 21, 22, 27, 28
May 2, 4, 5, 9, 11, 12, 16, 18, 19, 23

QUARTER HORSE, PAINT AND APPALOOSA RACE MEETING
[28 Race Days]

September 5, 6, 11, 12, 13, 18, 19, 20, 25, 26, 27
October 2, 3, 4, 9, 10, 11, 16, 17, 18, 23, 24, 25
November 6, 7, 8, 13, 14

REQUESTED
LIVE RACE DAYS FOR CY 2020
[continued]

FAIR MEADOWS AT TULSA
Tulsa County Public Facilities Authority; Amanda Blair, Chief Operating Officer, 4145 E. 21 Street, Tulsa, OK 74114; (918) 744-1113

TULSA STATE FAIR.....34 LIVE PARI-MUTUEL RACE DAYS

THOROUGHBRED, QUARTER HORSE, PAINT AND APPALOOSA RACE MEETING
[34 Race Days]

June 4, 5, 6, 7, 11, 12, 13, 14, 17, 18, 19, 20, 21, 25, 26, 27, 28
July 2, 3, 4, 5, 8, 9, 10, 11, 12, 16, 17, 18, 19, 22, 23, 24, 25

REQUESTED TOTAL NUMBER OF CY 2020 LIVE RACE DAYS

Live Race Days Except Fair Meets	**174**
Live Days – Fair Meets	**34**
Total Live Race Days	**208**

ATTACHMENT D

DRUG TESTING STANDARDS AND PRACTICES PROGRAM.

Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule.

January, 2019 (V.14.0)

Association of Racing Commissioners International
2365 Harrodsburg Road- B450
Lexington, Kentucky, USA
www.arci.com

Preamble to the Uniform Classification Guidelines of Foreign Substances

The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991.

"The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered. These drug classifications will be reviewed frequently and new drugs will be added when appropriate."

Notes Regarding Classification Guidelines

- Where the use of a drug is specifically permitted by a jurisdiction, then the jurisdiction's rule supersedes these penalty guidelines.
- Regulators should be aware that a laboratory report may identify a drug only by the name of its metabolite. The metabolite might not be listed here, but the parent compound may be.
- These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses.
- The facts of each case are different and there may be mitigating circumstances that should be considered.
- These drug classifications will be reviewed periodically. New drugs will be added or some drugs may be reclassified when appropriate.
- Racing Commissioners International (RCI) and/or the Racing Medication and Testing Consortium (RMTC) should be consulted for found substances or drugs not included in these guidelines and treated as Class 1 violations warranting a Class A penalty unless otherwise advised.

Classification Criteria

The RCI Drug Classification Scheme is based on 1) pharmacology, 2) drug use patterns, and 3) the appropriateness of a drug for use in the racing horse. Categorization is decided using the following general guidelines:

- ***Pharmacology***. Drugs that are known to be potent stimulants or depressants are placed in higher classes, while those that have (or would be expected to have) little effect on the outcome of a race are placed in lower classes.
- ***Drug Use Patterns***. Some consideration is given to placement of drugs based on practical experience with their use and the nature of positive tests. For example, procaine positives have in the past been associated primarily with the administration of procaine penicillin, and this has been taken into consideration in the placement of procaine into Class 3 instead of Class 2 with other injectable local anesthetics.
- ***Appropriateness of Drug Use***. Drugs that clearly are intended for use in equine therapeutics are placed in lower classes. Drugs that clearly are not intended for use in the horse are placed in higher classes, particularly if they might affect the outcome of a race. Drugs that are recognized as legitimately useful in equine therapeutics but could affect the outcome of a race are placed in the middle or higher classes.

The list includes most drugs that have been reported as detected by racing authority laboratories in the United States, Canada, the United Kingdom and other Association of Official Racing Chemists (AORC) laboratories, but does not include those which would seem to have no effect on the performance of the horse or drug detectability. For example, it does not include antibiotics, sulfonamides, vitamins, anthelmintics, or pangamic acid, all of which have been reported.

The list contains many drugs that have never been reported as detected. Usually, these are representatives of chemical classes that have the potential for producing an effect, and in many cases, for which at least one drug in that chemical class has been reported.

Most drugs have numerous effects, and each was judged on an individual basis. There are instances where there is a rather fine distinction between drugs in one category and those in the next. This is a reflection of a nearly continuous spectrum of effects from the most innocuous drug on the list to the drug that is the most offensive.

Classification Definitions

- **Class 1**: Stimulant and depressant drugs that have the highest potential to affect performance and that have no generally accepted medical use in the racing horse. Many of these agents are Drug Enforcement Agency (DEA) schedule II substances. These include the following drugs and their metabolites: Opiates, opium derivatives, synthetic opioids and psychoactive drugs, amphetamines and amphetamine-like drugs as well as related drugs, including but not limited to apomorphine, nikethamide, mazindol, pemoline, and pentylenetetrazol. Though not used as therapeutic agents, all DEA Schedule 1 agents are included in Class 1 because they are potent stimulant or depressant substances with psychotropic and often habituative actions. This class also includes all erythropoietin stimulating substances and their analogues.

- **Class 2**: Drugs that have a high potential to affect performance, but less of a potential than drugs in Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drugs in this class include: psychotropic drugs, certain nervous system and cardiovascular system stimulants, depressants, and neuromuscular blocking agents. Injectable local anesthetics are included in this class because of their high potential for abuse as nerve blocking agents.

- **Class 3**: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2. Drugs in this class include bronchodilators, anabolic steroids and other drugs with primary effects on the autonomic nervous system, procaine, antihistamines with sedative properties and the high-ceiling diuretics.

- **Class 4**: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drugs in this class includes less potent diuretics; corticosteroids; antihistamines and skeletal muscle relaxants without prominent central nervous system (CNS) effects; expectorants and mucolytics; hemostatics; cardiac glycosides and anti-arrhythmics; topical anesthetics; antidiarrheals and mild analgesics. This class also includes the non-steroidal anti-inflammatory drugs (NSAIDs), at concentrations greater than established limits.

- **Class 5**: This class includes those therapeutic medications that have very localized actions only, such as anti-ulcer drugs, and certain anti-allergic drugs. The anticoagulant drugs are also included.

- **Prohibited Practices:**

A) The possession and/or use of a drug, substance or medication, specified below, on the premises of a facility under the jurisdiction of the regulatory body for which a recognized analytical method has not been developed to detect and confirm the administration of such substance; or the use of which may endanger the health and welfare of the horse or endanger the safety of the rider or driver; or the use of which may adversely affect the integrity of racing:

1) Erythropoietin
2) Darbepoetin
3) Oxyglobin
4) Hemopure

B) The possession and/or use of a drug, substance, or medication on the premises of a facility under the jurisdiction of the regulatory body that has not been approved by the United States Food and Drug Administration (FDA) for use in the United States.

C) The practice, administration, or application of a treatment, procedure, therapy or method identified below, which is performed on the premises of a facility under jurisdiction of a regulatory body and which may endanger the health and welfare of the horse or endanger the safety of the rider or driver, or the use of which may adversely affect the integrity of racing:

Drug Classification Scheme

- **Class 1**: Opiates, opium derivatives, synthetic opioids, psychoactive drugs, amphetamines, and all DEA Schedule I substances (see http://www.deadiversion.usdoj.gov/schedules/#list), and many DEA Schedule II drugs. Also found in this class are drugs that are potent stimulants of the CNS. Drugs in this class have no generally accepted medical use in the racing horse and their pharmacologic potential for altering the performance of a racing horse is very high. This class also includes all erythropoietin stimulating substances and their analogues.

- **Class 2**: Drugs placed in this category have a high potential for affecting the outcome of a race. Most are not generally accepted as therapeutic agents in the racing horse. Many are products intended to alter consciousness or the psychic state of humans, and have no approved or indicated use in the horse. Some, such as injectable local anesthetics, have legitimate use in equine medicine, but should not be found in a racing horse. The following groups of drugs are placed in this class:

  A. Opiate partial agonists, or agonist-antagonists.
  B. Non-opiate psychotropic drugs. These drugs may have stimulant, depressant, analgesic or neuroleptic effects.
  C. Miscellaneous drugs, which might have a stimulant effect on the CNS.
  D. Drugs with prominent CNS depressant action.
  E. Anti-depressant and antipsychotic drugs, with or without prominent CNS stimulatory or depressant effects.
  F. Muscle blocking drugs - those that have a direct neuromuscular blocking action.
  G. Local anesthetics that have a reasonable potential for use as nerve-blocking agents (except procaine).
  H. Snake venoms and other biologic substances that may be used as nerve-blocking agents.

- **Class 3**: Drugs placed in this class may or may not have an accepted therapeutic use in the horse. Many are drugs that affect the cardiovascular, pulmonary and autonomic nervous systems. They all have the potential of affecting the performance of a racing horse. The following groups of drugs are placed in this class:

  A. Drugs affecting the autonomic nervous system that do not have prominent CNS effects, but which do have prominent cardiovascular or respiratory system effects. Bronchodilators are included in this class.
  B. A local anesthetic that has nerve-blocking potential but also has a high potential for producing urine residue levels from a method of use not related to the anesthetic effect of the drug (procaine).
  C. Miscellaneous drugs with mild sedative action, such as the sleep-inducing antihistamines.
  D. Primary vasodilating/hypotensive agents.
  E. Potent diuretics affecting renal function and body fluid composition.
  F. Anabolic and/or androgenic steroids and other drugs.

- **Class 4**: Drugs in this category comprise primarily therapeutic medications routinely used in racehorses. These may influence performance, but generally have a more limited ability to do so. Groups of drugs assigned to this category include the following:

  A. Non-opiate drugs that have a mild central antipyretic effect.
  B. Drugs affecting the autonomic nervous system that do not have prominent CNS, cardiovascular, or respiratory effects:
     1. Drugs used solely as topical vasoconstrictors or decongestants.
     2. Drugs used as gastrointestinal antispasmodics.
     3. Drugs used to void the urinary bladder.
     4. Drugs with a major effect on CNS vasculature or smooth muscle of visceral organs.
  C. Antihistamines that do not have a significant CNS depressant effect. This does not include the H2 blocking agents, which are in Class 5.
  D. Mineralocorticoid drugs.
  E. Skeletal muscle relaxants.
  F. Anti-inflammatory drugs. These drugs may reduce pain as a consequence of their anti-inflammatory action.
     1. Non-steroidal anti-inflammatory drugs (NSAIDs). (Aspirin-like drugs).
     2. Corticosteroids (glucocorticoids).
     3. Miscellaneous anti-inflammatory agents.
  G. Less potent diuretics.
  H. Cardiac glycosides and antiarrhythmic agents.
     1. Cardiac glycosides.
     2. Antiarrhythmic agents (exclusive of lidocaine, bretylium, and propranolol).
     3. Miscellaneous cardiotonic drugs.
  I. Topical Anesthetics - agents not available in injectable formulations.
  J. Antidiarrheal drugs.
  K. Miscellaneous drugs:
     1. Expectorants with little or no other pharmacologic action.
     2. Stomachics.
     3. Mucolytic agents.

- **Class 5**: Drugs in this category are therapeutic medications that have very localized actions only, such as anti-ulcer drugs, and certain antiallergic drugs. The anticoagulant drugs are also included.

UNIFORM CLASSIFICATION OF FOREIGN SUBSTANCES
Version 14.0 (January, 2019)

ALPHABETICAL SUBSTANCE LIST

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Δ-1-androstene-3, 17-diol		3	A		
Δ-1-androstene-3, 17-dione		3	A		
Δ-1-dihydrotestosterone		3	A		
1-androstenediol (5a-androst-1-ene-3β, 17β-diol)		3	B	Steroid - endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
1-androstenedione (5a-androst-1-ene-3, 17-dione)		3	B	Steroid - endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
1-testosterone (17β-hydroxy-5a-androst-1-en-3-one)		3	A	Steroid - chemically related to anabolic steroids.	AAS lacking FDA approval
19-Norandrostenediol		3	B		
19-Norandrostenedione		3	B		
19-noretiocholanolone.		3	B	Nandrolene Link - a metabolite of nandrolone (19-nortestosterone) and bolandione (19-norandrostenedione).	Metabolite of a B substance
2-Aminoheptane	*Tuamine*	4	B		
3-Methoxytyramine	*3-MT*	2	A		
3,4-methylenedioxypyprovalerone	*MDPV, "bath salts"*	1	A		
4-androstene-3,6,17 trione (6-oxo)		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
4-androstenediol (androst-4-ene-3β,17β-diol)		3	B	Testosterone Link - androstenediol that is converted to testosterone.	Metabolized to a B substance
4-Hydroxytestosterone		3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
5-androstenedione (androst-5-ene-3,17-dione)		3	B	Testosterone Link - prohormone of testosterone.	Metabolized to a B substance
5α-androstane-3α,17α-diol		3	B	Testosterone Link - testosterone metabolite.	Metabolite of a B substance
5α-androstane-3α,17β-diol		3	B	Testosterone Link - testosterone metabolite.	Metabolite of a B substance
5α-androstane-3β,17α-diol		3	B	Testosterone Link - testosterone metabolite.	Metabolite of a B substance
5α-androstane-3β,17β-diol		3	B	Testosterone Link - testosterone metabolite.	Metabolite of a B substance
5β-androstane-3 α, 17β-diol, androst-4-ene-3α,17α-diol		3	B	Testosterone Link - androstenediol that is converted to testosterone.	Metabolized to a B substance
7-keto-dhea;19-		3	B	DHEA Link - a steroid produced by metabolism of the prohormone dehydroepiandrosterone (DHEA).	Metabolite of a B substance
7α-hydroxy-dhea		3	B	DHEA Link - naturally occurring steroid and a major metabolite of dehydroepiandrosterone (DHEA).	Metabolite of a B substance
7β-hydroxy-dhea		3	B	DHEA Link - naturally occurring steroid and a major metabolite of dehydroepiandrosterone (DHEA).	Metabolite of a B substance
a-Cobratoxin		1	A		
Acebutolol	*Sectral*	3	B		
Acecarbromal		2	A		
Acenocoumarol		5	C		
Acepromazine	*Atrovet, Notensil, PromAce®*	3	B		
Acetaminophen (Paracetamol)	*Tylenol, Tempra, etc.*	4	C		
Acetanilid		4	B		
Acetazolamide	*Diamox, Vetamox*	4	C		
Acetophenazine	*Tindal*	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Acetophenetidin (Phenacetin)		4	B		
Acetylsalicylic acid (Aspirin)		4	C		
Activators of the AMP-activated protein kinase (AMPK) - E.g., AICAR, and Peroxisome Proliferator Activated Receptor δ (pparδ) agonists (e.g., GW 1516).	*AICAR*	2	A	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines.	PPARs are experimental drugs without FDA approval
Adinazolam		2	A		
Adrenochrome monosemicarbazone salicylate		4	B		
Albuterol (Salbutamol)	*Proventil, Ventolin*	3	B	NOTE: "A" penalty for quarter horse races.	
Alclofenac		2	B		
Alclometasone	*Aclovate*	4	C		
Alcuronium	*Alloferin*	2	A		
Aldosterone	*Aldocortin, Electrocortin*	4	B		
Alfentanil	*Alfenta*	1	A		
Almotriptan	*Axert*	3	A		
Alphaprodine	*Nisentil*	2	A		
Alpidem	*Anaxyl*	2	A		
Alprazolam	*Xanax*	2	A		
Alprenolol		2	A		
Althesin	*Saffan*	2	A		
Altrenogest	*Regumate*	4	C	*Classification for geldings, colts, adult intact males only.	
Ambenonium	*Mytelase, Myeuran*	3	B		
Ambroxol	*Ambril, etc.*	4	B		
Amcinonide	*Cyclocort*	4	C		
Amiloride	*Moduretic; Midamor*	4	B		
Aminocaproic acid	*Amicar, Caprocid*	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Aminoglutethimide		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines.	Testolactone has B classification
Aminophylline	*Aminophyllin, etc.*	3	B		
Aminopyrine		4	B		
Aminorex	*Aminoxafen, Aminoxaphen, Apiquel, McN-742, Menocil*	1	A		
Amiodarone		4	B		
Amisometradine	*Rolictron*	4	B		
Amisulpride	*Solian*	2	A		
Amitraz	*Mitaban*	3	B		
Amitriptyline	*Elavil, Amitril, Endep*	2	A		
Amlodipine	*Ammivin, Norvasc*	3	B		
Amobarbital	*Amytal*	2	A		
Amoxapine	*Asendin*	2	A		
Amperozide		2	A		
Amphetamine		1	A		
Amrinone		4	B		
Amyl nitrite		2	A		
Anastrozole		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Androst-4-ene-3α,17β-diol		3	B	Testosterone Link - an androstenediol that is converted to testosterone.	Metabolized to a B substance
Androst-4-ene-3β,17α-diol		3	B	Testosterone Link - an androstenediol that is converted to testosterone.	Metabolized to a B substance
Androst-5-ene-3α,17α-diol		3	B	Testosterone Link - androstenediol that is converted to testosterone.	Metabolized to a B substance

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Androst-5-ene-3α,17β-diol		3	B	Testosterone Link - prohormone of testosterone.	Metabolized to a B substance
Androst-5-ene-3β,17α-diol		3	B	Testosterone Link - prohormone of testosterone.	Metabolized to a B substance
Androsta-1,4,6-triene-3,17-dione (androstatrienedione)		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Androstenediol (androst-5-ene-3β, 17β-diol)		3	B	Steroid: weak androgen and estrogen steroid hormone and intermediate in the biosynthesis of testosterone from dehydropiandrosterone (DHEA)	Metabolite of a B substance
Androstenedione (androst-4-ene-3, 17-dione)		3	B	Steroid: endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
Androsterone (3 β-hydroxy-5 α – androstan-17-one)		3	B	Testosterone Link - a metabolite of testosterone and dihydrotestosterone (DHT).	Metabolite of a B substance
Anileridine	*Leritine*	1	A		
Anilopam	*Anisine*	2	A		
Anisindione		5	D		
Anisotropine	*Valpin*	4	B		
Antipyrine		4	B		
Apazone (Azapropazone)	*Rheumox*	4	B		
Apomorphine		1	A		
Aprindine		4	B		
Aprobarbital	*Alurate*	2	A		
ARA-290		1	A	Erythropoietin Link - a nonerythropoietic peptide engineered from erythropoietin.	Blood doping agent

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Arecoline		3	A		
Arformoterol		3	B		
Aromatase inhibitors listed:					
Articaine	*Septocaine; Ultracaine,*	2	B		
Asialo EPO		1	A	Erythropoietin Link - desialylated form of human glycoprotein hormone erythropoietin (EPO), which has been reported to be neuro-, cardio-, and renoprotective in animal models of organ injuries.	Blood doping agent
Atenolol	*Tenormin*	3	B		
Atipamazole		2	B		
Atomoxetine	*Strattera*	2	A		
Atracurium	*Tracrium*	2	A		
Atropine		3	B		
Azacylonol	*Frenque*	2	A		
Azaperone	*Stresnil, Suicalm, Fentaz (with Fentanyl)*	2	A		
Baclofen	*Lioresal*	4	B		
Barbital	*Veronal*	2	A		
Barbiturates		2	A		
Beclomethasone	*Propaderm*	4	C		
Bemegride	*Megimide, Mikedimide*	2	A		
Benazepril	*Lotrel, Lotensin*	3	A		
Bendroflumethiazide	*Naturetin*	4	B		
Benoxaprofen		2	B		
Benoxinate	*Dorsacaine*	4	C		
Benperidol	*Anquil*	2	A		
Bentazepam	*Tiadipona*	2	A		
Benzactizine	*Deprol, Bronchodiletten*	2	A		
Benzocaine		4	B		
Benzoctamine		2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Benzodiazepines		2	A		
Benzonatate	*Tessalon, Tessalon Perles, Zonatuss*	2	A		
Benzphetamine	*Didrex*	2	A		
Benzthiazide		4	B		
Benztropine	*Cogentin*	2	A		
Benzylpiperazine (BZP)		1	A		
Bepridil	*Bepadin*	4	B		
Betamethasone	*Betasone, etc.*	4	C		
Betaxolol	*Kerlone*	3	B		
Bethanechol	*Urecholine, Duvoid*	4	C		
Bethanidine	*Esbatal*	3	A		
Biperiden	*Akineton*	3	A		
Biriperone		2	A		
Bisoprolol	*Zebeta, Bisobloc, etc.*	3	B		
Bitolterol	*Effectin*	3	A		
Bolandiol (estr-4-ene-3β, 17β-diol)		3	A	Steroid	AAS lacking FDA approval
Bolasterone		3	A		
Boldenone	*Equipoise*	3	B		
Boldione		3	A		
Bretylium	*Bretylol*	3	B		
Brimonidine	*Alphagan*	2	A		
Bromazepam	*Lexotan, Lectopam*	2	A		
Bromfenac	*Duract*	3	A		
Bromhexine	*Oletor, etc.*	4	B		
Bromisovalum	*Diffucord, etc.*	2	A		
Bromocriptine	*Parlodel*	2	A		
Bromodiphenhydramine		3	B		
Bromperidol	*Bromidol*	2	A		
Brompheniramine	*Dimetane, Disomer*	3	B		
Brotizolam	*Brotocol*	2	A		
Budesonide	*Pulmacort, Rhinocort*	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Bufexamac		3	A		
Bumetanide	*Bumex*	3	B		
Bupivacaine	*Marcaine*	2	A		
Buprenorphine	*Temgesic*	2	A		
Bupropion	*Wellbutrin*	2	A		
Buspirone	*Buspar*	2	A		
Butabarbital (Secbutobarbitone)	*Butacaps, Butasol, etc.*	2	A		
Butacaine	*Butyn*	2	A		
Butalbital (Talbutal)	*Fiorinal*	2	A		
Butamben (butyl aminobenzoate)	*Butesin*	4	C		
Butanilicaine	*Hostacain*	2	A		
Butaperazine	*Repoise*	2	A		
Butoctamide	*Listomin*	2	A		
Butorphanol	*Stadol, Torbugesic*	3	B		
Butoxycaine	*Stadacain*	4	B		
Caffeine		2	B		
Calusterone	*Methosorb*	3	A		
Camazepam	*Paxor*	2	A		
Camphor		4	C		
Candesartan	*Atcand*	3	B		
Cannabidiol (CBD)[1]	Anti-epileptic, analgesic	2	B		
Canrenone		4	C	Metabololite of a C substance - steroidal antimineralocorticoid, active metabolite of spironolactone (a diuretic).	
Capsaicin		2	B		
Captodiame	*Covatine*	2	A		
Captopril	*Capolen*	3	B		
Carazolol	*Carbacel, Conducton*	3	A		
Carbachol	*Lentin, Doryl*	3	B		
Carbamezapine	*Tegretol*	3	B		
Carbamylated EPO		1	A	Erythropoietin Link - may be a beneficial tissue-protective cytokine.	Blood doping agent
Carbazochrome		4	B		
Carbidopa + levodopa	*Sinemet*	2	A		
Carbinoxamine	*Clistin*	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Carbromol	*Mifudorm*	2	A		
Cardarine (GW-501516)		2	A	No legit use in the racehorse. Lacks FDA approval	
Carfentanil		1	A		
Carisoprodol	*Rela, Soma*	2	B		
Carphenazine	*Proketazine*	2	A		
Carpipramine	*Prazinil*	2	A		
Carprofen	*Rimadyl*	4	B		
Carteolol	*Cartrol*	3	B		
Carticaine (see articaine)	*Septocaine; Ultracaine, etc.*	2	B		
Carvedilol	*Coreg*	3	B		
Cathinone	*khat, kat, qat, quat, chat, catha, Abyssinian tea, African tea*	1	A		
Celecoxib	*Celebrex*	3	B		
Cetirizine	*Zyrtec*	4	C		
Chloral betaine	*Beta-Chlor*	2	A		
Chloral hydrate	*Nactec, Oridrate, etc.*	2	A		
Chloraldehyde (chloral)		2	A		
Chloralose (Alpha-Chloralose)		2	A		
Chlordiazepoxide	*Librium*	2	A		
Chlorhexidol		2	A		
Chlormerodrin	*Neohydrin*	4	B		
Chlormezanone	*Trancopal*	2	A		
Chloroform		2	A		
Chlorophenesin	*Maolate*	4	C		
Chloroprocaine	*Nesacaine*	2	A		
Chloroquine	*Avloclor*	4	C		
Chlorothiazide	*Diuril*	4	B		
Chlorpheniramine	*Chlortriemton, etc.*	4	B		
Chlorproethazine	*Newiplege*	2	A		
Chlorpromazine	*Thorazine, Largactil*	1	A		
Chlorprothixene	*Taractan*	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Chlorthalidone	*Hydroton*	4	B		
Chlorzoxazone	*Paraflex*	4	B		
Chorionic Gonadotropin (CG)		3	B	Hormone and behavioral effects - a water soluble glycoprotein derived from human pregnancy urine. Used for behavior modification in colts / horses. There should be no restriction/regulation in fillies and mares.	
Ciclesonide		4	C		
Cilostazol	*Pletal*	4	B		
Cimeterol		3	A		
Cimetidine	*Tagamet*	5	D		
Cinchocaine	*Nupercaine*	2	B		
Citalopram	*Celex*	2	A		
Clanobutin		4	B		
Clemastine	*Tavist*	3	B		
Clenbuterol	*Ventipulmin*	3	B	NOTE: "A" penalty for quarter horse races.	
Clibucaine	*Batrax*	2	A		
Clidinium	*Quarezan, Clindex, etc.*	3	B		
Clobazam	*Urbanyl*	2	A		
Clobetasol	*Temovate*	4	C		
Clocapramine		2	A		
Clocortolone	*Cloderm*	4	C		
Clofenamide		4	B		
Clomethiazole (Chlormethiazole)		2	A		
Clomiphene		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Estrogen modulator.	Testolactone has B classification
Clomipramine	*Anafranil*	2	A		
Clonazepam	*Klonopin*	2	A		
Clonidine	*Catapres*	3	B		
Clorazepate	*Tranxene*	2	A		
Clormecaine	*Placacid*	2	A		
Clostebol		3	A		
Clothiapine	*Entermin*	2	A		
Clotiazepam	*Trecalmo, Rize*	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Cloxazolam	*Enadel, Sepazon, Tolestan*	2	A		
Clozapine	*Clozaril, Leponex*	2	A		
CNTO 530		1	A	Erythropoietin Link - a biopharmaceutical consisting of a novel peptide that mimics the actions of erythropoietin, CNTO 530 produced sustained increases in red blood cell parameters.	Blood doping agent
Cobalt (check note)		3	B1	For cobalt concentrations of less than 25 parts per billion (ppb) of blood serum or plasma no penalty is recommended. For concentrations of 25 ppb or greater but less than 50 ppb of blood plasma or serum the recommended penalty is a written warning, the placement of the horse on the Veterinarians List with removal from list only after a blood test confirms that the concentration is below 25 ppb of blood plasma or serum. Testing shall be paid by the owner(s) of the horse. Concentrations of 50 ppb or greater in blood plasma or serum have a recommended "B" penalty.	
Cocaine		1	A3	If it is determined by the State Veterinarian/Equine Medical Director; the Stewards, or the Racing Authority that the finding of cocaine or morphine was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Racing Authority may elect to assign a Class B penalty to the trainer.	
Codeine		1	A		
Colchicine		4	B		
Conorphone		2	A		
Corticaine	*Ultracain*	2	A		
Corticotrophind		3	B	Peptide hormone involved in the stress response.	
Cortisone	*Cortone, etc.*	4	C		
Cromolyn	*Intel*	5	D		
Crotetamide		2	A		
Cyamemazine	*Tercian*	2	A		
Cyclandelate	*Cyclospasmol*	3	A		
Cyclizine	*Merazine*	3	B		
Cyclobarbital	*Phanodorm*	2	A		
Cyclobenzaprine	*Flexeril*	4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Cyclofenil		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - selective estrogen receptor modulator (SERM).	Testolactone has B classification
Cyclomethycaine	*Surfacaine*	4	C		
Cyclothiazide	*Anhydron, Renazide*	4	B		
Cycrimine	*Pagitane*	3	B		
Cyproheptadine	*Periactin*	3	B		
Danazol	*Danocrine*	3	B		
Dantrolene	*Dantrium*	4	C		
Darbepoetin	*Aranesp*	1	A		
Darbepoetin (depo)		1	A	Erythropoietin Link - Bone marrow stimulant (Erythropoiesis-stimulating agents are medications which stimulates the bone marrow to make red blood cells).	Blood doping agent
Decamethonium	*Syncurine*	2	A		
Dehydrochloromethyltestosterone		3	A		
Dembroxol (Dembrexine)	*Sputolysin*	4	C		
Demoxepam		2	A		
Deoxycorticosterone	*Percortin, DOCA, Descotone, Dorcostrin*	4	C		
Deracoxib	*Deremaxx*	3	B		
Dermorphin		1	A		
Desipramine	*Norpromine, Pertofrane*	2	A		
Desonide	*Des Owen*	4	C		
Desoximetasone	*Topicort*	4	C		
Desoxymethyltestosterone		3	A		
Detomidine	*Dormosedan*	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Dexamethasone	*Azium, etc.*	4	C		
Dextromethorphan		4	B		
Dextromoramide	*Palfium, Narcolo*	1	A		
Dextropropoxyphene	*Darvon*	3	B		
Dezocine	*Dalgan*	2	A		
Diamorphine		1	A		
Diazepam	*Valium*	3	B		
Diazoxide	*Proglycem*	3	B		
Dibucaine	*Nupercainal, Cinchocaine*	2	B		
Dichloralphenazone	*Febenol, Isocom*	2	A		
Dichlorphenamide	*Daramide*	4	C		
Diclofenac	*Voltaren, Voltarol*	4	C		
Dicumarol	*Dicumarol*	5	D		
Diethylpropion	*Tepanil, etc.*	2	A		
Diethylthiambutene	*Themalon*	2	A		
Diflorasone	*Florone, Maxiflor*	4	C		
Diflucortolone	*Flu-Cortinest, etc.*	4	C		
Diflunisal		3	B		
Digitoxin	*Crystodigin*	4	B		
Digoxin	*Lanoxin*	4	B		
Dihydrocodeine	*Parcodin*	2	A		
Dihydroergotamine		4	B		
Dihydrotestosterone (17β-hydroxy-5a-androstan-3-one)		3	B	Steroid - endogenous androgen sex steroid and hormone.	Endogenous AAS
Dilorazepam	*Briantum*	2	A		
Diltiazem	*Cardizem*	4	B		
Dimefline		3	A		
Dimethisoquin	*Quotane*	4	B		
Dimethylsulfoxide (DMSO)	*Domoso*	4	C		
Diphenadione		5	C		
Diphenhydramine	*Benadryl*	3	B		
Diphenoxylate	*Difenoxin, Lomotil*	4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Diprenorphine	*M50/50*	2	A		
Dipyridamole	*Persantine*	3	B		
Dipyrone	*Novin, Methampyrone*	4	B		
Disopyramide	*Norpace*	4	B		
Divalproex	*Depakote*	3	A		
Dixyrazine	*Esucos*	2	A		
Dobutamine	*Dobutrex*	3	B		
Donepezil	*Aricept*	1	A		
Dopamine	*Intropin*	2	A		
Doxacurium	*Nuromax*	2	A		
Doxapram	*Dopram*	2	A		
Doxazosin		3	A		
Doxefazepam	*Doxans*	2	A		
Doxepin	*Adapin, Sinequan*	2	A		
Doxylamine	*Decapryn*	3	B		
Dromostanolone	*Drolban*	3	B		
Droperidol	*Inapsine, Droleptan, Innovar-Vet (with Fentanyl)*	2	A		
Drostanolone		3	A	Steroid	AAS lacking FDA approval
Duloxetine		2	A		
Dyclonine	*Dyclone*	4	C		
Dyphylline		3	B		
Edrophonium	*Tensilon*	3	B		
Eletripan	*Relpax*	3	A		
Eltenac		4	B		
Enalapril (metabolite enaloprilat)	*Vasotec*	3	A		
Enciprazine		2	A		
Endorphins		1	A		
Enkephalins		1	A		
Ephedrine		2	A		
Epi-dihydrotestosterone		3	B	Testosterone Link - androgenic metabolite of testosterone.	Metabolite of a B substance
Epibatidine		2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Epinephrine		2	A		
Epitestosterone		3	B	Testosterone Link - endogenous steroid and an epimer of the androgen sex hormone testosterone.	Endogenous, stereoisomer of a B substance.
EPO-Fc		1	A	Erythropoietin Link - fusion protein in human blood.	Blood doping agent
EPO-mimetic peptides (EMP):		1	A		
Ergoloid mesylates (dihydroergocornine mesylate, dihydroergocristine mesylate, and dihydroergocryptine mesylate)		2	A		
Ergonovine	*Ergotrate*	4	C		
Ergotamine	*Gynergen, Cafergot, etc.*	4	B		
Erthrityl tetranitrate	*Cardilate*	3	A		
Erythropoietin (EPO)	*Epogen, Procrit, etc.*	1	A		
Esmolol	*Brevibloc*	3	B		
Esomeprazole	*Nexium*	5	D		
Estazolam	*Domnamid, Eurodin, Nuctalon*	2	A		
Eszopiclone		2	A		
Etacrynic acid		3	C		
Etamiphylline		3	B		
Etanercept	*Enbrel*	4	B		
Ethacrynic acid	*Edecrin*	3	B		
Ethamivan		2	A		
Ethanol		2	A		
Ethchlorvynol	*Placidyl*	2	A		
Ethinamate	*Valmid*	2	A		
Ethoheptazine	*Zactane*	2	A		
Ethopropazine	*Parsidol*	2	A		
Ethosuximide	*Zarontin*	3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Ethotoin	*Peganone*	4	B		
Ethoxzolamide	*Cardrase, Ethamide*	4	C		
Ethylaminobenzoate (Benzocaine)	*Semets, etc.*	4	C		
Ethylestrenol	*Maxibolin, Organon*	3	B		
Ethylisobutrazine	*Diquel*	2	A		
Ethylmorphine	*Dionin*	1	A		
Ethylnorepinephrine	*Bronkephrine*	3	A		
Ethylphenidate		1	A		
Etidocaine	*Duranest*	2	A		
Etifoxin	*Stresam*	2	A		
Etiocholanolone		3	B	Testosterone Link - etiocholane steroid as well as an endogenous 17- ketosteroid that is produced from the metabolism of testosterone.	Metabolite of a B substance
Etizolam	*Depas, Pasaden*	2	A		
Etodolac	*Lodine*	3	B		
Etodroxizine	*Indunox*	2	A		
Etomidate		2	A		
Etorphine HCl	*M99*	1	A		
Exemestane	Aromatase inhibitors	3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Famotidine	*Gaster, etc.*	5	D		
Felbamate	*Felbatol*	3	B		
Felodipine	*Plendil*	4	B		
Fenarbamate	*Tymium*	2	A		
Fenbufen	*Cincopal*	3	B		
Fenclozic acid	*Myalex*	2	B		
Fenfluramine	*Pondimin*	2	A		
Fenoldopam	*Corlopam*	3	B		
Fenoprofen	*Nalfon*	3	B		
Fenoterol	*Berotec*	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Fenspiride	*Respiride, Respan, etc*	3	B		
Fentanyl	*Sublimaze*	1	A		
Fentiazac		3	B		
Fexofenadine	*Allegra*	4	C		
Fibroblast Growth Factors (fgfs), Hepatocyte Growth Factor (HGF), Insulin- like Growth Factor-1 (IGF-1) and its analogues, Mechano Growth Factors (mgfs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/ degradation, vascularization, energy utilization, regenerative capacity or fiber type switching.		3	A	Cardiac, Muscle effects - a family of peptide cytokines that are important in the regulation of many tissues.	Lack FDA approval; no legitimate use in race horse.
Firocoxib		4	C		
Flecainide	*Idalon*	4	B		
Floctafenine	*Idalon, Idarac*	4	B		
Fluanisone	*Sedalande*	2	A		
Fludiazepam	*Erispam*	2	A		
Fludrocortisone	*Alforone, etc.*	4	C		
Flufenamic acid		3	B		
Flumethasone	*Flucort, etc.*	4	C		
Flumethiazide	*Ademol*	4	B		
Flunarizine	*Sibelium*	4	B		
Flunisolide	*Bronilide, etc.*	4	C		
Flunitrazepam	*Rohypnol, Narcozep, Darkene, Hypnodorm*	2	A		
Flunixin	*Banamine*	4	C*		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Fluocinolone	*Synalar*	4	C		
Fluocinonide	*Licon, Lidex*	4	C		
Fluopromazine	*Psyquil, Siquil*	2	A		
Fluoresone	*Caducid*	2	A		
Fluorometholone	*FML*	4	C		
Fluoroprednisolone		4	B		
Fluoxetine	*Prozac*	2	A		
Fluoxymesterone	*Halotestin*	3	B		
Flupenthixol	*Depixol, Fluanxol*	2	A		
Fluphenazine	*Prolixin, Permitil, Anatensol, etc.*	2	B		
Flupirtine	*Katadolone*	3	A		
Fluprednisolone	*Alphadrol*	4	C		
Flurandrenolide	*Cordran*	4	C		
Flurazepam	*Dalmane*	2	A		
Flurbiprofen	*Froben*	3	B		
Fluspirilene	*Imap, Redeptin*	2	A		
Fluticasone	*Flixonase, Flutide*	4	C		
Flutoprazepam	*Restas*	2	A		
Fluvoxamine	*Dumirox, Faverin, etc.*	2	A		
Formebolone		3	A		
Formestane	Aromatase inhibitors	3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Formoterol	*Altram*	3	B		
Fosinopril	*Monopril*	3	A		
Fosphenytoin	*Cerebyx*	3	B		
Fulvestrant		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Estrogen receptor antagonist antineoplastic agent.	Testolactone has B classification

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Furazabol		3	A		
Furosemide	*Lasix*	N/A			
Gabapentin	*Neurontin*	3	B		
Galantamine	*Reminyl*	2	A		
Gallamine	*Flaxedil*	2	A		
Gamma Aminobutryic Acid (GABA)	*Carolina Gold*	3	B		
Gepirone		2	A		
Gestrinone		3	A		
GH-Releasing Peptides (ghrps), e.g., alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2)		3	A	Anabolic Effects - a synthetic GH secretagogue.	Anabolic agent lacking FDA approval
Glutethimide	*Doriden*	2	A		
Glycopyrrolate	*Robinul*	4	C		
Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g., CJC- 1295, sermorelin and tesamorelin		3	A	Anabolic Effects - peptide analogue of growth hormone-releasing hormone which is used as a diagnostic agent to assess growth hormone secretion for the purpose of diagnosing growth hormone deficiency.	Anabolic agent lacking FDA approval
Growth Hormone Secretagogues (GHS), e.g., ghrelin and ghrelin mimetics, e.g., anamorelin and ipamorelin		3	A	Anabolic Effects - hunger hormone, appetite-enhancing and anabolic effects.	Anabolic agent lacking FDA approval
Guaifenesin (glycerol guiacolate)	*Gecolate*	4	C		
Guanabenz	*Wytensin*	3	B		
Guanadrel	*Hylorel*	3	A		
Guanethidine	*Ismelin*	3	A		
Halazepam	*Paxipam*	2	A		
Halcinonide	*Halog*	4	C		
Halobetasol	*Ultravate*	4	C		
Haloperidol	*Haldol*	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Haloxazolam	*Somelin*	2	A		
Hemoglobin glutamers	*Oxyglobin Hemopure*	2	A		
Heptaminol	*Corofundol*	3	B		
Heroin		1	A		
Hexafluorenium	*Myalexen*	2	A		
Hexobarbital	*Evipal*	2	A		
Hexocyclium	*Tral*	4	B		
Hexylcaine	*Cyclaine*	2	B		
HIF activators (e.g. Argon, xenon)		3	A	Cardiovascular Effects - a key mediator of oxygen homeostasis that was first identified as a transcription factor that is induced and activated by decreased oxygen tension.	Blood doping agent
Homatropine	*Homapin*	3	B		
Homophenazine	*Pelvichthol*	2	A		
Hydralazine	*Apresoline*	3	B		
Hydrochlorthiazide	*Hydrodiuril*	4	B		
Hydrocodone (dihydrocodienone)	*Hycodan*	1	A		
Hydrocortisone (Cortisol)	*Cortef, etc.*	4	C		
Hydroflumethiazide	*Saluron*	4	B		
Hydromorphone	*Dilaudid*	1	A		
Hydroxyamphetamine	*Paradrine*	1	A		
Hydroxyzine	*Atarax*	2	B		
Ibomal	*Noctal*	2	A		
Ibuprofen	*Motrin, Advil, Nurpin, etc.*	4	C		
Ibutilide	*Corvert*	3	B		
Iloprost	*Ventavis*	3	A		
Imipramine	*Imavate, Presamine, Tofranil*	2	A		
Indapamide	Diuretic	3	C		
Indomethacin	*Indocin*	3	B		
Infliximab	*Remicade*	4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Insulins		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - protein hormone that is used as a medication to treat high blood sugar.	
Ipratropium		3	B		
Irbesarten	*Avapro*	3	A		
Isapirone		2	A		
Isocarboxazid	*Marplan*	2	A		
Isoetharine	*Bronkosol*	3	B		
Isoflupredone	*Predef 2x*	4	C		
Isomethadone		2	A		
Isometheptene	*Octin, Octon*	4	B		
Isopropamide	*Darbid*	4	B		
Isoproterenol	*Isoprel*	2	A		
Isosorbide dinitrate	*Isordil*	3	B		
Isoxicam	*Maxicam*	2	B		
Isoxsuprine	*Vasodilan*	4	D		
Isradipine	*DynaCirc*	4	B		
Kebuzone		3	B		
Ketamine	*Ketalar, Ketaset, Vetalar*	2	B		
Ketazolam	*Anxon, Laftram, Solatran, Loftran*	2	A		
Ketoprofen	*Orudis*	4	C*		
Ketorolac	*Toradol*	3	A		
Labetalol	*Normodyne*	3	B		
Lamotrigine	*Lamictal*	3	A		
Lansoprazole		5	D		
Lenperone	*Elanone-V*	2	A		
Letosteine	*Viscotiol, Visiotal*	4	B		
Letrozole		3	A		
Levamisole		2	B		
Levobunolol	*Betagan*	3	B		
Levomethorphan		2	A		
Levorphanol	*Levo-Dremoran*	1	A		
Lidocaine	*Xylocaine*	2	B		
Lisinopril	*Prinivil, Zestril*	3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Lithium	*Lithizine, Duralith, etc.*	2	A		
Lobeline		2	A		
Lofentanil		1	A		
Loflazepate, Ethyl	*Victan*	2	A		
Loperamide	*Imodium*	3	B		
Loprazolam	*Dormonort, Havlane*	2	A		
Loratidine	*Claritin*	4	C		
Lorazepam	*Ativan*	2	A		
Lormetazepam	*Noctamid*	2	A		
Losartan	*Hyzaar*	3	B		
Loxapine	*Laxitane*	2	A		
Luteinizing Hormone (LH)		3	B	Hormone and behavioral effects - a hormone produced by gonadotropic cells in the anterior pituitary gland. In females, an acute rise of LH triggers ovulation and development of the corpus luteum. Used for behavior modification in colts / horses. There should be no restriction/ regulation in fillies and mares.	
Mabuterol		3	A		
Maprotiline	*Ludiomil*	2	A		
Mazindol	*Sanorex*	1	A		
Mebutamate	*Axiten, Dormate, Capla*	2	A		
Mecamylamine	*Inversine*	3	B		
Meclizine	*Antivert, Bonine*	3	B		
Meclofenamic acid	*Arquel*	4	C		
Meclofenoxate	*Lucidiril, etc.*	2	A		
Medazepam	*Nobrium, etc.*	2	A		
Medetomidine	*Domitor*	3	B		
Medrysone	*Medriusar, etc.*	4	C		
Mefenamic acid	*Ponstel*	3	B		
Meldonium	*Mildronate, et al*	1	A		
Meloxicam	*Mobic*	4	B		
Melperone	*Eunerpan*	2	A		
Memantine	*Namenda*	2	A		
Meparfynol	*Oblivon*	2	A		
Mepazine	*Pacatal*	2	A		
Mepenzolate	*Cantil*	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Meperidine	*Demerol*	1	A		
Mephenesin	*Tolserol*	4	B		
Mephenoxalone	*Control, etc.*	2	A		
Mephentermine	*Wyamine*	1	A		
Mephenytoin	*Mesantoin*	2	A		
Mephobarbital (Methylphenobarbital)	*Mebaral*	2	A		
Mepivacaine	*Carbocaine*	2	B		
Meprobamate	*Equanil, Miltown*	2	A		
Meralluride	*Mercuhydrin*	4	B		
Merbaphen	*Novasural*	4	B		
Mercaptomerin	*Thiomerin*	4	B		
Mercumatilin	*Cumertilin*	4	B		
Mersalyl	*Salyrgan*	4	B		
Mesalamine	*Asacol*	5	C		
Mesoridazine	*Serentil*	2	A		
Mestanolone		3	A		
Mesterolone		3	A		
Metaclazepam	*Talis*	2	A		
Metandienone		3	A	Steroid	AAS lacking FDA approval
Metaproterenol	*Alupent, Metaprel*	3	B		
Metaraminol	*Aramine*	1	A		
Metaxalone	*Skelaxin*	4	B		
Metazocine		2	A		
Metenolone		3	A	Steroid	AAS lacking FDA approval
Metformin		2	B		
Methacholine		3	A		
Methadone	*Dolophine*	1	A		
Methamphetamine	*Desoxyn*	1	A4	Recommended Penalty B if testing can prove presence of only levo-methamphetamine is present in sample.	
Methandriol (Methylandrostenediol)	*Probolic*	3	A		
Methandrostenolone	*Dianobal*	3	A		
Methantheline	*Banthine*	3	B		
Methapyrilene	*Histadyl, etc.*	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Methaqualone	*Quaalude*	1	A		
Metharbital	*Gemonil*	2	A		
Methasterone		3	A		
Methazolamide	*Naptazane*	4	C		
Methcathinone		1	A		
Methdilazine	*Tacaryl*	3	B		
Methenolone	*Primobolan*	3	A		
Methixene	*Trest*	3	A		
Methocarbamol	*Robaxin*	4	C		
Methohexital	*Brevital*	2	A		
Methotrexate	*Folex, Nexate, etc.*	4	B		
Methotrimeprazine	*Levoprome, Neurocil, etc.*	2	A		
Methoxamine	*Vasoxyl*	3	A		
Methoxyphenamine	*Orthoxide*	3	A		
Methoxypolyethylene glycol-epoetin beta (CERA)		1	A	Erythropoietin Link - an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD in adult patients on dialysis and patients not on dialysis.	Blood doping agent
Methscopolamine	*Pamine*	4	B		
Methsuximide	*Celontin*	4	B		
Methyclothiazide	*Enduron*	4	B		
Methyl-1-testosterone		3	A		
Methylatropine		3	B		
Methyldienolone		3	A		
Methyldopa	*Aldomet*	3	A		
Methylergonovine	*Methergine*	4	C		
Methylhexanamine (Methylhexaneamine)	*Geranamine*	1	A		
Methylnortestosterone (Trestolone)		3	A		
Methylphenidate	*Ritalin*	1	A		
Methylprednisolone	*Medrol*	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Methyltestosterone	*Metandren*	3	B		
Methyprylon	*Noludar*	2	A		
Methysergide	*Sansert*	4	B		
Metiamide		4	B		
Metoclopramide	*Reglan*	4	C		
Metocurine	*Metubine*	2	A		
Metolazone		3	B		
Metomidate	*Hypnodil*	2	A		
Metopon (methydihydromorphinone)		1	A		
Metoprolol	*Lopressor*	3	B		
Metribolone		3	A	Steroid	AAS lacking FDA approval
Mexazolam	*Melex*	2	A		
Mexiletine	*Mexitil*	4	B		
Mibefradil	*Posicor*	3	B		
Mibolerone		3	B		
Midazolam	*Versed*	3	B		
Midodrine	*Pro-Amiline*	3	B		
Milrinone		4	B		
Minoxidil	*Loniten*	3	B		
Mirtazepine	*Remeron*	2	A		
Misoprostol	*Cytotec*	5	D		
Mitragynine	*Kratom*	1	A		
Mivacurium	*Mivacron*	2	A		
Modafinil	*Provigil*	2	A		
Moexipril (metabolite, moexiprilat)	*Uniretic*	3	B		
Molindone	*Moban*	2	A		
Mometasone	*Elocon*	4	C		
Montelukast	*Singulair*	4	C		
Moperone	*Luvatren*	2	A		
Morphine		1	A6	If it is determined by the State Veterinarian/Equine Medical Director; the Stewards, or the Racing Authority that the finding of cocaine or morphine was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Racing Authority may elect to assign a Class B penalty to the trainer.	

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Mosaprimine		2	A		
Muscarine		3	A		
myo-inositol trispyrophosphate (ITPP)		1	A		
N-Butylscopolamine		4	C		
Nabumetone	*Anthraxan, Relafen, Reliflex*	3	A		
Nadol	*Corgard*	3	B		
Naepaine	*Amylsine*	2	A		
Nalbuphine	*Nubain*	2	A		
Nalorphine	*Nalline, Lethidrone*	2	A		
Naloxone	*Narcan*	3	B		
Naltrexone	*Revia*	3	B		
Nandrolone	*Nandrolin, Laurabolin, Durabolin*	3	B		
Naphazoline	*Privine*	4	B		
Naproxen	*Equiproxen, Naprosyn*	4	C		
Naratriptan	*Amerge*	3	B		
Nebivolol		3	A		
Nedocromil	*Tilade*	5	D		
Nefazodone	*Serzone*	2	A		
Nefopam		3	A		
Neostigmine	*Prostigmine*	3	B		
Nicardipine	*Cardine*	4	B		
Nifedipine	*Procardia*	4	B		
Niflumic acid	*Nifluril*	3	B		
Nikethamide	*Coramine*	1	A		
Nimesulide		3	B		
Nimetazepam	*Erimin*	2	A		
Nimodipine	*Nemotop*	4	B		
Nitrazepam	*Mogadon*	2	A		
Nitroglycerin		2	B		
Nizatidine	*Axid*	5	D		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Norandrosterone		3	B	Nandrolene Link - a detectable metabolite of nandrolone, an anabolic-androgenic steroid.	Metabolite of a B substance
Norbolethone/Norboletone		3	A		
Norclostebol		3	A		
Nordiazepam	*Calmday, Nordaz, etc.*	2	A		
Norepinephrine		2	A		
Norethandrolone		3	A		
Nortestosterone		3	B		
Nortriptyline	*Aventyl, Pamelor*	2	A		
Nylidrine	*Arlidin*	3	A		
Olanzepine	*Zyprexa*	2	A		
Olmesartan	*Benicar*	3	A		
Olsalazine	*Dipentum*	5	C		
Omeprazole	*Prilosec, Losec*	5	D		
Orphenadrine	*Norlfex*	4	B		
Oxabolone		3	A		
Oxandrolone	*Anavar*	3	B		
Oxaprozin	*Daypro, Deflam*	4	B		
Oxazepam	*Serax*	2	A		
Oxazolam	*Serenal*	2	A		
Oxcarbazepine	*Trileptal*	3	A		
Oxilofrine (hydroxyephedrine)		2	A		
Oxprenolol	*Trasicor*	3	A		
Oxycodone	*Percodan*	1	A		
Oxymesterone		3	A		
Oxymetazoline	*Afrin*	4	B		
Oxymetholone	*Adroyd, Anadrol*	3	B		
Oxymorphone	*Numorphan*	1	A		
Oxyperitine	*Forit, Integrin*	2	A		
Oxyphenbutazone	*Tandearil*	4	C		
Oxyphencyclimine	*Daricon*	4	B		
Oxyphenonium	*Antrenyl*	4	B		
Paliperidone		2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Pancuronium	*Pavulon*	2	A		
Pantoprazole	*Protonix*	5	D		
Papaverine	*Pavagen, etc.*	3	A		
Paraldehyde	*Paral*	2	A		
Paramethadione	*Paradione*	3	A		
Paramethasone	*Haldrone*	4	C		
Pargyline	*Eutonyl*	3	A		
Paroxetine	*Paxil, Seroxat*	2	A		
Peginesatide		1	A	Erythropoietin Link - an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.	Blood doping agent
Pemoline	*Cylert*	1	A		
Penbutolol	*Levatol*	3	B		
Penfluridol	*Cyperon*	2	A		
Pentaerythritol tetranitrate	*Duotrate*	3	A		
Pentazocine	*Talwin*	3	B		
Pentobarbital	*Nembutal*	2	A		
Pentoxyfylline	*Trental, Vazofirin*	4	D		
Pentylenetetrazol	*Metrazol, Nioric*	1	A		
Perazine	*Taxilan*	2	A		
Perfluorocarbons		2	A		
Perfluorodecahydronophthalene		2	A		
Perfluorodecolin		2	A		
Perfluorooctylbromide		2	A		
Perfluorotripropylamine		2	A		
Pergolide	*Permax*	3	B		
Periciazine	*Alodept, etc.*	2	A		
Perindopril	*Biprel*	3	A		
Perlapine	*Hypnodin*	2	A		
Perphenazine	*Trilafon*	2	A		
Phenacemide	*Phenurone*	4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Phenaglycodol	*Acalo, Alcamid, etc.*	2	A		
Phenazocine	*Narphen*	1	A		
Phencyclidine (PCP)	*Sernylan*	1	A		
Phendimetrazine	*Bontril, etc.*	1	A		
Phenelzine	*Nardelzine, Nardil*	2	A		
Phenindione	*Hedulin*	5	D		
Phenmetrazine	*Preludin*	1	A		
Phenobarbital	*Luminal*	2	A		
Phenoxybenzamine	*Dibenzyline*	3	B		
Phenprocoumon	*Liquamar*	5	D		
Phensuximide	*Milontin*	4	B		
Phentermine	*Iomamin*	2	A		
Phentolamine	*Regitine*	3	B		
Phenylbutazone	*Butazolidin*	4	C*		
Phenylephrine	*Isophrin, Neo-Synephrine*	3	B		
Phenylpropanolamine	*Propadrine*	3	B		
Phenytoin	*Dilantin*	4	B		
Physostigmine	*Eserine*	3	A		
Picrotoxin		1	A		
Piminodine	*Alvodine, Cimadon*	2	A		
Pimobendan		2	B		
Pimozide	*Orap*	2	A		
Pinazepam	*Domar*	2	A		
Pindolol	*Viskin*	3	B		
Pipamperone	*Dipiperon*	2	A		
Pipecuronium	*Arduan*	2	A		
Pipequaline		2	A		
Piperacetazine	*Psymod, Quide*	2	A		
Piperocaine	*Metycaine*	2	A		
Pipotiazine	*Lonseren, Piportil*	2	A		
Pipradrol	*Dataril, Gerondyl, etc.*	2	A		
Piquindone		2	A		
Pirbuterol	*Maxair*	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Pirenzepine	*Gastrozepin*	5	C		
Piretanide	*Arelix, Tauliz*	3	B		
Piritramide		1	A		
Piroxicam	*Feldene*	4	B		
Plasma expanders (e.g. Bycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol)		3	A	No legit use in the racehorse. Lacks FDA approval.	
Polyethylene glycol		5	D		
Polythiazide	*Renese*	4	B		
Pramoxine	*Tronothaine*	4	C		
Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one)		3	B	Steroid - inactive endogenous steroid.	Endogenous AAS
Prazepam	*Verstran, Centrax*	2	A		
Prazosin	*Minipress*	3	B		
Prednisolone	*Delta-Cortef, etc.*	4	C		
Prednisone	*Meticorten, etc.*	4	C		
Prilocaine	*Citanest*	2	B		
Primidone	*Mysoline*	3	B		
Probenecid		4	C		
Procainamide	*Pronestyl*	4	B		
Procaine		3	B		
Procaterol	*Pro Air*	3	A		
Prochlorperazine	*Darbazine, Compazine*	2	A		
Procyclidine	*Kemadrin*	3	B		
Promazine	*Sparine*	3	B		
Promethazine	*Phenergan*	3	B		
Propafenone	*Rythmol*	4	B		
Propanidid		2	A		
Propantheline	*Pro-Banthine*	3	B		
Proparacaine	*Ophthaine*	4	C		
Propentophylline	*Karsivan*	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Propiomazine	*Largon*	2	A		
Propionylpromazine	*Tranvet*	2	A		
Propiram		2	A		
Propofol	*Diprivan, Disoprivan*	2	A		
Propoxycaine	*Ravocaine*	2	A		
Propranolol	*Inderal*	3	B		
Propylhexedrine	*Benzedrex*	4	B		
Prostanazol		3	A		
Prothipendyl	*Dominal*	2	A		
Protokylol	*Ventaire*	3	A		
Protriptyline	*Concordin, Triptil*	2	A		
Proxibarbital	*Axeen, Centralgol*	2	A		
Pseudoephedrine	*Cenafed, Novafed*	3	B		
Pyridostigmine	*Mestinon, Regonol*	3	B		
Pyrilamine	*Neoantergan, Equihist*	3	B		
Pyrithyldione	*Hybersulfan, Sonodor*	2	A		
Quazipam	*Doral*	2	A		
Quetiapine	*Seroquel*	2	A		
Quinapril, Quinaprilat	*Accupril*	3	A		
Quinbolone		3	A		
Quinidine	*Quinidex, Quinicardine*	4	B		
Rabeprazole	*Aciphex*	5	D		
Racemethorphan		2	A		
Racemorphan		2	A		
Raclopride		2	A		
Ractopamine	*Paylean*	2	A		
Raloxifene		3	B	Estrogen effects, same classification as Testolactone on Human Olympic Guidelines - selective estrogen receptor modulators-SERMs.	Testolactone has B classification

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Ramipril, metabolite Ramiprilat	*Altace*	3	A		
Ranitidine	*Zantac*	5	D		
Remifentanil	*Ultiva*	1	A		
Remoxipride	*Roxiam*	2	A		
Reserpine	*Serpasil*	2	B		
Rilmazafone		2	A		
Risperidone		2	A		
Ritanserin		2	A		
Ritodrine	*Yutopar*	3	B		
Rivastigmine	*Exelon*	2	A		
Rizatriptan	*Maxalt*	3	B		
Rocuronium	*Zemuron*	2	A		
Rofecoxib	*Vioxx*	2	B		
Romifidine	*Sedivet*	3	B		
Ropivacaine	*Naropin*	2	A		
Roxadustat (FG-4592)		1	A	Erythropoietin Link - HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells.	Blood doping agent
Salicylamide		4	C		
Salicylate		4	C		
Salmeterol		3	B		
Scopolamine (Hyoscine)	*Triptone*	4	C		
Secobarbital (Quinalbarbitone)	*Seconal*	2	A		
Selegiline	*Eldepryl, Jumex, etc.*	2	A		
Sertraline	*Lustral, Zoloft*	2	A		
Sibutramine	*Meridia*	3	B		
Sildenafil	*Viagra*	3	A		
Snake Venoms		1	A		
Somatrem	*Protropin*	2	A		
Somatropin	*Nutropin*	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Sotalol	*Betapace, Sotacor*	3	B		
Spiclomazine		2	A		
Spiperone		2	A		
Spirapril, metabolite Spiraprilat	*Renomax*	3	A		
Spironalactone	*Aldactone*	4	B		
Spironolactone	Diuretic	3	C		
Stanozolol	*Winstrol-V*	3	B		
Stenbolone		3	A		
Strychnine		1	A		
Succinylcholine	*Sucostrin, Quelin, etc.*	2	A		
Sufentanil	*Sufenta*	1	A		
Sulfasalazine	*Azulfidine, Azaline*	4	C		
Sulfondiethylmethane		2	A		
Sulfonmethane		2	A		
Sulforidazine	*Inofal*	2	A		
Sulindac	*Clinoril*	3	B		
Sulpiride	*Aiglonyl, Sulpitil*	2	A		
Sultopride	*Barnetil*	2	A		
Sumatriptan	*Imitrex*	3	B		
Synthetic cannabis	*Spice, K2, Kronic*	1	A		
Tadalasil	*Cialis*	3	A		
Talbutal	*Lotusate*	2	A		
Tamoxifen		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Estrogen receptor antagonist antineoplastic agent.	Testolactone has B classification
Tandospirone		2	A		
TCO2		3	B		
Telmisartin	*Micardis*	3	B		
Temazepam	*Restoril*	2	A		
Tenoxicam	*Alganex, etc.*	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Tepoxalin		3	B		
Terazosin	*Hytrin*	3	A		
Terbutaline	*Brethine, Bricanyl*	3	B		
Terfenadine	*Seldane, Triludan*	4	C		
Testolactone	*Teslac*	3	B		
Testosterone		3	B		
Tetrabenazine	*Nitoman*	2	A		
Tetracaine	*Pontocaine*	2	A		
Tetrahydrogestrinone		3	A		
Tetrahydrozoline	*Tyzine*	4	B		
Tetrazepam	*Musaril, Myolastin*	2	A		
THC (tetrahydrocannabinol)[2]	Drug of human abuse	1	A	Drug of human abuse.	
Thebaine		2	A		
Theobromine		4	B		
Theophylline	*Aqualphyllin, etc.*	3	B		
Thialbarbital	*Kemithal*	2	A		
Thiamylal	*Surital*	2	A		
Thiethylperazine	*Torecan*	2	A		
Thiopental	*Pentothal*	2	A		
Thiopropazate	*Dartal*	2	A		
Thioproperazine	*Majeptil*	2	A		
Thioridazine	*Mellaril*	2	A		
Thiosalicylate		4	B		
Thiothixene	*Navane*	2	A		
Thiphenamil	*Trocinate*	4	B		
Thyroxine and thyroid modulators/hormones, including but not limited to those containing T4 (tetraiodothyronine/thyroxine), T3 (triiodothyronine), or combinations thereof.	Levothyroxine	3	C	FDA approvad but has (limited) legitimate use in care of racehorses.	
Tiapride	*Italprid, Luxoben, etc.*	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Tiaprofenic acid	*Surgam*	3	B		
Tibolone		3	A	Steroid - synthetic steroid.	AAS lacking FDA approval
Tiletamine	*Component of Telazol*	2	A		
Timiperone	*Tolopelon*	2	A		
Timolol	*Blocardrin*	3	B		
Tocainide	*Tonocard*	4	B		
Tofisopam	*Grandaxain, Seriel*	2	A		
Tolazoline	*Priscoline*	3	B		
Tolfenamic Acid		4	B		
Tolmetin	*Tolectin*	3	B		
Topirimate	*Topamax*	2	A		
Toremifene		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Selective estrogen receptor modulator.	
Torsemide (Torasemide)	*Demadex*	3	A		
Tramadol	*Ultram*	2	B		
Trandolapril (and metabolite, trandolaprilat)	*Tarka*	3	B		
Tranexamic acid		4	C		
Tranylcypromine	*Parnate*	2	A		
Trazodone	*Desyrel*	2	A		
Trenbolone	*Finoplix*	3	B		
Tretoquinol	*Inolin*	2	A		
Triamcinolone	*Vetalog, etc.*	4	C		
Triamterene	*Dyrenium*	4	B		
Triazolam	*Halcion*	2	A		
Tribromethanol		2	A		
Tricaine methanesulfonate	*Finquel*	2	A		
Trichlormethiazide	*Naqua, Naquasone*	4	C		
Trichloroethanol		2	A		
Tricholoethylene	*Trilene, Trimar*	2	A		
Triclofos	*Triclos*	2	A		
Tridihexethyl	*Pathilon*	4	B		
Trifluomeprazine	*Nortran*	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Trifluoperazine	*Stelazine*	2	A		
Trifluperidol	*Triperidol*	2	A		
Triflupromazine	*Vetame, Vesprin*	2	A		
Trihexylphenidyl	*Artane*	3	A		
Trimeprazine	*Temaril*	4	B		
Trimetazidine		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - a drug for angina pectoris, the first cytoprotective anti- ischemic agent.	
Trimethadione	*Tridione*	3	B		
Trimethaphan	*Arfonad*	3	A		
Trimipramine	*Surmontil*	2	A		
Tripelennamine	*PBZ*	3	B		
Triprolidine	*Actidil*	3	B		
Tubocurarine (Curare)	*Metubin*	2	A		
Tybamate	*Benvil, Nospan, etc.*	2	A		
Urethane		2	A		
Valdecoxib		2	B		
Valerenic acid		3	A		
Valnoctamide	*Nirvanyl*	2	A		
Valsartan	*Diovan*	3	B		
Vardenafil	*Levitra*	3	A		
Vedaprofen		4	B		
Venlafaxine	*Efflexor*	2	A		
Veralipride	*Accional, Veralipril*	2	A		
Verapamil	*Calan, Isoptin*	4	B		
Vercuronium	*Norcuron*	2	A		
Viloxazine	*Catatrol, Vivalan, etc.*	2	A		
Vinbarbital	*Delvinol*	2	A		
Vinylbital	*Optanox, Speda*	2	A		
Warfarin	*Coumadin, Coufarin*	5	D		
Xylazine	*Rompun, Bay Va 1470*	3	B		
Xylometazoline	*Otrivin*	4	B		
Yohimbine		2	B		
Zafirlukast	*Accolate*	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Zaleplon	*Sonata*	2	A		
Zeranol	*Ralgro*	4	C		
Ziconotide		1	A		
Zileuton	*Zyflo*	4	C		
Zilpaterol hydrochloride	*Zilpaterol*	2	A		
Ziprasidone	*Geoden*	2	A		
Zolazepam		2	A		
Zolmitriptan	*Zomig*	3	B		
Zolpidem	*Ambien, Stilnox*	2	A		
Zomepirac	*Zomax*	2	B		
Zonisamide	*Zonegran*	3	B		
Zopiclone	*Imovan*	2	A		
Zotepine	*Lodopin*	2	A		
Zuclopenthixol	*Ciatyl, Cesordinol*	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.

Non-Classified Substances

Substances that are considered to have no effect on the physiology of a racing animal except to improve nutrition or treat or prevent infections or parasite infestations, are not classified. These Substances normally include antimicrobials, antiparasitic drugs, and nutrients such as vitamins. Examples of such substances include the following:

Sulfonamides and trimethoprim		Bufotenine	1. Note: Bufotenine is not commerically available in any form.
Antibiotics:	Penicillins Cephalosporins Chloramphenicol Aminoglycosides Tetractckubes Nitrofurans Metronidazole		2. Note: Bufotenine is a metabolite of5-methoxy-N-N dimethyltryptamine, found in reed canary grass (and potentially other food source plants). It may be found in the urine of horses eating this grass (and potentially other plant foods), and has been reported as a positive finding. Findings of bufotenine in equine urine should not be considered for regulatory action.
Anthelmintics:	Avermectins Benzimadaziles Piperazines Pyrantel		
Antifungals			
Vitamins	A,D,E,K,B vitamins Vitamin C		

NOTE: Dimethylsulphone (MSM) has been removed from the classification document and its status is "Do Not Report".

UNIFORM CLASSIFICATION OF FOREIGN SUBSTANCES
Version 14.0

PENALTY GUIDELINES

Association of Racing Commissioners International
1510 Newtown Pike, Lexington, Kentucky, United States
www.arci.com

PENALTY CATEGORY "A"

The following are recommended penalties for violations due to the presence of a drug carrying a **Category "A" penalty** and for violations of ARCI-011-015 and ARCI-025-015: Prohibited Practices:

LICENSED TRAINER:		
1st Offense	**2nd LIFETIME offense in any jurisdiction**	**3rd LIFETIME offense in any jurisdiction**
• Minimum one-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a three-year suspension **AND** • Minimum fine of $10,000 or 10% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of $25,000 or 25% of purse (greater of the two). **AND** • May be referred to the Commission for any further action deemed necessary by the Commission.	• Minimum three-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a three-year period. **AND** • Minimum fine of $25,000 or 25% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of $50,000 or 50% purse (greater of the two). **AND** • May be referred to the Commission for any further action deemed necessary by the Commission.	• Minimum five-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a five-year period. **AND** • Minimum fine of $50,000 or 50% of total purse (greater of the two) absent mitigating circumstances. The preence of aggravating factors could be used to impose a maximum of $100,000 or 100% purse (greater of the two). **AND** • May be referred to the Commission for any further action deemed necessary by the Commission.
LICENSED OWNER:		
1st Offense	**2nd LIFETIME offense in owner's stable any jurisdiction**	**3rd LIFETIME offense in owner's stable in any jurisdiction**
• Disqualification and loss of purse **AND** • Horse shall be placed on the Veterinarian's List for 180 days and must pass a commission-approved examination before becoming eligible to be entered.	• Disqualification and loss of purse **AND** • Horse shall be placed on the Veterinarian's List for 180 days and must pass a commission-approved examination before becoming eligible to be entered.	• Disqualification, loss of purse and $50,000 fine **AND** • Horse shall be placed on the Veterinarian's List for 180 days and must pass a commission-approved examination before becoming eligible to be entered. **AND** • Referral to the Commission with a recommendation of a suspension for a minimum of 90 days.

PENALTY CATEGORY "B"

The following are recommended penalties for violations due to the presence of a drug carrying Category "B" penalty, for the presence of more than one NSAID a plasma/serum sample, subject to the provisions set forth in ARCI-011-020(E) and ARCI-025-020(E) and for violations of the established levels for total carbon dioxide:

LICENSED TRAINER:		
1st Offense	**2nd offense (365-day period) in any jurisdiction**	**3rd offense (365-day period) in any jurisdiction**
• Minimum 15-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 60-day suspension **AND** • Minimum fine of $500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of $1,000.	• Minimum 30-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 180-day suspension **AND** • Minimum fine of $1,000 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of $2,500.	• Minimum 60-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a one-year suspension. **AND** • Minimum fine of $2,500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of $5,000 or 5% purse (greater of the two). **AND** • May be referred to the Commission for any further action deemed necessary by the Commission.
LICENSED OWNER:		
1st Offense	**2nd offense (365-day period) in owner's stable any jurisdiction**	**3rd offense (365-day period) in owner's stable in any jurisdiction**
• Disqualification and loss of purse [in the absence of mitigating circumstances]* **AND** • Horse must pass a commission-approved examination before becoming eligible to be entered.	• Disqualification and loss of purse [in the absence of mitigating circumstances]* **AND** • Horse must pass a commission-approved examination before becoming eligible to be entered.	• Disqualification, loss of purse, and in the absence of mitigating circumstances a $5,000 fine.* **AND** • Horse shall be placed on the Veterinarian's List for 45 days and must pass a commission-approved examination before becoming eligible to be entered.

PENALTY CATEGORY "C"

The following are recommended penalties for violations due to the presence of a drug carrying a Category "C" penalty and overages for permitted NSAIDs and furosemide: (***All concentrations are for measurements in serum or plasma.)***

LICENSED TRAINER	**Phenylbutazone (>2.0-5.0 mcg/ml)* Flunixin (>20 - 100 ng/ml) Ketoprofen (>2- 50 ng/ml) Furosemide (>100 ng/ml) and/or no furosemide when identified as administered**	**Phenylbutazone (>5.0 mcg/ml) Flunxin (>100 ng/ml) Ketoprofen (>50 ng/ml) and CLASS C Violations**
1st Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of $500	Minimum fine of $1,000 absent mitigating circumstances
2nd Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of $750	Minimum fine of $1,500 and 15-day suspension absent mitigating circumstances
3rd Offense (365-day period) in any jurisdiction	Minimum fine of $500 to a maximum fine of $1,000	Minimum fine of $2,500 and 30-day suspension absent mitigating circumstances
LICENSED OWNER	**Phenylbutazone (>2.0-5.0 mcg/ml)* Flunixin (>20 - 100 ng/ml) Ketoprofen (>2- 50 ng/ml) Furosemide (>100 ng/ml) and/or no furosemide when identified as administered**	**Phenylbutazone (>5.0 mcg/ml) Flunxin (>100 ng/ml) Ketoprofen (>50 ng/ml) and CLASS C Violations**
1st Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. Horse must pass commission-approved examination before being eligible to run.
2nd Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. If same horse, placed on veterinarian's list for 45 days, must pass commission-approved examination before being eligible to run
3rd Offense (365-day period) in any jurisdiction	Disqualification and loss of purse. Horse must pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. Minimum $5,000 fine. If same horse, placed on veterinarian's list for 60 days, must pass commission-approved examination before being eligible to run

*If the trainer has not had more than one violation within the previous two years, the Stewards/Judges are encouraged to issue a warning in lieu of a fine provided the reported level is below 3.0 mcg/ml absent of aggravating factors.

After a two-year period, if the licensee has had no further violations, any penalty due to an overage in the 2.0-5.0 category will be expunged from the licensee's record for penalty purposes.

PENALTY CATEGORY “D”

The recommended penalty for a violation involving a drug that carries a Category “D” penalty is a written warning to the trainer and owner. Multiple violations may result in fines and/or suspension.

MMV Point System

Multiple Medication Violation Model Rule.

ARCI-011-020 (B)(13)

Officials are advised to check a licensee's ARCI regulatory record to see if multiple medication violations should be considered as an aggravating factor in the determination of an appropriate penalty.

(1) Multiple Medication Violations (MMV)

(a) A trainer who receives a penalty for a medication violation based upon a horse testing positive for a Class 1-5 medication with Penalty Class A-C, as provided in the most recent version of the ARCI Uniform Classification Guidelines for Foreign Substances, or similar state regulatory guidelines, shall be assigned points as follows:

Penalty Class	Points If Controlled Therapeutic Substance	Points If Non-Controlled Substance
Class A	N/A	6
Class B	2	4
Class C	½ for first violation with an additional ½ point for each additional violation within 365 days[1]	1 for first violation with an additional ½ point for each additional violation within 365 days
Class D	0	0

[1] *Points for NSAID violations only apply when the primary threshold of the NSAID is exceeded. Points are not to be separately assigned for a stacking violation*.

If the Stewards or Commission determine that the violation is due to environmental contamination, they may assign lesser or no points against the trainer based upon the specific facts of the case.

(b) The points assigned to a medication violation by the Stewards or Commission ruling shall be included in the ARCI official database. The ARCI shall record points consistent with Section 13(a) including when appropriate, a designation that points have been suspended for the medication violation. Points assigned by such regulatory ruling shall reflect, in the case of multiple positive tests as described in paragraph

(d), whether they constitute a single violation. The Stewards' or Commission Ruling shall be posted on the official website of the Commission and within the official database of the Association of Racing Commissioners International. If an appeal is pending, that fact shall be noted in such Ruling. No points shall be applied until a final adjudication of the enforcement of any such violation.

(c) A trainer's cumulative points for violations in all racing jurisdictions shall be maintained by the ARCI. Once all appeals are waived or exhausted, the points shall immediately become part of the trainer's official ARCI record and shall be considered by the Commission in its determination to subject the trainer to the mandatory enhanced penalties by the Stewards or Commission as provided in this regulation.

(d) Multiple positive tests for the same medication incurred by a trainer prior to delivery of official notice by the commission may be treated as a single violation. In the case of a positive test indicating multiple substances found in a single post-race sample, the Stewards may treat each substance found as an individual violation for which points will be assigned, depending upon the facts and circumstances of the case.

(e) The official ARCI record shall be used to advise the Stewards or Commission of a trainer's past record of violations and cumulative points. Nothing in this administrative regulation shall be construed to confer upon a licensed trainer the right to appeal a violation for which all remedies have been exhausted or for which the appeal time has expired as provided by applicable law.

(f) The Stewards or Commission shall consider all points for violations in all racing jurisdictions as contained in the trainer's official ARCI record when determining whether the mandatory enhancements provided in this regulation shall be imposed.

(g) In addition to the penalty for the underlying offense, the following enhancements shall be imposed upon a licensed trainer based upon the cumulative points contained in his/her official ARCI record:

Points	**Suspension in days**
5-5.5	15 to 30
6-8.5	30 to 60
9-10.5	90 to 180
11 or more	180 to 360

MMV penalties are not a substitute for the current penalty system and are intended to be an additional uniform penalty when the licensee:

(i) Has had more than one medication violation for the relevant time period, and
(ii) Exceeds the permissible number of points.

The Stewards and Commission shall consider aggravating and mitigating circumstances, including the trainer's prior record for medication violations, when determining the appropriate penalty for the underlying offense. The MMP is intended to be a separate and additional penalty for a pattern of violations.

(h) The suspension periods as provided in Section 13(g) shall run consecutive to any suspension imposed for the underlying offense.

(i) The Stewards' or Commission Ruling shall distinguish between the penalty for the underlying offense and any enhancement based upon a Stewards or Commission review of the trainer's cumulative points and regulatory record, which may be considered an aggravating factor in a case.

(j) Points shall expire as follows:

Penalty Classification	Time to Expire
A	3 years
B	2 years
C	1 year

In the case of a medication violation that results in a suspension, any points assessed expire on the anniversary date of the date the suspension is completed.

NSAID STACKING MODEL RULE
ARCI-011-020 (E)

E. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

(1) The use of NSAIDs shall be governed by the following conditions:

(a) (BLANK)

(b) NSAIDs included in the ARCI Controlled Therapeutic Medication Schedule, Version 2.2, are not to be used in a manner inconsistent with the restrictions contained therein. NSAIDs not included on the ARCI Controlled Therapeutic Medication Schedule, Version 2.2, are not be present in a racing horse biological sample at the laboratory concentration of detection.

(c) The presence of more than one NSAID may constitute a NSAID stacking violation consistent with the following restrictions:

A. A Class 1 NSAID Stacking Violation (Penalty Class B) occurs when:

i. Two non-steroidal anti-inflammatory drugs are found at individual levels determined to exceed the following restrictions:

a. Diclofenac – 5 nanograms per milliliter of plasma or serum;

b. Firocoxib - 20 nanograms per milliliter of plasma or serum;

c. Flunixin – 20 nanograms per milliliter of plasma or serum;

d. Ketoprofen – 2 nanograms per milliliter of plasma or serum;

e. Phenylbutazone – 2 micrograms per milliliter of plasma or serum; or

f. all other non-steroidal anti-inflammatory drugs – laboratory concentration of detection

ii. Three or more non-steroidal anti-inflammatory drugs are found at individual levels determined to exceed the following restrictions:

a. Diclofenac – 5 nanograms per milliliter of plasma or serum;

b. Firocoxib - 20 nanograms per milliliter of plasma or serum;

c. Flunixin – 3 nanograms per milliliter of plasma or serum;

d. Ketoprofen – 1 nanograms per milliliter of plasma or serum;

e. Phenylbutazone – 0.3 micrograms per milliliter of plasma or serum; or

f. all other non-steroidal anti-inflammatory drugs – laboratory concentration of detection.

B. A Class 2 NSAID Stacking Violation (Penalty Class C) occurs when:

i. Any one substance noted in Subsection (A)(i) above is found in excess of the restrictions contained therein in combination with any one of the following substances at levels below the restrictions so noted but in excess of the following levels:

a. Flunixin – 3 nanograms per milliliter of plasma or serum;

b. Ketoprofen – 1 nanogram per milliliter of plasma or serum; or

c. Phenylbutazone – 0.3 micrograms per milliliter of plasma or serum;

C. A Class 3 NSAID Stacking Violation (Penalty Class C, fines only) occurs when:

i. Any combination of two of the following non-steroidal anti-inflammatory drugs are found at or below the restrictions in Subsection (A)(i)(a through e) above but in excess of the noted restrictions:

a. Flunixin – 3 nanograms per milliliter of plasma or serum;

b. Ketoprofen – 1 nanogram per milliliter of plasma or serum; or

c. Phenylbutazone – 0.3 micrograms per milliliter of plasma or serum;

(2) Any horse to which a NSAID has been administered shall be subject to having a blood and/or urine sample(s) taken at the direction of the official veterinarian to determine the quantitative NSAID level(s) and/or the presence of other drugs which may be present in the blood or urine sample(s).

Recent Document Revisions

Version	Date	Drug/Substance	Notes
13.4.1	August 2018	Altrenogest	Added a missing footnote.
13.4	January 2018	Dipyrone	Penalty Classification changed from C to B; Drug Class remains 4
13.4	January 2018	Tolfenamic Acid	Added as Drug Class 4, Penalty Class B
13.4	January 2018	Pimobendan	Added as Drug Class 2, Penalty Class B
13.4	January 2018	Mitragynine	Added as Drug Class 1, Penalty Class A
13.4	January 2018	Metformin	Added as Drug Class 2, Penalty Class B
13.4	January 2018	Letrozole	Added as Drug Class 3, Penalty Class A
13.4	January 2018	Capsaicin	Added as Drug Class 2, Penalty Class B
13.4	January 2018	Altrenogest	Added as Drug Class 4, Penalty Class C in male horses only; no restriction in female horses.
13.3	July 2017	Penalty C Guideline Modification	Added "[in the absence of mitigating circumstances]" for owner 1st offense
13.2	April 2017	Pemalty A Guideline Modification	Increase time on vets list to 180 days
13.2	April 2017	Articaine, Carticaine, and Priolocaine	Penalty Class Changed from A to B
13.2	April 2017	Cinchocaine	Penalty Class Changed from A to B
13.2	April 2017	Formebolone	Penalty Class Change from B to A
13.2	April 2017	Methyltestosterone	Penalty Class Change from A to B
13.2	April 2017	Methyl-1-testosterone	Added; Class 3, Penalty Class A
13.2	April 2017	Oxymesterone	Penalty Class Change from B to A
13.2	April 2017	Sulindac	Penalty Class Change from A to B
13.2	April 2017	Valdecoxib	Penalty Change from A to B
13.2	April 2017	Benazepril	Penalty Class Changed to A
13.2	April 2017	Eszopiclone	Added Class 2; Penalty Class A
13.2	April 2017	Propantheline	Penalty Class B assigned.
13.00	January 11, 2017		Version 13.00 Publication Date
13.00	December 2016	Methdilazine	Changed from Class 4 to Class 3
13.00	December 2016	Naepaine	Changed from Class 4/Penalty C to Class 2/Penalty A
13.00	December	Nortestosterone	Changed from Class 4/Penalty C to Class 3/Penalty B

	2016		
13.00	December 2016	Olsalazine	Changed from Class 4/Penalty B to Class 5/Penalty C
13.00	December 2016	Oxaprozin	Changed from Penalty C to Penalty B
13.00	December 2016	Pentoxyfylline	Changed from Penalty C to Penalty D
13.00	December 2016	Terfenadine	Changed from Penalty B to Penalty C
13.00	December 2016	Thiosalicylate	Changed from Penalty C to Penalty B
13.00	December 2016	Triprolidine	Changed from Class 4 to Class 3
13.00	December 2016	Anisindione	Changed from Penalty C to Penalty D
13.00	December 2016	Cilostazol	Changed from Class 5/Penalty C to Class 4/Penalty B
13.00	December 2016	Cromolyn	Changed from Penalty C to Penalty D
13.00	December 2016	Dimethylsulphone (MSM)	Removed from classifications; recommended “do not report”
13.00	December 2016	Misoprostol	Changed from Penalty C to Penalty D
13.00	December 2016	Nedocromil	Changed from Penalty C to Penalty D
13.00	December 2016	Phenindione	Changed from Penalty C to Penalty D

Version	Date	Drug/Substance	Notes	Approx. Page(s)
13.00	December 2016	Phenprocoumon	Changed from Penalty C to Penalty D	9, 26
13.00	December 2016	Polyethylene Glycol	Changed from Penalty C to Penalty D	9, 26
13.00	December 2016	Warfarin	Changed from Penalty C to Penalty D	11, 26
13.00	December 2016	Pirbuterol	Changed from Penalty A to Penalty B	9, 21
13.00	December 2016	Piroxicam	Changed from Class 3 to Class 4	9, 24
13.00	December 2016	Prostanazol	Changed from Penalty B to Penalty A	9, 21
13.00	December 2016	Quinbolone	Changed from Penalty B to Penalty A	9, 21
13.00	December 2016	Scopolamine	Changed from Class 3/Penalty B to Class 4/Penalty C	10, 25
13.00	December 2016	Stenbolone	Changed from Penalty B to Penalty A	10, 22
13.00	December 2016	TCO_2	Changed from Unclassified with Penalty B recommended to Class 3/Penalty B	10, 22
13.00	December 2016	Acetazolamide	Changed from Penalty B to Penalty C	1, 23
13.00	December 2016	Ambroxol	Changed from Penalty C to Penalty B	1, 23
13.01	December 2016	Cocaine and Morphine	Added a footnote inadvertently excluded from V.13.0	
13.00	December 2016	Brompheniramine	Changed from Class 4 to Class 3	2, 19
13.00	December 2016	Butacaine	Changed from Class 4/Penalty C to Class 2/Penalty A	2, 14
13.00	December 2016	Carbazochrome	Changed from Penalty C to Penalty B	2, 23
13.00	December 2016	Ciclesonide	Changed from Penalty B to Penalty C	3, 23
13.00	December 2016	Cinchocaine	Changed from Class 4/Penalty C to Class 2/Penalty A	3,4,14, 15
13.00	December 2016	Clibucaine	Changed from Class 4/Penalty C to Class 2/Penalty A	3,15
13.00	December 2016	Clormecaine	Changed from Class 4/Penalty C to Class 2/Penalty A	3,15
13.00	December 2016	Cyclizine	Changed from Class 4 to Class 3	3,19
13.00	December 2016	Cyproheptadine	Changed from Class 4/Penalty C to Class 3/Penalty B	3,19
13.00	December 2016	Dibucaine	Changed from Class 4/Penalty C to Class 2/Penalty B	4,15
13.00	December 2016	Eltenac	Changed from Penalty C to Penalty B	4,23
13.00	December 2016	Ethoheptazine	Changed from Class 4/Penalty C to Class 2/Penalty A	4,15
13.00	December 2016	Fluorometholone	Changed from Penalty B to Penalty C	5,24
13.00	December 2016	Fluoroprednisolone	Changed from Penalty C to Penalty B	5,24
13.00	December 2016	Hexylcaine	Changed from Class 4/Penalty C to Class 2/Penalty B	5,16
13.00	December 2016	Isoxsuprine	Changed from Penalty C to Penalty D	6,24
13.00	December 2016	Letosteine	Changed from Penalty C to Penalty B	6,24

Version	Date	Drug/Substance	Notes	Approx. Page(s)
13.00	December 2016	Loratidine	Changed from Penalty B to Penalty C	6,24
13.00	December 2016	Meclizine	Changed from Class 4 to Class 3	6,20
13.00	December 2016	Methapyrilene	Changed from Class 4 to Class 3	7,20
13.00	December 2016	Amyl Nitrite	Changed from Class 3 to Class 2	1,14
13.00	December 2016	Arformoterol	Changed from Penalty A to Penalty B	1,19
13.00	December 2016	Calusterone	Changed from Penalty B to Penalty A	2,19
13.00	December 2016	Clostebol	Changed from Penalty B to Penalty A	3,19
13.00	December 2016	Dehydrochloromethyltestosterone	Changed from Penalty B to Penalty A	3,19
13.00	December 2016	Desoxymethyltestosterone	Changed from Penalty B to Penalty A	3,19
13.00	December 2016	Enalapril	Changed from Penalty B to Penalty A	4,20
13.00	December 2016	Felbamate	Changed from Penalty A to Penalty B	5,20
13.00	December 2016	Furazabol	Changed from Penalty B to Penalty A	5,20
13.00	December 2016	Glycopyrrolate	Changed from Class 3/Penalty B to Class 4/Penalty C	5,24
13.00	December 2016	Mepenzolate	Changed from Penalty A to Penalty B	6,20
13.00	December 2016	Mestanolone	Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Mesterolone	Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Methandrostenolone (Methandienone)	Added alternate name, Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Methandriol (Methylandrostenediol)	Added alternate name, Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Metenolone	Chagned from Penalty B to Penalty A	7,20
13.00	December 2016	Methyldienolone	Changed from Penalty B to Penalty A	7,21
13.00	December 2016	Methylnortestosterone (Trestolone)	Added alternate name, Changed from Penalty B to Penalty A	7,21
13.00	December 2016	Methsuximide	Changed from Class 3/Penalty A to Class 4/Penalty B	7,24
13.00	December 2016	Methyltestosterone	Changed from Penalty B to Penalty A	7,21
13.00	December 2016	Naloxone	Changed from Penalty A to Penalty B	8,21
13.00	December 2016	Naltrexone	Changed from Penalty A to Penalty B	8,21
13.00	December 2016	N-Butylscopolamine	Changed from Class 3/Penalty B to Class 4/Penalty C	2,7,24
13.00	December 2016	Nitroglycerin	Changed from Class 3 to Class 2	8,16
13.00	December 2016	Norbolethone/Norboletone	Added alternate spelling, Changed from Penalty B to Penalty A	8,21
13.00	December 2016	Norclostebol	Changed from Penalty B to Penalty A	8,21
13.00	December 2016	Oxabolone	Changed from Penalty B to Penalty A	8,21
13.00	December 2016	Oxprenolol	Changed from Penalty B to Penalty A	8,21
13.00	December 2016	Physostigmine	Changed from Penalty B to Penalty A	9,21

Version	Date	Drug/Substance	Notes	Approx. Page(s)
13.00	December 2016	Pindolol	Changed from Penalty A to Penalty B	9,21
13.00	December 2016	Amitraz	Changed from Penalty A to Penalty B	1,19
13.00	December 2016	Alprenolol	Changed from Class 3 to Class 2	1,14
13.00	December 2016	Zomepirac	Changed from Penalty A to Penalty B	11,18
13.00	December 2016	Yohimbine	Changed from Penalty A to Penalty B	11,18
13.00	December 2016	Snake Venoms	Changed from Class 2 to Class 1	10,13
13.00	December 2016	Romifidine	Changed from Class 2 to Class 3	10,21
13.00	December 2016	Rofecoxib	Changed from Penalty A to Penalty B	10,17
13.00	December 2016	Reserpine	Changed from Penalty A to Penalty B	10,17
13.00	December 2016	Midazolam	Changed from Class 2/Penalty A to Class 3/Penalty B	7,21
13.00	December 2016	Loperamide	Changed from Class 2/Penalty A to Class 3/Penalty B	6,20
13.00	December 2016	Isoxicam	Changed from Penalty A to Penalty B	6,16
13.00	December 2016	Fluphenazine	Changed from Penalty A to Penalty B	5,15
13.00	December 2016	Fenclozic Acid	Changed from Penalty A to Penalty B	5,15
13.00	December 2016	Erythropoietin	Changed from Class 2 to Class 1	4,12
13.00	December 2016	Diazepam	Changed from Class 2 to Class 3	4,19
13.00	December 2016	Darbepoetin	Changed from Class 2 to Class 1; Corrected spelling under "Prohibited Practices"	vi,3,12
13.00	December 2016	Chlorpromazine	Changed from Class 2 to Class 1	3,12
13.00	December 2016	Benoxaprofen	Changed from Penalty A to Penalty B	1,14
13.00	December 2016	Alclofenac	Changed from Penalty A to Penalty B	1,14
13.00	December 2016	Atipamazole	Added to Uniform Classification Guide as Class 2, Penalty B	1,14
13.00	December 2016	Cocaine	Changed from Penalty B to Penalty A	3,12
13.00	December 2016	Ethylphenidate	Added to Uniform Classification Guide as Class 1, Penalty A	5,12
13.00	December 2016	Meldonium	Added to Uniform Classification Guide as Class 1, Penalty A	6,12
13.00	December 2016	Morphine	Changed from Penalty B to Penalty A	7,12
13.00	December 2016	Strychnine	Changed from Penalty B to Penalty A	10,13
12.00	March 2016	Methamphetamine	Added footnote language recommending Penalty B if testing can prove presence of only levo-methamphetamine is present in sample.	7, 13
12.00	March 2016	Tramadol	Changed from Penalty A to Penalty B	11, 19
12.00	March 2016	Cetirizine	Changed from Penalty B to Penalty C after inclusion into ARCI Controlled Therapeutic Medicaion Schedule	2, 24

Version	Date	Drug/Substance	Notes	Approx. Page(s)
12.00	March 2016	Morphine	Added footnote language recommending Penalty A if intentional administration can be proven by regulators.	8, 13
12.00	March 2016	Cocaine	Added footnote language recommending Penalty A if intentional administration can be proven by regulators.	3, 13
12.00	March 2016	Methacholine	Corrected spelling error in Alphabetical Listing by Substance Section and Listing by Classification Section	7, 20
12.00	March 2016	myo-inositol trispyrophosphate (ITPP)	Corrected spelling error in Alphabetical Listing by Substance Section and Listing by Classification Section	8, 13
11.00	December 2015	2-Aminoheptane	Corrected typographical error to reflect Class 4, Penalty B Substance	1, 23
11.00	December 2015	Xylometazoline	Corrected typographical error to reflect Class 4, Penalty B Substance	11, 25
11.00	December 2015	Rivastigmine	Corrected typographical error to reflect Class 2, Penalty A Substance	10, 17
11.00	December 2015	Rabeprazole	Corrected typographical error to reflect Class 5, Penalty D Substance	10 26
11.00	December 2015	Prilocaine	Corrected typographical error to reflect Class 2, Penalty A Substance	9, 17
11.00	December 2015	Hexocyclium	Corrected typographical error to reflect Class 4, Penalty B Substance	6, 24
11.00	December 2015	Gabapentin	Corrected typographical error to reflect Class 3, Penalty B Substance	5, 20
11.00	December 2015	Ergoloid Mesylates	Corrected typographical error to reflect Class 2, Penalty A Substance	4, 15
11.00	December 2015	Butacaine	Corrected typographical error to reflect Class 4, Penalty B Substance	2, 23
11.00	December 2015	Budesonide	Corrected typographical error to reflect Class 4, Penalty C Substance	2, 23
11.00	December 2015	Brimonidine	Corrected typographical error to reflect Class 2, Penalty A Substance	2, 14
11.00	December 2015	Benazepril	Corrected typographical error to reflect Class 3, Penalty B Substance	2, 19

Version	Date	Drug/Substance	Notes	Approx. Page(s)
11.00	December 2015	Amlodipine	Corrected typographical error to reflect Class 3, Penalty B Substance	1, 19
11.00	December 2015	3-Methoxytyramine	Added as Class 2, Penalty A Substance	1, 14
10.00	July 2015	Methylhexanamine	Added alternative spelling	7, 13
10.00	July 2015	Gamma Aminobutryic Acid (GABA)	Added as Class 3, Penalty B Substance	5, 19
9.00	April 2015	Cobalt	Added as Class 3, Penalty B with note to refer to ARCI Endogenous, Dietary, or Environmental Substances Schedule for threshold and penalty information for contrations of less than 50 parts per billion (ppb) in blood serum or plasma	3, 18
8.00	December 2014	Firocoxib	Changed Penalty Class from “B” to “C” to conform to the ARCI Controlled Therapeutic Medication Schedule	5, 23
8.00	December 2014	Acenocoumarol	Had been previously omitted from Listing by Classification Section, Added to section	25
8.00	December 2014	Deracoxib	Corrected Spelling in Alphabetical Listing by Substance Section	3
8.00	December 2014	Norclostebol	Corrected Spelling in Alphabetical Listing by Substance Section	8
8.00	December 2014	Rizatriptan	Corrected Spelling in Alphabetical Listing by Substance Section	10
8.00	December 2014	Dehydrochloromethyltestosterone	Corrected Spelling in Alphabetical Listing by Substance Section	3
8.00	December 2014	Amiodarone	Corrected Spelling in Listing by Classification Section	22
8.00	December 2014	2-Aminoheptane	Corrected Spelling in Listing by Classification Section	22
8.00	December 2014	Bupropion	Corrected Spelling in Listing by Classification Section	13
8.00	December 2014	Alclofenac	Assigned Penalty Class A	1, 13
8.00	December 2014	Recommended Penalties for Ketoprofen	Updated the recommended penalty for Ketoprofen to comply with the primary threshold established in the ARCI Controlled Therapeutic Medication Schedule.	29
8.00	December 2014	Class B Recommended Penalties	Corrected typographical error on recommended penalties for Class B substances for licensed owners. Version 7.00 incorrectly recommended penalties for second or third offense in the owner’s lifetime. Version 8.00 corrects error and recommends penalty for second or third offense in 365-day period.	28
8.00	December 2014	Aminorex	Addition is not a change ot the Uniform Classification Guidelines. Aminorex has been a DEA Schedule 1 substance. All DEA Schedule	1, 13

Version	Date	Drug/Substance	Notes	Approx. Page(s)
			1 substances are considered Class 1, Penalty A substances by reference. By request, Aminorex has been listed to avoid confusion.	
8.00	December 2014	Bufotenine	Corrected the precursor to 5-methoxy-N-N dimethyltryptamine	26
7.00	January 2014	Pergolide	Added as Class 3, Penalty B	8, 20
6.00	December 2013	Methylhexaneamine	Added as Class 1, Penalty A	7, 12
5.00	December 2012	Zilpaterol hydrochloride	Moved from Class 3 to Class 2 Substance, Penalty Remains Unchanged	11, 17
5.00	December 2012	Tetramisole hydrochloride	Removed from Non-Classified Substance list	26
5.00	December 2012	Ambroxol	Moved from Class 4, Penalty B to Class 4, Penalty C	1, 22
4.01	October 2012	Ractopamine	Corrected typographical error in Drug Class (Incorrectly listed as a Class 3 substance)	9, 16
4.01	October 2012	Pyrilamine	Corrected typographical error on Penalty Class (Listed as Penalty Class A in "Listing by Classification" section.	9, 20
4.00	July 2012	myo-inositol trispyrophosphate (ITPP)	Added as Class 1, Penalty A	7, 12
4.00	July 2012	Benzonatate	Added as Class 2, Penalty A	2, 13
3.00	December 2011	Almotriptan	Corrected Penalty Class omission in Alphabetical Listing section of document	1, 18
3.00	December 2011	Naltrexone	Corrected Penalty Class omission in Alphabetical Listing section of document	7, 20
3.00	December 2011	Amiloride	Corrected Penalty Class omission in Alphabetical Listing section of document	1, 22
3.00	December 2011	Butanilicaine	Corrected Penalty Class omission in Alphabetical Listing section of document	2, 13
3.00	December 2011	3,4-methylenedioxy-pyrovalerone, aka MDPV, "Bath Salts"	Corrected typographical error in Trade Name sections	1, 12
3.00	December 2011	Carbazochrome	Added as Class 4, Penalty C	2, 22
2.01	August 2011	Dimethylsulfoxide (DMSO)	Edited Drug Classification definitions to remove mention of DMSO from Class 5 definition	vii

Version	Date	Drug/Substance	Notes	Approx. Page(s)
2.00	July 2011	<<Drugs Not Listed>>	Language pertaining to all drugs/substances not found in this document shall be considered a Class I, Penalty A Substance	ii
2.00	July 2011	Phenylbutazone	Penalties for tests over 2.0 micrograms per milliliter of plasma or serum but less than 5.0 micrograms per milliliter of plasma or serum added.	29
2.00	July 2011	Dermorphin	Added as Class 1, Penalty A	3, 12
2.00	July 2011	3,4-methylenedioxy-pyrovalerone, aka MDPV, “Bath Salts”	Added as Class 1, Penalty A	1, 12
2.00	July 2011	Synthetic cannabis	Added as Class 1, Penalty A	10, 12
2.00	July 2011	Alclomethasone	Corrected typographical error in spelling	1, 22
1.01	January 2011	Methocarbamol	Corrected typographical error on Penalty Class from Class B to Class C	7, 23
1.00	December 2010	Zilpaterol	Added as Class 3, Penalty a	11, 17
1.00	December 2010	Dimethylsulfoxide (DMSO)	Changed from Class 5 to Class 4	4, 23

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

RCI Class 1 Drugs

Mandatory drugs to be tested	20
Optional drugs to be tested	30
Total Class 1 drugs to be tested	50

Drug	Category	Analyte	RCI Class	Minimum Performance Standard ng/mL	
Testing for the following drugs or their analytes must be performed:					
Alfentanil	Mandatory	Alfentanil	1	2	urine
Amphetamine	Mandatory	Amphetamine	1	10	urine
Apomorphine	Mandatory	Apomorphine	1	10	urine
Carfentanil	Mandatory	Carfentanil	1	2	urine
Cocaine	Mandatory	Benzoylecgonine	1	20	urine
Codeine	Mandatory	Morphine	1	20	urine
Dermorphin	Mandatory	Dermorphin	1	1	urine
Diacetylmorphine	Mandatory	Morphine	1	30	urine
Etorphine	Mandatory	Etorphine	1	1	urine
Fentanyl	Mandatory	Despropionylfentanyl	1	1	urine
Hydromorphone	Mandatory	Hydromorphone	1	2	urine
Levorphanol	Mandatory	Levorphanol	1	2	urine
Meperidine	Mandatory	Meperidine + Normeperidine	1	10	urine
Mephentermine	Mandatory	Mephentermine	1	10	urine
Methamphetamine	Mandatory	Methamphetamine + Amphetamine	1	10	urine
Methylphenidate	Mandatory	Ritalinic Acid	1	20	urine
Morphine	Mandatory	Morphine	1	30	urine
Oxycodone	Mandatory	Oxymorphone	1	2	urine
Oxymorphone	Mandatory	Oxymorphone	1	2	urine
Sufentanil	Mandatory	Sufentanil	1	1	urine
*Select **30** drugs from the following list for testing:*					
1-(1-Phenylcyclohexyl)pyrrolidine	Optional		1		
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine	Optional		1		
1-[1-(2-Thienyl)cyclohexyl]piperidine	Optional		1		
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine	Optional		1		
1-Methyl-4-phenyl-4-propionoxypiperidine	Optional		1		
2,5-Dimethoxy-4-ethylamphetamine	Optional		1		
2,5-Dimethoxyamphetamine	Optional		1		
3,4,5-Trimethoxyamphetamine	Optional		1		
3,4-Methylenedioxyamphetamine	Optional		1		
3,4-Methylenedioxymethamphetamine	Optional		1		
3,4-Methylenedioxy-N-ethylamphetamine	Optional		1		
3-Methylfentanyl	Optional		1		
3-Methylthiofentanyl	Optional		1		
4-Bromo-2,5-dimethoxyamphetamine	Optional		1		
4-Bromo-2,5-dimethoxyphenethylamine	Optional		1		
4-Methoxyamphetamine	Optional		1		
4-Methyl-2,5-dimethoxyamphetamine	Optional		1		
4-Methylaminorex (cis isomer)	Optional		1		
5-Methoxy-3,4-methylenedioxyamphetamine	Optional		1		
Acetorphine	Optional		1		
Acetyl-alpha-methylfentanyl	Optional		1		
Acetyldihydrocodeine	Optional		1		
Acetylmethadol	Optional		1		

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Allylprodine	Optional	1
Alphacetylmethadol except levo-alphacetylmethadol	Optional	1
Alpha-Ethyltryptamine	Optional	1
Alphameprodine	Optional	1
Alphamethadol	Optional	1
Alpha-Methylfentanyl	Optional	1
Alpha-Methylthiofentanyl	Optional	1
Alpha-Cobratoxin	Optional	1
Aminorex	Optional	1
Anileridine	Optional	1
Benzethidine	Optional	1
Benzylmorphine	Optional	1
Benzylpiperazine	Optional	1
Betacetylmethadol	Optional	1
Beta-Hydroxy-3-methylfentanyl	Optional	1
Beta-Hydroxyfentanyl	Optional	1
Betameprodine	Optional	1
Betamethadol	Optional	1
Betaprodine	Optional	1
Bufotenine	Optional	1
Carfentanil	Optional	1
Cathinone	Optional	1
Clonitazene	Optional	1
Codeine methylbromide	Optional	1
Codeine-N-oxide	Optional	1
Cyprenorphine	Optional	1
Desomorphine	Optional	1
Dextromoramide	Optional	1
Diamorphine	Optional	1
Diampromide	Optional	1
Diethylthiambutene	Optional	1
Diethyltryptamine	Optional	1
Difenoxin	Optional	1
Dihydromorphine	Optional	1
Dimenoxadol	Optional	1
Dimepheptanol	Optional	1
Dimethylthiambutene	Optional	1
Dimethyltryptamine	Optional	1
Dioxaphetyl butyrate	Optional	1
Dipipanone	Optional	1
Donepezil	Optional	1
Drotebanol	Optional	1
Endorphins	Optional	1
Enkephalins	Optional	1
Ethylmethylthiambutene	Optional	1
Ethylmorphine	Optional	1
Etonitazene	Optional	1
Etoxeridine	Optional	1
Fenethylline	Optional	1
Furethidine	Optional	1
Gama Hydroxybutyric Acid (GHB)	Optional	1
Heroin	Optional	1

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Hydrocodone (dihydrocodienone)	Optional	1
Hydromorphinol	Optional	1
Hydroxyamphetamine	Optional	1
Hydroxypethidine	Optional	1
Ibogaine	Optional	1
Ketobemidone	Optional	1
Levomoramide	Optional	1
Levophenacylmorphan	Optional	1
Lofentanil	Optional	1
Lysergic acid diethylamide	Optional	1
Mazindol	Optional	1
Mecloqualone	Optional	1
Mescaline	Optional	1
Metaraminol	Optional	1
Methadone	Optional	1
Methaqualone	Optional	1
Methcathinone	Optional	1
Methyldesorphine	Optional	1
Methyldihydromorphine	Optional	1
Methylhexaneamine	Optional	1
Metopon (methyldihydromorphinone)	Optional	1
Morpheridine	Optional	1
Morphine methylbromide	Optional	1
Morphine methylsulfonate	Optional	1
Morphine-N-oxide	Optional	1
Myo-inositol-trispyrophosphate (ITPP)	Optional	1
Myrophine	Optional	1
N,N-Dimethylamphetamine	Optional	1
N-Ethyl-1-phenylcyclohexylamine	Optional	1
N-Ethyl-3-piperidyl benzilate	Optional	1
N-Ethylamphetamine	Optional	1
N-Hydroxy-3,4-methylenedioxyamphetamine	Optional	1
Nicocodeine	Optional	1
Nicomorphine	Optional	1
Nikethamide	Optional	1
N-Methyl-3-piperidyl benzilate	Optional	1
Noracymethadol	Optional	1
Norlevorphanol	Optional	1
Normethadone	Optional	1
Normorphine	Optional	1
Norpipanone	Optional	1
Para-Fluorofentanyl	Optional	1
Parahexyl	Optional	1
Pemoline	Optional	1
Pentylenetetrazol	Optional	1
Peyote	Optional	1
Phenadoxone	Optional	1
Phenampromide	Optional	1
Phenazocine	Optional	1
Phencyclidine (PCP)	Optional	1
Phendimetrazine	Optional	1
Phenmetrazine	Optional	1

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Phenomorphan	Optional	1
Phenoperidine	Optional	1
Pholcodine	Optional	1
Picrotoxin	Optional	1
Piritramide	Optional	1
Proheptazine	Optional	1
Properidine	Optional	1
Propiram	Optional	1
Psilocybin	Optional	1
Psilocyn	Optional	1
Racemoramide	Optional	1
Remifentanil	Optional	1
Strychnine	Optional	1
Sufentanil	Optional	1
Tetrahydrocannabinols	Optional	1
Thebacon	Optional	1
Thiofentanyl	Optional	1
Tilidine	Optional	1
Trimeperidine	Optional	1
Ziconotide	Optional	1

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

RCI Class 2 Drugs

Mandatory drugs to be tested	22
Optional drugs to be tested	30
Total Class 2 drugs to be tested	52

Drug	Category	Analyte	RCI Class	(Unless otherwise indicated) **Minimum Performance Standard ng/mL**		
Testing for the following drugs or their analytes must be performed:						
Amitriptyline	Mandatory	Nortriptyline	2	2	urine	
Buprenorphine	Mandatory	Buprenorphine	2	10	urine	
Buspirone	Mandatory	Buspirone	2	20	urine	
Caffeine	Mandatory	Caffeine	2	100	plasma	
Carisoprodol	Mandatory	Meprobamate, Hydroxycarisoprodol	2	20	urine	
Chlorpromazine	Mandatory	7-Hydroxychlorpromazine	2	20	urine	
Desipramine	Mandatory	Desipramine	2	20	urine	
Dezocine	Mandatory	Dezocine	2	20	urine	
Diazepam	Mandatory	Nordiazepam, Oxazepam, Temazepam	2	20	urine	
Ephedrine	Mandatory	Ephedrine + Phenylpropanolamine	2	20	urine	
Fluoxetine	Mandatory	Fluoxetine + Norfluoxetine	2	20	urine	
Fluphenazine	Mandatory	Fluphenazine Sulfoxide, 7-Hydroxyl Fluphenazii	2	0.2	plasma	
Imipramine	Mandatory	Desipramine	2	20	urine	
Lidocaine	Mandatory	3-Hydroxylidocaine	2	20	urine	
Mepivacaine	Mandatory	3-Hydroxymepivacaine	2	10	urine	*
AND Mepivacaine	Mandatory	Mepivacaine	2	0.05	plasma	*&
Modafinil	Mandatory	Modafinil	2	20	urine	
Nalbuphine	Mandatory	Nalbuphine	2	20	urine	
Nalorphine	Mandatory	Nalorphine	2	20	urine	
Nortriptyline	Mandatory	Nortriptyline	2	20	urine	
Oxazepam	Mandatory	Oxazepam	2	20	urine	
Propionylpromazine	Mandatory	2-(1-Hydroxypropyl)promazine sulfoxide	2	20	urine	
Tramadol	Mandatory	O-Desmethyltramadol	2	2	urine	
*Select **30** drugs from the following list for testing:*						
Acecarbromal	Optional		2			
Acetophenazine	Optional		2			
Adinazolam	Optional		2			
Alclofenac	Optional		2			
Alcuronium	Optional		2			
Alphaprodine	Optional		2			
Alpidem	Optional		2			
Alprazolam	Optional		2			
Althesin	Optional		2			
Amisulpride	Optional		2			
Amobarbital	Optional		2			
Amoxapine	Optional		2			
Amperozide	Optional		2			
Anilopam	Optional		2			
Aprobarbital	Optional		2			
Articaine	Optional		2			
Atomoxetine	Optional		2			
Atracurium	Optional		2			
Azacylonol	Optional		2			

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Azaperone	Optional	2
Barbital	Optional	2
Bemegride	Optional	2
Benoxaprofen	Optional	2
Benperidol	Optional	2
Bentazepam	Optional	2
Benzactizine	Optional	2
Benzonatate	Optional	2
Benzoctamine	Optional	2
Benzphetamine	Optional	2
Benztropine	Optional	2
Biriperone	Optional	2
Brimonidine	Optional	2
Bromazepam	Optional	2
Bromisovalum	Optional	2
Bromocriptine	Optional	2
Bromperidol	Optional	2
Brotizolam	Optional	2
Brotocol	Optional	2
Bupivacaine	Optional	2
Buspropion	Optional	2
Butabarbital	Optional	2
Butalbital	Optional	2
Butanilicaine	Optional	2
Butaperazine	Optional	2
Butoctamide	Optional	2
Camazepam	Optional	2
Captodiame	Optional	2
Carbidopa + levodopa	Optional	2
Carbromol	Optional	2
Carisoprodol	Optional	2
Carphenazine	Optional	2
Carpipramine	Optional	2
Carticaine	Optional	2
Chloralose	Optional	2
Chloral betaine	Optional	2
Chloral hydrate	Optional	2
Chloraldehyde (chloral)	Optional	2
Chlordiazepoxide	Optional	2
Chlorhexidol	Optional	2
Chlormezanone	Optional	2
Chloroprocaine	Optional	2
Chlorproethazine	Optional	2
Chlorprothixene	Optional	2
Citalopram	Optional	2
Clobazam	Optional	2
Clocapramine	Optional	2
Clomethiazole	Optional	2
Clomipramine	Optional	2
Clonazepam	Optional	2
Clorazepate	Optional	2
Clothiapine	Optional	2

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Clotiazepam	Optional	2
Cloxazolam	Optional	2
Clozapine	Optional	2
Clozaril	Optional	2
Conorphone	Optional	2
Corticaine	Optional	2
Crotetamide	Optional	2
Cyamemazine	Optional	2
Cyclobarbital	Optional	2
Decamethonium	Optional	2
Demoxepam	Optional	2
Dichloralphenazone	Optional	2
Diethylpropion	Optional	2
Diethylthiambutene	Optional	2
Dihydrocodeine	Optional	2
Dihydroergocornine mesylate	Optional	2
Dihydroergocristine mesylate	Optional	2
Dihydroergocryptine mesylate	Optional	2
Dilorazepam	Optional	2
Diprenorphine	Optional	2
Dixyrazine	Optional	2
Doxacurium	Optional	2
Doxapram	Optional	2
Doxefazepam	Optional	2
Doxepin	Optional	2
Droperidol	Optional	2
Duloxetine	Optional	2
Enciprazine	Optional	2
Epibatidine	Optional	2
Estazolam	Optional	2
Ethamivan	Optional	2
Ethanol	Optional	2
Ethchlorvynol	Optional	2
Ethinamate	Optional	2
Ethopropazine	Optional	2
Ethylisobutrazine	Optional	2
Etidocaine	Optional	2
Etifoxin	Optional	2
Etizolam	Optional	2
Etodroxizine	Optional	2
Etomidate	Optional	2
Fenarbamate	Optional	2
Fenclozic acid	Optional	2
Fenfluramine	Optional	2
Fluanisone	Optional	2
Fludiazepam	Optional	2
Flunitrazepam	Optional	2
Fluopromazine	Optional	2
Fluoresone	Optional	2
Flupenthixol	Optional	2
Flurazepam	Optional	2
Fluspirilene	Optional	2

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Flutoprazepam	Optional	2
Fluvoxamine	Optional	2
Galantamine	Optional	2
Gallamine	Optional	2
Gepirone	Optional	2
Glutethimide	Optional	2
Halazepam	Optional	2
Haloperidol	Optional	2
Haloxazolam	Optional	2
Hemoglobin glutamers	Optional	2
Hexafluorenium	Optional	2
Hexobarbital	Optional	2
Homophenazine	Optional	2
Hydroxyzine	Optional	2
Ibomal	Optional	2
Isapirone	Optional	2
Isocarboxazid	Optional	2
Isomethadone	Optional	2
Isoproterenol	Optional	2
Isoxicam	Optional	2
Ketamine	Optional	2
Ketazolam	Optional	2
Lenperone	Optional	2
Levamisole	Optional	2
Levomethorphan	Optional	2
Lithium	Optional	2
Lobeline	Optional	2
Loflazepate, ethyl	Optional	2
Loperamide	Optional	2
Loprazelam	Optional	2
Lorazepam	Optional	2
Lormetazepam	Optional	2
Loxapine	Optional	2
Maprotiline	Optional	2
Mebutamate	Optional	2
Meclofenoxate	Optional	2
Medazepam	Optional	2
Melperone	Optional	2
Memantine	Optional	2
Meparfynol	Optional	2
Mepazine	Optional	2
Mephenoxalone	Optional	2
Mephenytoin	Optional	2
Mephobarbital	Optional	2
Meprobamate	Optional	2
Mesoridazine	Optional	2
Metaclazepam	Optional	2
Metazocine	Optional	2
Metharbital	Optional	2
Methohexital	Optional	2
Methotrimeprazine	Optional	2
Methyprylon	Optional	2

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Metocurine	Optional	2
Metomidate	Optional	2
Mexazolam	Optional	2
Midazolam	Optional	2
Mirtazepine	Optional	2
Mivacurium	Optional	2
Molindone	Optional	2
Moperone	Optional	2
Mosaprimine	Optional	2
Nalorphine	Optional	2
Nefazodone	Optional	2
Nimetazepam	Optional	2
Nitrazepam	Optional	2
Olanzepine	Optional	2
Oxazolam	Optional	2
Oxyperitine	Optional	2
Paliperidone	Optional	2
Pancuronium	Optional	2
Paroxetine	Optional	2
Penfluridol	Optional	2
Pentobarbital	Optional	2
Perazine	Optional	2
Perfluorodecolin	Optional	2
Perfluorodecahydronophthalene	Optional	2
Perfluorooctylbromide	Optional	2
Perfluorotripropylamine	Optional	2
Periciazine	Optional	2
Perlapine	Optional	2
Perphenazine	Optional	2
Phenaglycodol	Optional	2
Phenobarbital	Optional	2
Phenelzine	Optional	2
Phentermine	Optional	2
Piminodine	Optional	2
Pimozide	Optional	2
Pinazepam	Optional	2
Pipamperone	Optional	2
Pipecuronium	Optional	2
Pipequaline	Optional	2
Piperacetazine	Optional	2
Piperocaine	Optional	2
Pipotiazine	Optional	2
Pipradrol	Optional	2
Piquindone	Optional	2
Prazepam	Optional	2
Prilocaine	Optional	2
Prochlorperazine	Optional	2
Propanidid	Optional	2
Propiomazine	Optional	2
Propiram	Optional	2
Propoxycaine	Optional	2
Prothipendyl	Optional	2

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Protriptyline	Optional	2
Proxibarbital	Optional	2
Pyrithyldione	Optional	2
Quazipam	Optional	2
Quetiapine	Optional	2
Racemethorphan	Optional	2
Racemorphan	Optional	2
Raclopride	Optional	2
Remoxipride	Optional	2
Reserpine	Optional	2
Rilmazafone	Optional	2
Risperidone	Optional	2
Ritanserin	Optional	2
Rocuronium	Optional	2
Rofecoxib	Optional	2
Romifidine	Optional	2
Ropivacaine	Optional	2
Secobarbital	Optional	2
Selegiline	Optional	2
Sertraline	Optional	2
Snake Venoms	Optional	2
Somatrem	Optional	2
Somatropin	Optional	2
Spiclomazine	Optional	2
Spiperone	Optional	2
Succinylcholine	Optional	2
Sulfondiethylmethane	Optional	2
Sulfonmethane	Optional	2
Sulforidazine	Optional	2
Sulpiride	Optional	2
Sultopride	Optional	2
Sultopridealbutal	Optional	2
Talbutol	Optional	2
Tandospirone	Optional	2
Temazepam	Optional	2
Tetrabenazine	Optional	2
Tetracaine	Optional	2
Tetrazepam	Optional	2
Thebaine	Optional	2
Thialbarbital	Optional	2
Thiamylal	Optional	2
Thiethylperazine	Optional	2
Thiopental	Optional	2
Thiopropazate	Optional	2
Thioproperazine	Optional	2
Thioridazine	Optional	2
Thiothixene	Optional	2
Tiapride	Optional	2
Tiletamine	Optional	2
Timiperone	Optional	2
Tofisopam	Optional	2
Topirimate	Optional	2

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Tramadol	Optional	2
Tranylcypromine	Optional	2
Trazodone	Optional	2
Tretoquinol	Optional	2
Triazolam	Optional	2
Tribromethanol	Optional	2
Tricaine methanesulfonate	Optional	2
Trichloroethanol	Optional	2
Tricholoethylene	Optional	2
Triclofos	Optional	2
Trifluomeprazine	Optional	2
Trifluoperazine	Optional	2
Trifluperidol	Optional	2
Triflupromazine	Optional	2
Trimipramine	Optional	2
Tubocurarine (Curare)	Optional	2
Tybamate	Optional	2
Valdecoxib	Optional	2
Valnoctamide	Optional	2
Venlafaxine	Optional	2
Veralipride	Optional	2
Vercuronium	Optional	2
Viloxazine	Optional	2
Vinbarbital	Optional	2
Vinylbital	Optional	2
Yohimbine	Optional	2
Zaleplon	Optional	2
Zilpaterol	Optional	2
Ziprasidone	Optional	2
Zolazepam	Optional	2
Zolpidem	Optional	2
Zomepirac	Optional	2
Zopiclone	Optional	2
Zotepine	Optional	2
Zuclopenthixol	Optional	2

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

RCI Class 3 Drugs

Mandatory drugs to be tested	43
Optional drugs to be tested	30
Total Class 3 drugs to be tested	73

Drug	Category	Analyte	RCI Class	Minimum Performance Standard ng/mL		
Testing for the following drugs or their analytes must be performed:						
Acepromazine	Mandatory	2-(1-Hydroxyethyl)promazine sulfoxide	3	10	urine	*
Albuterol	Mandatory	Albuterol	3	1	urine	*
Boldenone	Mandatory	Boldenone	3	15	urine	*
OR Boldenone	Mandatory	Boldenone	3	0.025	plasma	*
Bumetanide	Mandatory	Bumetanide	3	20	urine	
Butorphanol	Mandatory	Butorphanol	3	2	plasma	*
Clenbuterol	Mandatory	Clenbuterol	3	0.14	urine	*
OR Clenbuterol	Mandatory	Clenbuterol	3	0.002	plasma	*&
Cobalt (please see note below)	Mandatory	Cobalt	3	0.025	plasma	*
Derecoxib	Mandatory	Derecoxib	3	20	urine	
Detomidine	Mandatory	Carboxydetomidine	3	2	urine	*
AND Detomidine	Mandatory	Detomidine	3	1	plasma	*
Etodolac	Mandatory	Etodolac	3	20	urine	
Fenoprofen	Mandatory	Fenoprofen	3	20	urine	
Flufenamic acid	Mandatory	Flufenamic acid	3	20	urine	
Flurbiprofen	Mandatory	Flurbiprofen	3	20	urine	
Formoterol	Mandatory	Formoterol	3	10	urine	
Furosemide	Mandatory	Furosemide	3	50	plasma	
Gabapentin	Mandatory	Gabapentin	3	50	urine	
Glycopyrrolate	Mandatory	Glycopyrrolate	3	1	urine	
OR Glycopyrrolate	Mandatory	Glycopyrrolate	3	0.0035	plasma	*
Guanabenz	Mandatory	Guanabenz	3	10	urine	
Ipratropium	Mandatory	Ipratropium	3	1	urine	
Ketorolac	Mandatory	Ketorolac	3	20	urine	
Metaproterenol	Mandatory	Metaproterenol	3	10	urine	
Methyltestosterone	Mandatory	Methyltestosterone	3	1	urine	
OR Methyltestosterone	Mandatory	Methyltestosterone	3	0.1	plasma	
Metoprolol	Mandatory	Hydroxymetoprolol + Desmethylmetoprolol	3	20	urine	
Nabumetone	Mandatory	6-methoxy-naphthyl-acetic acid	3	20	urine	
Nandrolone (geldings, fillies and mares)	Mandatory	Nandrolone	3	1	urine	*
OR Nandrolone (geldings, fillies and mares)	Mandatory	Nandrolone	3	0.025	plasma	*
Pentazocine	Mandatory	Pentazocine	3	10	urine	
Phenylpropanolamine	Mandatory	Phenylpropanolamine	3	20	urine	
Pirbuterol	Mandatory	Pirbuterol	3	1	urine	
Piroxicam	Mandatory	Piroxicam	3	500	urine	
Procaine	Mandatory	Procaine	3	20	urine	
Promazine	Mandatory	3-Hydroxypromazine	3	20	urine	
Propranolol	Mandatory	4-Hydroxypropranolol	3	20	urine	
Pyrilamine	Mandatory	O-Desmethylpyrilamine	3	20	urine	
Ractopamine	Mandatory	Ractopamine	3	5	urine	
Sildenafil	Mandatory	Sildenafil	3	5	urine	
Stanozolol	Mandatory	16β-hydroxystanozolol	3	1	urine	*
OR Stanozolol	Mandatory	Stanozolol	3	0.025	plasma	*
Tenoxicam	Mandatory	Tenoxicam	3	20	urine	
Terbutaline	Mandatory	Terbutaline	3	1	urine	

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Testosterone (geldings)	Mandatory	Testosterone	3	20	urine	*
OR Testosterone (geldings)	Mandatory	Testosterone	3	0.1	plasma	*
Testosterone (fillies and mares)	Mandatory	Testosterone	3	55	urine	*
OR Testosterone (fillies and mares, non-pregnar	Mandatory	Testosterone	3	0.1	plasma	*
Testosterone (males)	Mandatory	Testosterone	3	2	plasma	*
Tetrahydrogestrinone	Mandatory	Tetrahydrogestrinone	3	1	urine	
OR Tetrahydrogestrinone	Mandatory	Tetrahydrogestrinone	3	0.1	plasma	
Theophylline	Mandatory	Theophylline	3	20	urine	
Trenbolone	Mandatory	Trenbolone	3	1	urine	
Xylazine	Mandatory	Xylazine	3	0.2	plasma	*

FOR COBALT TESTING ONLY, NO LESS THAN TEN PERCENT (10%) OF GRADED AND LISTED STAKES SAMPLES COLLECTED ANNUALLY FOR POST-RACE TESTING SHALL BE SELECTED FOR COBALT TESTING. IF LESS THAN TEN (10) GRADED AND LISTED STAKES SAMPLES ARE COLLECTED ANNUALLY FOR POST-RACE TESTING, THEN NO LESS THAN ONE (1) SAMPLE MUST BE SELECTED FOR COBALT TESTING.

*Select **30** drugs from the following list for testing:*

Acebutolol	Optional	3
Arformoterol	Optional	3
Almotriptan	Optional	3
Alprenolol	Optional	3
Ambenonium	Optional	3
Amitraz	Optional	3
Amyl nitrite	Optional	3
Arecoline	Optional	3
Atenolol	Optional	3
Atropine	Optional	3
Benazeprilat, Benazepril	Optional	3
Betaxolol	Optional	3
Bethanidine	Optional	3
Biperiden	Optional	3
Bisoprolol	Optional	3
Bitolterol	Optional	3
Bretylium	Optional	3
Brimonidine	Optional	3
Bromfenac	Optional	3
Bromodiphenhydramine	Optional	3
Bufexamac	Optional	3
Calusterone	Optional	3
Candesartan	Optional	3
Captopril	Optional	3
Carazolol	Optional	3
Carbachol	Optional	3
Carbamezapine	Optional	3
Carbinoxamine	Optional	3
Carteolol	Optional	3
Carvedilol	Optional	3
Celecoxib	Optional	3
Cimeterol	Optional	3
Clemastine	Optional	3
Clidinium	Optional	3
Clonidine	Optional	3

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Cyclandelate	Optional	3
Cycrimine	Optional	3
Danazol	Optional	3
Dextropropoxyphene	Optional	3
Diazoxide	Optional	3
Dimefline	Optional	3
Diphenhydramine	Optional	3
Dipyridamole	Optional	3
Divalproex	Optional	3
Dobutamine	Optional	3
Doxazosin	Optional	3
Doxylamine	Optional	3
Dromostanolone	Optional	3
Dyphylline	Optional	3
Edrophonium	Optional	3
Enalapril (metabolite enaloprilat)	Optional	3
Erthrityl tetranitrate	Optional	3
Esmolol	Optional	3
Etamiphylline	Optional	3
Ethacrynic acid	Optional	3
Ethosuximide	Optional	3
Ethylestrenol	Optional	3
Ethylnorepinephrine	Optional	3
Felbamate	Optional	3
Fenbufen	Optional	3
Fenoldopam	Optional	3
Fenoterol	Optional	3
Fenspiride	Optional	3
Fluoxymesterone	Optional	3
Flupirtine	Optional	3
Formebolone	Optional	3
Fosinopril, Fosinoprilat	Optional	3
Fosphenytoin	Optional	3
Guanadrel	Optional	3
Guanethidine	Optional	3
Heptaminol	Optional	3
Homatropine	Optional	3
Hydralazine	Optional	3
4-Hydroxytestosterone	Optional	3
Ibutilide	Optional	3
Iloprost	Optional	3
Indomethacin	Optional	3
Irbesarten	Optional	3
Isoetharine	Optional	3
Isosorbide dinitrate	Optional	3
Kebuzone	Optional	3
Labetalol	Optional	3
Lamotrigine	Optional	3
Levobunolol	Optional	3
Lisinopril	Optional	3
Losartan	Optional	3
Mabuterol	Optional	3

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Mecamylamine	Optional	3
Medetomidine	Optional	3
Mefenamic acid	Optional	3
Mepenzolate	Optional	3
Mestanolone	Optional	3
Mesterolone	Optional	3
Metenolone	Optional	3
Methachloline	Optional	3
Methandienone	Optional	3
Methandriol	Optional	3
Methandrostenolone	Optional	3
Methantheline	Optional	3
Methasterone	Optional	3
Methixene	Optional	3
Methoxamine	Optional	3
Methoxyphenamine	Optional	3
Methsuximide	Optional	3
Methylatropine	Optional	3
Methyldienolone	Optional	3
Methyldopa	Optional	3
Methylnortestosterone	Optional	3
Methylscopolamine	Optional	3
Methyl-1-testosterone	Optional	3
Metolazone	Optional	3
Mibefradil	Optional	3
Mibolerone	Optional	3
Midodrine	Optional	3
Minoxidil	Optional	3
Moexipril (metabolite moexiprilat)	Optional	3
Muscarine	Optional	3
N-Butylscopolamine	Optional	3
Nadol	Optional	3
Naloxone	Optional	3
Naltrexone	Optional	3
Naratriptan	Optional	3
Nebivolol	Optional	3
Nefopam	Optional	3
Neostigmine	Optional	3
Niflumic acid	Optional	3
Nimesulide	Optional	3
Nitroglycerin	Optional	3
19-Norandrostenediol	Optional	3
19-Norandrostenedione	Optional	3
Norbolethone	Optional	3
Norclosterbol	Optional	3
Norethandrolone	Optional	3
Nylidrine	Optional	3
Olmesartan	Optional	3
Oxabolone	Optional	3
Oxandrolone	Optional	3
Oxcarbazepine	Optional	3
Oxprenolol	Optional	3

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Oxymesterone	Optional	3
Oxymetholone	Optional	3
Papaverine	Optional	3
Paramethadione	Optional	3
Pargyline	Optional	3
Penbutolol	Optional	3
Pentaerythritol tetranitrate	Optional	3
Pergolide	Optional	3
Perindopril	Optional	3
Phenoxybenzamine	Optional	3
Phentolamine	Optional	3
Phenylephrine	Optional	3
Physostigmine	Optional	3
Pindolol	Optional	3
Piretanide	Optional	3
Prazosin	Optional	3
Primidone	Optional	3
Procaterol	Optional	3
Procyclidine	Optional	3
Promethazine	Optional	3
Propantheline	Optional	3
Propentophylline	Optional	3
Prostanazol	Optional	3
Protokylol	Optional	3
Pseudoephedrine	Optional	3
Pyridostigmine	Optional	3
Quinbolone	Optional	3
Quinapril, Quinaprilat	Optional	3
Ramipril, metabolite Ramiprilat	Optional	3
Ritodrine	Optional	3
Rivastigmime	Optional	3
Rizatriptan	Optional	3
Salmeterol	Optional	3
Scopolamine (Hyoscine)	Optional	3
Sibutramine	Optional	3
Sotalol	Optional	3
Spirapril, metabolite Spiraprilat	Optional	3
Stenbolone	Optional	3
Sulindac	Optional	3
Sumatriptan	Optional	3
Tadalafil	Optional	3
Telmisartin	Optional	3
Tepoxalin	Optional	3
Terazosin	Optional	3
Testolactone	Optional	3
Tiaprofenic acid	Optional	3
Timolol	Optional	3
Tolazoline	Optional	3
Tolmetin	Optional	3
Torsemide	Optional	3
Trandolapril (and metabolite, Trandolaprilat)	Optional	3
Trihexylphenidyl	Optional	3

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Trimethadione	Optional	3
Trimethaphan	Optional	3
Tripelennamine	Optional	3
Valerenic acid	Optional	3
Valsartan	Optional	3
Vardenafil	Optional	3
Zolmitriptan	Optional	3
Zonisamide	Optional	3
Δ-1-androstene-3, 17 diol	Optional	3
Δ-1-androstene-3, 17 dione	Optional	3
Δ-1-dihydrotestosterone	Optional	3

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

RCI Class 4 Drugs

Mandatory drugs to be tested	19
Optional drugs to be tested	20
Total Class 4 drugs to be tested	39

Drug	Category	Analyte	RCI Class	Minimum Performance Standard ng/mL		
Testing for the following drugs or their analytes must be performed:						
Betamethasone	Mandatory	Betamethasone	4	0.01	plasma	*
Dantrolene	Mandatory	Dantrolene	4	0.1	plasma	*
Dexamethasone	Mandatory	Dexamethasone	4	0.005	plasma	*
Diclofenac	Mandatory	Diclofenac	4	500	urine	
Diflunisal	Mandatory	Diflunisal	4	500	urine	
Firocoxib	Mandatory	Firocoxib	4	20	plasma	*
Flumethasone	Mandatory	Flumethasone	4	20	urine	
Flunixin	Mandatory	Flunixin	4	20	plasma	*
Ibuprofen	Mandatory	Ibuprofen	4	500	urine	
Isoflupredone	Mandatory	Isoflupredone	4	0.1	plasma	*
Ketoprofen	Mandatory	Ketoprofen	4	2	plasma	*
Meclofenamic Acid	Mandatory	Meclofenamic Acid	4	100	urine	
Methocarbamol	Mandatory	Methocarbamol	4	1	plasma	*
Methylprednisolone	Mandatory	Methylprednisolone	4	0.1	plasma	*
Naproxen	Mandatory	Naproxen	4	1000	plasma	
Phenylbutazone	Mandatory	Phenylbutazone	4	2000	plasma	*
Prednisolone	Mandatory	Prednisolone	4	1	plasma	*
Prednisone	Mandatory	Prednisone	4	20	urine	
Triamcinolone Acetonide	Mandatory	Triamcinolone Acetonide	4	0.1	plasma	*
*Select **20** drugs from the following list for testing:*						
Acetaminophen	Optional		4			
Acetanilid	Optional		4			
Acetazolamide	Optional		4			
Acetophenetidin (Phenacetin)	Optional		4			
Acetylsalicylic acid (Aspirin)	Optional		4			
Aclomethasone	Optional		4			
Adrenochrome Monosemicarbazone Salicylate	Optional		4			
Aldosterone	Optional		4			
Aldocortin	Optional		4			
Ambroxol	Optional		4			
Amcinonide	Optional		4			
Amiloride	Optional		4			
Aminocaproic acid	Optional		4			
Aminodarone	Optional		4			
2-Aminoheptaine	Optional		4			
Aminopyrine	Optional		4			
Amisometradine	Optional		4			
Amlopidine	Optional		4			
Anisotropine	Optional		4			
Antipyrine	Optional		4			
Apazone (Azapropazone)	Optional		4			
Aprindine	Optional		4			
Baclofen	Optional		4			
Beclomethasone	Optional		4			

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Bendroflumethiazide	Optional	4
Benoxinate	Optional	4
Benzocaine	Optional	4
Benzthiazide	Optional	4
Bepridil	Optional	4
Bethanechol	Optional	4
Bromhexine	Optional	4
Brompheniramine	Optional	4
Budesonide	Optional	4
Butacaine	Optional	4
Butamben (butyl aminobenzoate)	Optional	4
Butoxycaine	Optional	4
Camphor	Optional	4
Carprofen	Optional	4
Chlormerodrin	Optional	4
Chlorophenesin	Optional	4
Chloroquine	Optional	4
Chlorothiazide	Optional	4
Chlorpheniramine	Optional	4
Chlorthalidone	Optional	4
Chlorzoxazone	Optional	4
Ciclesonide	Optional	4
Cinchocaine	Optional	4
Clibucaine	Optional	4
Clobetasol	Optional	4
Clocortolone	Optional	4
Clofenamide	Optional	4
Clormecaine	Optional	4
Colchicine	Optional	4
Cortisone	Optional	4
Cyclizine	Optional	4
Cyclobenzaprine	Optional	4
Cyclomethylcaine	Optional	4
Cyclothiazide	Optional	4
Cyproheptadine	Optional	4
Dembroxol (Dembrexine)	Optional	4
Deoxycorticosterone	Optional	4
Desonite	Optional	4
Desoximetasone	Optional	4
Dextromethorphan	Optional	4
Dibucaine	Optional	4
Dichlorphenamide	Optional	4
Diflorasone	Optional	4
Diflucortolone	Optional	4
Digitoxin	Optional	4
Digoxin	Optional	4
Dihydroergotamine	Optional	4
Diltiazem	Optional	4
Dimethisoquin	Optional	4
Diphenoxylate	Optional	4
Dipyrone	Optional	4
Disopyramide	Optional	4

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Dyclonine	Optional	4
Eltenac	Optional	4
Ergonovine	Optional	4
Ergotamine	Optional	4
Etanercept	Optional	4
Ethoheptazine	Optional	4
Ethotoin	Optional	4
Ethoxzolamide	Optional	4
Ethylaminobenzoate (Benzocaine)	Optional	4
Felodipine	Optional	4
Fexofenadine	Optional	4
Flecainide	Optional	4
Floctafenine	Optional	4
Flucinolone	Optional	4
Fludrocortisone	Optional	4
Flumethiazide	Optional	4
Flunarizine	Optional	4
Flunisolide	Optional	4
Fluocinolone	Optional	4
Fluocinonide	Optional	4
Fluorometholone	Optional	4
Fluoroprednisolone	Optional	4
Fluprednisolone	Optional	4
Flurandrenolide	Optional	4
Fluticasone	Optional	4
Guaifenesin (glycerol guiacolate)	Optional	4
Halcinonide	Optional	4
Halobetasol	Optional	4
Hexocyclium	Optional	4
Hexylcaine	Optional	4
Hydrochlorthiazide	Optional	4
Hydrocortisone (Cortisol)	Optional	4
Hydroflumethiazide	Optional	4
Infliximab	Optional	4
Isometheptene	Optional	4
Isopropamide	Optional	4
Isoxsuprine	Optional	4
Isradipine	Optional	4
Letosteine	Optional	4
Loratidine	Optional	4
Meclizine	Optional	4
Medrysone	Optional	4
Mefenamic Acid	Optional	4
Meloxicam	Optional	4
Mephenesin	Optional	4
Meralluride	Optional	4
Merbaphen	Optional	4
Mercaptomerin	Optional	4
Mercumalilin	Optional	4
Mersalyl	Optional	4
Metaxalone	Optional	4
Methapyrilene	Optional	4

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Methazolamide	Optional	4
Methdilazine	Optional	4
Methotrexate	Optional	4
Methscopolamine	Optional	4
Methylchlorthiazide	Optional	4
Methylergonovine	Optional	4
Methysergide	Optional	4
Metiamide	Optional	4
Metoclopramide	Optional	4
Mexilitine	Optional	4
Milrinone	Optional	4
Mometasone	Optional	4
Montelukast	Optional	4
Naepaine	Optional	4
Naphazoline	Optional	4
Nicardipine	Optional	4
Nifedipine	Optional	4
Nimodipine	Optional	4
Norethandrone	Optional	4
Nortestosterone	Optional	4
Olsalazine	Optional	4
Orphenadrine	Optional	4
Oxaprozin	Optional	4
Oxymetazoline	Optional	4
Oxyphencyclimine	Optional	4
Oxyphenonium	Optional	4
Paramethasone	Optional	4
Pentoxyfylline	Optional	4
Phenacemide	Optional	4
Phensuximide	Optional	4
Phenytoin	Optional	4
Polythiazide	Optional	4
Pramoxine	Optional	4
Probenecid	Optional	4
Procainamide	Optional	4
Propafenone	Optional	4
Proparacaine	Optional	4
Propylhexedrine	Optional	4
Quinidine	Optional	4
Salicylamide	Optional	4
Salicylate	Optional	4
Spironalactone	Optional	4
Sulfasalazine	Optional	4
Terfenadine	Optional	4
Tetrahydrozoline	Optional	4
Theobromine	Optional	4
Thiosalicylate	Optional	4
Thiphenamil	Optional	4
Tocainide	Optional	4
Tolectin	Optional	4
Tranexamic acid	Optional	4
Trichlormethiazide	Optional	4

2019 AGSC DRUG TESTING LIST

Note: Unless indicated by an *****, the values listed in this document are minimum performance standards and **NOT** regulatory threshold levels.
Those values denoted by an ***** are regulatory threshholds recommended by the Racing Medication and Testing Consortium.
An & indicates the value is the maximum performance standard recommended by the Racing Medication and Testing Consortium.

Triamterene	Optional	4
Tridihexethyl	Optional	4
Trimeprazine	Optional	4
Triprolidine	Optional	4
Tuaminoheptane	Optional	4
Vedaprofen	Optional	4
Verapamil	Optional	4
Xylometazoline	Optional	4
Zafirlukast	Optional	4
Zeranol	Optional	4
Zileuton	Optional	4

ATTACHMENT F

ARCI Endogenous, Dietary, or Environmental Substances Schedule - Version 4.0
Updated December 2018

Substance	Threshold	Reason for Threshold
Arsenic	0.3 micrograms/milliliter total arsenic in urine	Feed Contaminant
Caffeine	100 nanograms/milliliter of serum or plasma	Feed Contaminant
Cobalt[1]	25 ppb in blood plasma or serum	Endogenous Substance and Feed Contaminant
Estranediol	0.045 micrograms/milliliter, free + conjugated 5α-estrane-3β, 17α-diol, in the urine of male horses other than geldings	Endogenous Substance
Gamma Aminobutryic Acid (GABA)	110 nanograms/milliliter of plasma or serum	Endogenous Substance
Hydrocortisone	1 microgram/milliliter of urine	Endogenous Substance
Methoxytyramine	4 micrograms/milliliter, free + conjugated in urine	Endogenous Substance
Morphine	30 ng/ml total morphine in urine	Feed Contaminant
Salicylate Salicylic Acid	750 micrograms/milliliter of urine or 6.5 micrograms/milliliter of serum or plasma	Feed Contaminant
Theobromine	2 micrograms/milliliter of urine or 0.3 micrograms/milliliter serum or plasma	Feed Contaminant

[1] Penalties for cobalt vary depending on the concentration. Please see Uniform Classification Guidelines for Foreign Substances for recommended penalty for concentrations of 25 parts per billion or greater of blood plasma or serum and for concentrations of 50 parts per billion of blood plasma or serum.

ARCI Endogenous, Dietary, or Environmental Substances Schedule - Version 4.0
Updated December 2018

Recent Document Revisions

Date	Version	Substance	Description of Change
December 2018	4.0	Morphine	Added to List at 30 ng/ml urine
July 2015	3.0	Salicylate Salicylic Acid	Corrected typographical error in measurement to "6.5 micrograms/**milliliter of** serum or plasma"
July 2015	3.0	Gamma Aminobutryic Acid (GABA)	Added to List
April 2015	2.0	Cobalt	Added to List
December 2013	1.0	Arsenic, Caffeine, Estranediol, Hydrocortisone, Methoxytyramine, Salicylate and Salicylic Acid, Theobromine	Document Created

Vendor/Payee Form

Agency: OMES Vendor Management requires the following information for all new non-registered vendors (payees) before payments may be processed. Information is used to establish the payee in the State's PeopleSoft vendor file for payment and procurement activities.

DO NOT use this form for:

- **Garnishment Payees:** Use **OMES Form GarnVendor**
- **State Employees:** Use **OMES Employee Vendor Request Form**
- ***Vendors pending contract award*** *to a solicitation released by the division of Central Purchasing or another Oklahoma state agency MUST first register online with the state unless exempt per statute. For additional information, please refer to* ***Central Purchasing Vendor Registration***.

AGENCY SECTION (To be completed by state agency representative):

State agency representative should provide form to payee for completion of the vendor section shown below. Upon receipt of the completed form the agency should enter request instructions below. Please email completed and signed form to vendor.form@omes.ok.gov or fax to 405-522-3663.

Agency Name				**Contact Name**	
Phone #		**Fax #**		**Email**	

Agency Request To – Please select all applicable request types

☐ Add New Vendor	☐ Update Existing Vendor	PeopleSoft 10-digit Vendor ID	
☐ Add New Address	☐ Change Address/Location	PeopleSoft Address #	PeopleSoft Location #
☐ Change Vendor Tax ID	☐ Change Vendor Name	☐ Add Alternate Payee Name	PeopleSoft Location #
☐ Other	Explain		

Vendor 1099 Reportable Status

Attention Paying Agency: Please check the ***Add*** box on the left if payments to this vendor/payee are represented by Account Codes listed on page 3 of this form. If the vendor is incorrectly showing as 1099 Reportable, check the ***Remove*** box. The PeopleSoft system requires specific details regarding the type of transaction. Please check the box that applies to this vendor:

☐ **Add:**
☐ **Remove:**

☐ 1 - Rents	☐ 2 - Royalties	☐ 3 – Other Income
☐ 6 - Medical & Health Care	☐ 7 - Non-Employee Compensation	☐ 10 - Crop Insurance Proceeds
☐ 14 - Gross Proceeds to an Attorney		

VENDOR/PAYEE SECTION (To be completed by vendor/payee)

Please print legibly or type information. Form must be completed and signed by authorized individual. Email or fax to requesting state agency.

Payee Information: *Please provide the requested information for the payee receiving funds from the Oklahoma state agency. All information should match U.S. Internal Revenue Service filing records for the business, individual or government entity receiving payment.*

Name		**Contact Name**	
Payee Legal Name for Business, Individual or Government Entity as filed with IRS		**Contact Title**	
DBA Name		**Phone #**	
Doing Business As "DBA", or Disregarded Entity Name if different than Legal Name		**Fax #**	
Tax Identification Number (TIN) and Type:		☐ Federal Employer ID (FEIN) ☐ Social Security Number (SSN)	

Business Address -- *Please provide primary address as reflected on payee's annual U.S. Internal Revenue Service tax documentation*

Address				**City**	
State		**Zip+4**		**Remittance Email**	

Optional Addresses – *Please select address type as applicable*

Type:	☐ Remitting	☐ Ordering	☐ Pricing	☐ Returning	☐ Mailing	☐ Other:	
Address						**City**	
State		**Zip+4**			**Remittance Email**		

Financial Registration: *Please provide contact information for the Authorized Individual who can provide financial information used for ACH Electronic Funds Transfer payment processes***. An email will be sent providing instructions for accessing the State of Oklahoma online registration system.**

Name		**Title**		**Email**	

The information below is requested under U.S. Tax Laws. Failure to provide this information may prevent you from being able to do business with the state, or may result in the state having to deduct backup withholding amounts from future payments.

U.S. Taxpayer Identification Number (TIN) Please provide tax identification number applicable for payee IRS tax reporting

Federal Employer Identification Number (FEIN) _____ If none, but applied for, date applied _____

U.S. Social Security Number (SSN) _____ If none, but applied for, date applied _____

Entity Filing Classification:

☐ Domestic (U.S.) Sole Proprietor or Individual ☐ Domestic (U.S.) Partnership ☐ Domestic (U.S.) Corporation Type: _____

☐ Limited Liability Company Type: _____

LLC Disregarded Entity: ☐ YES ☐ NO **Must be verified by LLC's tax division. If applicable, parent name/tax id is required.**

☐ Domestic (U.S.) Other Explain: _____

☐ Foreign (Non-U.S.) Sole Proprietor or Individual* ☐ Foreign (Non-U.S.) Partnership* ☐ Foreign (Non-U.S.) Type: _____

☐ Foreign (Non-U.S.) Other* Explain: _____

FOREIGN VENDOR INSTRUCTIONS: *** ADDITIONAL DOCUMENTATION IS REQUIRED.**

Please submit the proper U.S. Internal Revenue Service (IRS) Form W-8, Certificate of Foreign Status. Select form below matching the payee's entity or individual description. Please refer to IRS for additional instructions (http://www.irs.gov/pub/irs-pdf/iw8.pdf).

- **Form W-8BEN**: *Certificate of Foreign Status of Beneficial Owner for United States Tax Withholding and Reporting (Individuals)*. http://www.irs.gov/pub/irs-pdf/fw8ben.pdf
- **Form W-BEN-E**: *Certificate of Status of Beneficial Owner for United States Tax Withholding and Reporting (Entities)*. http://www.irs.gov/pub/irs-pdf/fw8bene.pdf
- **Form W-8ECI**: *Certificate of Foreign Person's Claim That Income is Effectively Connected With the Conduct of a Trade or Business in the United States*. http://www.irs.gov/pub/irs-pdf/fw8eci.pdf
- **Form W-8EXP**: *Certificate of Foreign Government or Other Foreign Organization for United States Tax Withholding and Reporting*. http://www.irs.gov/pub/irs-pdf/fw8exp.pdf
- **Form W-8IMY**: *Certificate of Foreign Intermediary, Foreign Flow-Through Entity, or Certain U.S. Branches for United States Tax Withholding and Reporting*. http://www.irs.gov/pub/irs-pdf/fw8imy.pdf

This may exempt you from backup withholding. Form W-8 does not exempt you from the 30% (or lower percentage by treaty) non-resident withholding taxes. To claim this exemption, you must file IRS Form 8233 with us. For more information, refer to IRS Publication 519.

SIGNATURE - AND SUBSTITUTE IRS FORM W-9 CERTIFICATION

Under penalties of perjury, I certify that:

1. The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me), and

2. I am not subject to backup withholding because: (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding, and

3. I am a U.S. citizen or other U.S. person (defined below), and

4. The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

Certification instructions: You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement account (IRA), and generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN.

_____ _____

Signature of Vendor Representative or Individual Payee Date

_____

Title of individual signing form for company

_____

Vendor/Payee (Must be the same as Payee Name from page 1)

Account Codes for 1099 Reporting - By Category *(TO BE COMPLETED BY AGENCY REPRESENTATIVE)*

☐ 1 - RENTS

532110 Rent of Office Space
532120 Rent of Land
532130 Rent of Other Building Space
532140 Rent of Equipment and Machinery
532150 Rent of Telecommunications Equip
532160 Rent of Electronic Data Processing Equipment
532170 Rent of Electronic Data Processing Software
532190 Other Rents

☐ 1- RENTS (continued)

532141 Rent of Motor Vehicles
532142 Lease of Motor Vehicles

☐ 2 – ROYALTIES

553170 Royalties

☐ 3 – OTHER INCOME

552120 Incentive Awards – Monetary & Material
552160 Incentive Payments – Oklahoma Horse Breeders & Owners
552170 Incentive Payments – Oklahoma Film Enhancement Rebate
553165 Current/Former Employee Reportable Court Ordered or Legal Settlements
553220 Other IRS Reportable Income

☐ 6 - MEDICAL & HEALTH CARE PAYMENTS

515530 Veterinary Services
515700 Offices of Physicians (except Mental Health Specialists)
515710 Offices of Physicians, Mental Health Specialists
515720 Offices of Dentists
515730 Offices of Chiropractors
515740 Offices of Optometrists
515750 Offices of Mental Health Practitioners (except Physicians)
515760 Offices of Physical, Occupational & Speech Therapists, & Audiologists
515770 Offices of Podiatrists
515780 Offices of all other Miscellaneous Health Practitioners
515790 Family Planning Centers
515800 Outpatient Mental Health & Substance Abuse Centers
515810 Other Outpatient Care Centers
515820 Medical and Diagnostic Laboratories
515830 Home Health Care Services
515840 Ambulance Services
515850 All other Ambulatory Health Care Services
515860 General Medical & Surgical Hospitals
515870 Psychiatric & Substance Abuse Hospitals
515880 Specialty Hospitals (except Psychiatric & Substance Abuse)
515890 Nursing Care Facilities
515900 Residential Services for People with Developmental Disabilities
515910 Residential Mental Health & Substance Abuse Facilities
515920 Community Care Facilities for the Elderly
515930 Other Residential Care Facilities
537210 Laboratory Services & Supplies
551230 Medical Services to Indigents (from agencies other than DHS)
551240 Hospital Services to Indigents (from agencies other than DHS)
551250 Other Health Services to Indigents (from agencies other than DHS)

☐ 7 - NON-EMPLOYEE COMPENSATION

515010 Office of Lawyers
515020 Offices of Notaries
515030 Other Legal Services
515060 Accounting, Tax Preparation, Bookkeeping & Payroll Services
515210 Payments for Contract Mentor Services
515220 Architectural Services
515230 Landscape Architectural Services
515240 Engineering Services
515250 Drafting Services
515260 Building Inspection Services
515270 Geophysical Surveying & Mapping Services
515280 Surveying and Mapping (except geophysical) Services
515290 Testing Laboratories
515300 Interior Design Services
515310 Industrial Design Services
515320 Graphic Design Services
515330 Other Specialized Design Services
515350 Custom Computer Programming Services
515360 Computer Systems Design Services
515370 Computer Facilities Management Services
515380 Other Computer Related Services
515400 Administrative Management & General Management Consulting Services
515410 Human Resources & Executive Search Consulting Services
515420 Marketing Consulting Services
515430 Process, Physical Distribution, & Logistics Consulting Services
515440 Other Management Consulting Services
515450 Environmental Consulting Services
515460 Other Scientific & Technical Consulting Services
515470 Research & Development in the Physical, Engineering, & Life Sciences
515480 Research & Development in the Social Sciences & Humanities
515490 Advertising and Related Services
515500 Marketing Research & Public Opinion Polling
515510 Photographic Services
515520 Translation & Interpretation Services
515540 All other Professional, Scientific and Technical Services
515550 Management of Companies & Enterprises
515560 Office Administrative Services
515570 Employment Placement Services
515580 Business Support Services
515590 Document Preparation Services
515600 Telephone Call Centers
515610 Business Service Centers
515620 Collection Agencies
515630 Credit Bureaus
515640 Other Business Support Services
515650 Investigation & Security Services
515660 Educational Services
515940 Individual & Family Services
515950 Community Food, Housing & Emergency & Other Relief Services
515960 Vocational Rehabilitation Services
515970 Child Day Care Services
515980 Arts, Entertainment and Recreation
515990 Other Services (except Public Administration)
517110 Moving Expense – Employee Transfer
531150 Printing and Binding Contract
531160 Advertising
531170 Informational Services
531190 Exhibitions, Shows and Special Events
531220 Burial Charges
531330 Jury and Witness Fees
531500 Moving Expenses – General
533100 Maintenance & Repair – Other Items
533110 Maintenance & Repair of Buildings & Grounds (outside vendors)
533120 Maintenance & Repair – Equipment (outside vendors)
533130 Maintenance & Repair of Telephone Equipment (outside vendors)
533140 Maintenance & Repair of Data Processing Equipment (outside vendors)
533150 Maintenance & Repair of Data Processing Software (outside vendors)
533190 Maintenance & Repair – Employee Uniforms
545110 Purchase of Land Improvements
545210 CIP (Construction in Progress) – Land Improvements
546210 Buildings and Other Structures – Construction and Renovation
546220 Major Maintenance and Repair of Equipment
547110 Highway and Bridge Construction Expense – Contractual
547120 Maintenance and Repairs to Highways and Bridges
547210 Major Maintenance and Renovation – Bridges
552100 Stipends – Other
552120 Teacher Stipends (“Incentive” payments)
552130 Oklahoma Police Corps Stipends
553160 Non-Employee Reportable Court Ordered or Legal Settlements
554190 Voter Registration Services
561140 Pollution Remediation

☐ 14 - GROSS PROCEEDS TO AN ATTORNEY

553180 Settlements – Paid To/Thru Attorney